

**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549**

**FORM 10-Q/A
Amendment No.1**

(Mark One)
 QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended September 30, 2024 or

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from _____ to _____

Commission File Number: 001-40493

ATAI Life Sciences N.V.

(Exact name of registrant as specified in its charter)

The Netherlands
(State or other jurisdiction of
incorporation or organization)

ATAI Life Sciences N.V.
Wallstraße 16, 10179

Berlin, Germany
(Address of principal executive offices)

Not Applicable
(I.R.S. Employer
Identification No.)

Not Applicable
(Zip Code)

+49 89 2153 9035

(Registrant's telephone number, including area code)

N/A

(Former name, former address and former fiscal year, if changed since last report)

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common shares, par value €0.10 per share	ATAI	The Nasdaq Stock Market LLC (Nasdaq Global Market)

Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes No

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes No

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company," and "emerging growth company" in Rule 12b-2 of the Exchange Act.

Large accelerated filer	<input type="checkbox"/>	Accelerated filer	<input type="checkbox"/>
Non-accelerated filer	<input checked="" type="checkbox"/>	Smaller reporting company	<input checked="" type="checkbox"/>
		Emerging growth company	<input checked="" type="checkbox"/>

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes No

As of November 5, 2024, the registrant had 167,802,396 common shares, par value €0.10 per share, outstanding.

Explanatory Note

The sole purpose of this Amendment No. 1 on Form 10-Q/A is to amend the certifications filed as Exhibit 31.3 and Exhibit 32.1 to the Quarterly Report on Form 10-Q of ATAI Life Sciences N.V. (the "Company") for the quarterly period ended September 30, 2024, filed with the U.S. Securities and Exchange Commission on November 13, 2024 (the "Original Filing") to correct the inadvertent omission of the conformed signatures and to correct a scrivener's error in the title line in the signature block in Exhibit 31.2 to refer in parentheses to "Co-Principal Executive Officer." The certifications were fully executed on November 13, 2024 and were in the Company's possession at the time of the Original Filing. Pursuant to Rule 12b-15 under the Securities Exchange Act of 1934, as amended, currently-dated certifications have been provided as Exhibits 31.1 - 31.3 and Exhibit 32.1.

Other than as set forth above, this Amendment No. 1 does not modify, amend or update in any way the financial or other information contained in the Original Filing, nor does this Amendment No. 1 reflect events that may have occurred after the Original Filing. This Amendment No. 1 should be read in conjunction with the Original Filing.

ATAI Life Sciences N.V.

FORM 10-Q/A

Table of Contents

	<u>Page</u>
<u>Forward-Looking Statements</u>	1
<u>PART I. FINANCIAL INFORMATION</u>	
Item 1. <u>Financial Statements (Unaudited)</u>	3
<u>Condensed Consolidated Balance Sheets as of September 30, 2024 and December 31, 2023</u>	3
<u>Condensed Consolidated Statements of Operations for the Three and Nine Months Ended September 30, 2024 and 2023</u>	4
<u>Condensed Consolidated Statements of Comprehensive Income (Loss) for the Three and Nine Months Ended September 30, 2024 and 2023</u>	5
<u>Condensed Consolidated Statements of Changes in Stockholders' Equity for the Nine Months Ended September 30, 2024 and 2023</u>	6
<u>Condensed Consolidated Statements of Cash Flows for the Nine Months Ended September 30, 2024 and 2023</u>	7
<u>Notes to Condensed Consolidated Financial Statements</u>	8
Item 2. <u>Management's Discussion and Analysis of Financial Condition and Results of Operations</u>	41
Item 3. <u>Quantitative and Qualitative Disclosures About Market Risk</u>	60
Item 4. <u>Controls and Procedures</u>	61
<u>PART II. OTHER INFORMATION</u>	
Item 1. <u>Legal Proceedings</u>	62
Item 1A. <u>Risk Factors</u>	62
Item 2. <u>Unregistered Sales of Equity Securities and Use of Proceeds</u>	62
Item 3. <u>Defaults Upon Senior Securities</u>	62
Item 4. <u>Mine Safety Disclosures</u>	62
Item 5. <u>Other Information</u>	62
Item 6. <u>Exhibits</u>	63
<u>Signatures</u>	65

CAUTIONARY NOTE REGARDING FORWARD LOOKING STATEMENTS

This Quarterly Report on Form 10-Q/A for the quarterly period ended September 30, 2024 (the "Quarterly Report") contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. We intend such forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements contained in this Quarterly Report other than statements of historical fact are forward-looking statements, including without limitation statements regarding our future operating results and financial position; the success, cost, and timing of development of our product candidates, including the progress of non-clinical, preclinical studies and clinical trials and related milestones; the commercialization of our current product candidates and any other product candidates we may identify and pursue, if approved, including our ability to successfully build a specialty sales force and commercial infrastructure to market our current product candidates and any other product candidates we may identify and pursue; the timing of and our ability to obtain and maintain regulatory approvals; our business strategy and plans; potential acquisitions, partnerships and other strategic arrangements; the ability to generate revenue from any current or future licensing agreements and other strategic arrangements, the sufficiency of our cash and cash equivalents and short-term securities to fund our operations; available funding under the Hercules Capital, Inc. loan facility; and the plans and objectives of management for future operations and capital expenditures. The words "believe," "may," "will," "estimate," "continue," "anticipate," "intend," "expect," "could," "would," "project," "plan," "potentially," "preliminary," "likely," and similar expressions are intended to identify forward-looking statements.

We have based these forward-looking statements largely on our current expectations and projections about future events and trends that we believe may affect our financial condition, results of operations, business strategy, short-term and long-term business operations and objectives, and financial needs. These forward-looking statements are neither promises nor guarantees, and are subject to a number of important factors that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by the forward-looking statements, including without limitation: we are a clinical-stage biopharmaceutical company and have incurred significant losses since our inception, and we expect to incur losses for the foreseeable future and may never be profitable; if we are unable to obtain funding when needed and on acceptable terms, we could be forced to delay, limit or discontinue our product candidate development efforts; our limited operating history may make it difficult for you to evaluate the success of our business and to assess our future viability; we rely on third parties to assist in conducting our clinical trials and some aspects of our research and preclinical testing; we currently rely on qualified therapists working at third-party clinical trial sites to administer certain of our product candidates in our clinical trials and we expect this to continue upon approval, if any, of our current or future product candidates, and if third-party sites fail to recruit and retain a sufficient number of therapists or effectively manage their therapists, our business, financial condition and results of operations would be materially harmed; our product candidates are in preclinical or clinical development, which is a lengthy and expensive process with uncertain outcomes, and we cannot give any assurance that any of our product candidates will be successfully developed and/or receive regulatory approval, which is necessary before they can be commercialized; research and development of drugs targeting the central nervous system, or CNS, is particularly difficult, and it can be difficult to predict and understand why a drug has a positive effect on some patients but not others, which may reduce the likelihood our product candidates are ultimately approved and therefore may have a material adverse effect on our business and operating results; the production and sale of our product candidates may be considered illegal or may otherwise be restricted due to the use of controlled substances, which may also have consequences for the legality of investments from foreign jurisdictions and therefore we may not be successful in commercializing our product candidates in such jurisdictions, which will adversely affect our business, financial condition and results of operations; we face significant competition in an environment of rapid technological and scientific change, and there is a possibility that our competitors may achieve regulatory approval before we do or develop therapies that are safer, more advanced or more effective than ours, which may negatively impact our ability to successfully market or commercialize any product candidates we may develop and ultimately harm our financial condition; if we are unable to obtain and maintain sufficient intellectual property protection for our existing product candidates or any other product candidates that we may identify, or if the scope of the intellectual property protection we currently have or obtain in the future is not sufficiently broad, our competitors could develop and commercialize product candidates similar or identical to ours, and our ability to successfully commercialize our existing product candidates and any other product candidates that we may pursue may be impaired; third parties may claim that we are infringing, misappropriating or otherwise violating their intellectual property rights, the outcome of which would be uncertain and may prevent or delay our development and commercialization efforts; our future success depends on our ability to retain key employees, directors, consultants and advisors and to attract, retain and motivate qualified personnel; as a result of covenants related to our Loan Agreement with Hercules Capital, Inc., our operating activities may be restricted and we may be required to repay the outstanding indebtedness in the event of a breach by us, or an event of default thereunder, which could have a materially adverse effect on our business; if we fail to maintain an effective system of disclosure controls and internal control over financial reporting our ability to produce timely and accurate financial statements or comply with applicable regulations could be impaired; our business is subject to economic, political, regulatory and other risks associated with international operations; a pandemic, epidemic, or outbreak of an infectious disease, such as the COVID-19 pandemic, may materially and adversely affect our business, including our preclinical studies, clinical trials, trial sites, third parties on whom we rely, our supply chain, our ability to raise capital, our ability to conduct regular business and our financial results, and other risks, uncertainties, and assumptions described under "Risk Factors" in Item 1A of Part I, "Management's Discussion and Analysis of Financial Condition and Results of Operations" in Item 7 of Part II and elsewhere in our Form 10-K for the year ended December 31, 2023 (the "Form 10-K"), as further updated in "Management's

Discussion and Analysis of Financial Condition and Results of Operations” in Item 2 of this Quarterly Report, and in our subsequent filings with the Securities and Exchange Commission (“SEC”).

Any forward-looking statements made herein speak only as of the date of the Original Filing, and you should not rely on forward-looking statements as predictions of future events. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee that the future results, performance, or achievements reflected in the forward-looking statements will be achieved or will occur. Except as required by applicable law, we undertake no obligation to update any of these forward-looking statements for any reason after the date of the Original Filing or to conform these statements to actual results or revised expectations.

GENERAL

Unless the context otherwise requires, all references in this Quarterly Report to “we,” “us,” “our,” “atai” or the “Company” refer to ATAI Life Sciences N.V. and its consolidated subsidiaries. References to “Quarterly Report” herein refer to this Quarterly Report on Form 10-Q/A for the quarterly period ended September 30, 2024 and references to “Form 10-K” and “Annual Report” herein refer to our Annual Report on Form 10-K for the fiscal year ended December 31, 2023.

All reports we file with the SEC are available for download free of charge via the Electronic Data Gathering Analysis and Retrieval (EDGAR) System on the SEC’s website at www.sec.gov. We also make electronic copies of our reports available for download, free of charge, through our investor relations website at ir.atai.life as soon as reasonably practicable after filing such material with the SEC.

We may announce material business and financial information to our investors using our investor relations website at ir.atai.life. We therefore encourage investors and others interested in atai to review the information that we make available on our website, in addition to following our filings with the SEC, webcasts, press releases and conference calls. Information contained on our website is not incorporated into, and does not form a part of this Quarterly Report.

PART I - FINANCIAL INFORMATION

Item 1. Financial Statements

ATAI LIFE SCIENCES N.V.
CONDENSED CONSOLIDATED BALANCE SHEETS
(Amounts in thousands, except share and per share amounts)
(unaudited)

	<u>September 30,</u> <u>2024</u>	<u>December 31,</u> <u>2023</u>
Assets		
Current assets:		
Cash and cash equivalents	\$ 29,963	\$ 45,034
Securities carried at fair value	55,957	109,223
Short-term restricted cash for other investments	15,000	—
Committed investment funds	—	25,000
Prepaid expenses and other current assets	7,454	5,830
Short-term notes receivable - related party, net	5,700	505
Total current assets	114,074	185,592
Property and equipment, net	865	981
Operating lease right-of-use asset, net	1,032	1,223
Other investments held at fair value	45,227	89,825
Other investments	33,893	1,838
Long-term notes receivable - related party, net	—	97
Convertible notes receivable - related party	—	11,202
Other assets	2,428	2,720
Total assets	<u>\$ 197,519</u>	<u>\$ 293,478</u>
Liabilities and Stockholders' Equity		
Current liabilities:		
Accounts payable	\$ 4,880	\$ 4,589
Accrued liabilities	11,953	15,256
Current portion of lease liability	257	275
Short-term convertible promissory notes and derivative liability - related party	925	—
Short-term convertible promissory notes and derivative liability	1,481	—
Other current liability	147	—
Total current liabilities	19,643	20,120
Contingent consideration liability - related parties	650	620
Contingent consideration liability	1,388	1,637
Noncurrent portion of lease liability	808	990
Convertible promissory notes and derivative liability - related party	—	164
Convertible promissory notes and derivative liability	—	2,666
Long-term debt, net	20,336	15,047
Other liabilities	8,378	7,918
Total liabilities	<u>\$ 51,203</u>	<u>\$ 49,162</u>
Commitments and contingencies (Note 16)		
Stockholders' equity:		
Common stock, €0.10 par value (\$0.11 and \$0.12 par value at September 30, 2024 and December 31, 2023, respectively); 750,000,000 shares authorized at September 30, 2024 and December 31, 2023, respectively; 167,818,316 and 166,026,396 shares issued and outstanding at September 30, 2024 and December 31, 2023, respectively	18,770	18,573
Additional paid-in capital	808,355	794,787
Accumulated other comprehensive loss	(20,156)	(19,460)
Accumulated deficit	(661,249)	(550,938)
Total stockholders' equity attributable to ATAI Life Sciences N.V. stockholders	145,720	242,962
Noncontrolling interests	596	1,354
Total stockholders' equity	<u>146,316</u>	<u>244,316</u>
Total liabilities and stockholders' equity	<u>\$ 197,519</u>	<u>\$ 293,478</u>

See accompanying Notes to the unaudited condensed consolidated financial statements.

ATAI LIFE SCIENCES N.V.
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(Amounts in thousands, except share and per share amounts)
(unaudited)

	For the three months ended September 30,		For the nine months ended September 30,	
	2024	2023	2024	2023
License revenue	\$ 40	\$ 87	\$ 313	\$ 296
Operating expenses:				
Research and development	12,377	13,290	36,513	48,047
General and administrative	10,265	13,631	36,226	44,159
Total operating expenses	<u>22,642</u>	<u>26,921</u>	<u>72,739</u>	<u>92,206</u>
Loss from operations	<u>(22,602)</u>	<u>(26,834)</u>	<u>(72,426)</u>	<u>(91,910)</u>
Other income (expense), net:				
Interest income	160	612	585	1,191
Interest expense	(783)	(686)	(2,172)	(1,965)
Benefit from research and development tax credit	31	—	617	—
Change in fair value of assets and liabilities, net	(1,964)	70,810	(33,764)	72,411
Foreign exchange gain (loss), net	770	253	676	(593)
Other expense, net	(2,075)	(308)	(2,737)	(100)
Total other income (expense), net	<u>(3,861)</u>	<u>70,681</u>	<u>(36,795)</u>	<u>70,944</u>
Net income (loss) before income taxes	<u>(26,463)</u>	<u>43,847</u>	<u>(109,221)</u>	<u>(20,966)</u>
Benefit from (provision for) income taxes	178	(238)	163	(588)
Losses from investments in equity method investees, net of tax	<u>(26)</u>	<u>(238)</u>	<u>(2,000)</u>	<u>(3,199)</u>
Net income (loss)	<u>(26,311)</u>	<u>43,371</u>	<u>(111,058)</u>	<u>(24,753)</u>
Net loss attributable to noncontrolling interests	<u>(25)</u>	<u>(873)</u>	<u>(747)</u>	<u>(2,821)</u>
Net income (loss) attributable to ATAI Life Sciences N.V. stockholders	<u>\$ (26,286)</u>	<u>\$ 44,244</u>	<u>\$ (110,311)</u>	<u>\$ (21,932)</u>
Net income (loss) per share attributable to ATAI Life Sciences N.V. stockholders — basic	<u>\$ (0.16)</u>	<u>\$ 0.28</u>	<u>\$ (0.69)</u>	<u>\$ (0.14)</u>
Net income (loss) per share attributable to ATAI Life Sciences N.V. stockholders — diluted	<u>\$ (0.16)</u>	<u>\$ 0.25</u>	<u>\$ (0.69)</u>	<u>\$ (0.14)</u>
Weighted average common shares outstanding attributable to ATAI Life Sciences N.V. stockholders — basic	<u>160,621,817</u>	<u>155,792,490</u>	<u>159,973,201</u>	<u>155,793,601</u>
Weighted average common shares outstanding attributable to ATAI Life Sciences N.V. stockholders — diluted	<u>160,621,817</u>	<u>177,565,973</u>	<u>159,973,201</u>	<u>155,793,601</u>

See accompanying Notes to the unaudited condensed consolidated financial statements.

ATAI LIFE SCIENCES N.V.
CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS)
(Amounts in thousands)
(unaudited)

	For the three months ended September 30,		For the nine months ended September 30,	
	2024	2023	2024	2023
Net income (loss)	\$ (26,311)	\$ 43,371	\$ (111,058)	\$ (24,753)
Other comprehensive income (loss):				
Foreign currency translation adjustments, net of tax	(985)	1,709	(696)	2,593
Comprehensive income (loss)	\$ (27,296)	\$ 45,080	\$ (111,754)	\$ (22,160)
Net loss attributable to noncontrolling interests	(25)	(873)	(747)	(2,821)
Foreign currency translation adjustments, net of tax attributable to noncontrolling interests	(22)	22	(11)	31
Comprehensive loss attributable to noncontrolling interests	(47)	(851)	(758)	(2,790)
Comprehensive gain (loss) attributable to ATAI Life Sciences N.V. stockholders	<u>\$ (27,249)</u>	<u>\$ 45,931</u>	<u>\$ (110,996)</u>	<u>\$ (19,370)</u>

See accompanying Notes to the unaudited condensed consolidated financial statements.

ATAI LIFE SCIENCES N.V.
CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY
(Amounts in thousands, except share amounts)
(unaudited)

	Common Stock		Additional Paid-In Capital	Accumulated Other Comprehen sive Loss	Accumulated Deficit	Total Stockholders' Equity Attributable to		Total Stockholders' Equity	
	Shares	Amount				ATAI Life Sciences N.V. Stockholders			Noncontroll ing Interests
Balances at December 31, 2023	166,026,396	\$ 18,573	\$ 794,787	\$ (19,460)	\$ (550,938)	\$ 242,962	\$ 1,354	\$ 244,316	
Issuance of shares upon restricted stock units vest	248,030	27	(27)	—	—	—	—	—	
Stock-based compensation expense	—	—	5,760	—	—	5,760	—	5,760	
Foreign currency translation adjustment, net of tax	—	—	—	535	—	535	24	559	
Net loss	—	—	—	—	(26,713)	(26,713)	(665)	(27,378)	
Balances at March 31, 2024	166,274,426	\$ 18,600	\$ 800,520	\$ (18,925)	\$ (577,651)	\$ 222,544	\$ 713	\$ 223,257	
Issuance of shares upon restricted stock units vest	1,221,033	135	(135)	—	—	—	—	—	
Issuance of shares upon exercise of stock options	276,531	30	296	—	—	326	—	326	
Adjustment to additional paid in capital upon acquiring additional interest in variable interest entity	—	—	(115)	—	—	(115)	—	(115)	
Stock-based compensation expense	—	—	6,282	—	—	6,282	—	6,282	
Adjustment to additional paid in capital upon debt modification	—	—	(3,590)	—	—	(3,590)	—	(3,590)	
Foreign currency translation adjustment, net of tax	—	—	—	(246)	—	(246)	(13)	(259)	
Net loss	—	—	—	—	(57,312)	(57,312)	(57)	(57,369)	
Balances at June 30, 2024	167,771,990	\$ 18,765	\$ 803,259	\$ (19,171)	\$ (634,963)	\$ 167,890	\$ 643	\$ 168,533	
Issuance of shares upon exercise of stock options	46,326	5	50	—	—	55	—	55	
Stock-based compensation expense	—	—	5,046	—	—	5,046	—	5,046	
Foreign currency translation adjustment, net of tax	—	—	—	(985)	—	(985)	(22)	(1,007)	
Net loss	—	—	—	—	(26,286)	(26,286)	(25)	(26,311)	
Balances at September 30, 2024	167,818,316	\$ 18,770	\$ 808,355	\$ (20,156)	\$ (661,249)	\$ 145,720	\$ 596	\$ 146,316	

	Common Stock		Additional Paid-In Capital	Share Subscription s Receivable	Accumulate d Other Comprehen sive Loss	Accumulate d Deficit	Total Stockholders' Equity Attributable to		Total Stockholder s' Equity	
	Shares	Amount					ATAI Life Sciences N.V. Stockholders			Noncontroll ing Interests
Balances at December 31, 2022	165,935,914	\$ 18,562	\$ 774,092	\$ (24)	\$ (21,702)	\$ (510,188)	\$ 260,740	\$ 5,026	\$ 265,766	
Issuance of shares upon exercise of stock options	74,562	9	172	—	—	—	181	—	181	
Settlement of issuance of shares upon exercise of stock options	—	—	—	24	—	—	24	—	24	
Stock-based compensation expense	—	—	8,662	—	—	—	8,662	—	8,662	
Adjustment to accumulated deficit (pursuant to adoption of ASU 2016-13)	—	—	—	—	—	(526)	(526)	—	(526)	
Foreign currency translation adjustment, net of tax	—	—	—	—	879	—	879	8	887	
Net loss	—	—	—	—	—	(33,135)	(33,135)	(1,219)	(34,354)	
Balances at March 31, 2023	166,010,476	\$ 18,571	\$ 782,926	\$ —	\$ (20,823)	\$ (543,849)	\$ 236,825	\$ 3,815	\$ 240,640	
Stock-based compensation expense	—	—	8,762	—	—	—	8,762	—	8,762	
Foreign currency translation adjustment, net of tax	—	—	—	—	5	—	5	1	6	
Net loss	—	—	—	—	—	(33,042)	(33,042)	(729)	(33,771)	
Balances at June 30, 2023	166,010,476	\$ 18,571	\$ 791,688	\$ —	\$ (20,818)	\$ (576,891)	\$ 212,550	\$ 3,087	\$ 215,637	
Stock-based compensation expense	—	—	8,253	—	—	—	8,253	—	8,253	
Adjustment to additional paid in capital upon acquiring additional interest in variable interest entity	—	—	(480)	—	—	—	(480)	—	(480)	
Foreign currency translation adjustment, net of tax	—	—	—	—	1,709	—	1,709	22	1,731	
Net income (loss)	—	—	—	—	—	44,244	44,244	(873)	43,371	
Balances at September 30, 2023	166,010,476	\$ 18,571	\$ 799,461	\$ —	\$ (19,109)	\$ (532,647)	\$ 266,276	\$ 2,236	\$ 268,512	

See accompanying Notes to the unaudited condensed consolidated financial statements.

ATAI LIFE SCIENCES N.V.
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(Amounts in thousands)
(unaudited)

	For the nine months ended September 30.	
	2024	2023
Cash flows from operating activities		
Net loss	\$ (111,058)	\$ (24,753)
Adjustments to reconcile net loss to net cash used in operating activities:		
Depreciation and amortization of long-term assets	248	218
Noncash lease expense	202	297
Amortization of debt discount	327	272
Stock-based compensation expense	17,088	25,677
Noncash change in the fair value of assets and liabilities, net	35,965	(72,411)
Loss on sale of investment held at fair value	2,075	—
Unrealized foreign exchange (gain) loss	(789)	555
Losses from investments in equity method investees, net of tax	2,000	3,199
Other income (expense)	965	(42)
Changes in operating assets and liabilities:		
Prepaid expenses and other current assets	(1,599)	6,716
Accounts payable	261	3,096
Accrued liabilities	(3,827)	(4,980)
Net cash used in operating activities	(58,142)	(62,156)
Cash flows from investing activities		
Proceeds from sale and maturities of securities carried at fair value	54,270	130,363
Proceeds from sale of other investment held at fair value	16,093	—
Cash paid for securities carried at fair value	—	(177,047)
Cash paid for investments	(10,000)	—
Cash paid for short-term convertible notes receivable and warrant - related party	(2,000)	—
Cash paid for short-term notes receivable - related party	(5,745)	—
Cash paid for long-term notes receivable - related parties, net	—	(3,000)
Cash paid for convertible notes receivable - related party	—	(1,497)
Cash paid for other investments held at fair value	—	(724)
Cash paid for additional interest in variable interest entity	—	(480)
Proceeds from sale of other investment	—	486
Cash paid for capitalized internal-use software development costs	(6)	(322)
Cash paid for property and equipment	—	(251)
Net cash provided by (used in) investing activities	52,612	(52,472)
Cash flows from financing activities		
Proceeds from debt financing	5,000	—
Proceeds from issuance of shares upon exercise of stock options	381	206
Financing costs paid	(161)	(100)
Net cash provided by financing activities	5,220	106
Effect of foreign exchange rate changes on cash	239	401
Net decrease in cash, cash equivalents and restricted cash	(71)	(114,121)
Cash, cash equivalents and restricted cash – beginning of the period	45,034	190,613
Cash, cash equivalents and restricted cash – end of the period	\$ 44,963	\$ 76,492
Supplemental disclosures:		
Cash paid for taxes	\$ 376	\$ 1,475
Cash paid for interest	\$ 1,654	\$ 1,428
Supplemental disclosures of noncash investing and financing information:		
Noncash exchange of convertible promissory note modification	\$ 3,586	\$ —
Right of use asset obtained in exchange for operating lease liabilities	\$ —	\$ 1,356
Noncash commitment for debtor-in-possession loan	\$ 147	\$ —
Noncash consideration for variable interest deconsolidation	\$ 115	\$ —

See accompanying Notes to the unaudited condensed consolidated financial statements.

ATAI LIFE SCIENCES N.V.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(unaudited)

1. Organization and Description of Business

ATAI Life Sciences N.V. ("atai" or the "Company"), headquartered in Berlin, Germany is the parent company of ATAI Life Sciences AG and, along with its subsidiaries, is a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders. atai was founded in 2018 as a response to the significant unmet need and lack of innovation in the mental health treatment landscape and is dedicated to efficiently developing innovative therapeutics to treat depression, anxiety, addiction, and other mental health disorders. By pooling resources and best practices, atai aims to responsibly accelerate the development of new medicines to achieve clinically meaningful and sustained behavioral change in mental health patients.

The Company is subject to risks and uncertainties common to clinical stage companies in the biotechnology industry, including, but not limited to, development by competitors of new technological innovations, dependence on key personnel, third-party clinical research organizations and manufacturers, protection of proprietary intellectual property and technology, compliance with government regulations and the ability to secure additional capital to fund operations. Therapeutic candidates currently under development will require significant additional research and development efforts, including preclinical and clinical testing and regulatory approval, prior to commercialization. These efforts require significant amounts of capital, adequate personnel and infrastructure and extensive compliance-reporting capabilities. Even if the Company's therapeutic development efforts are successful, it is uncertain when, if ever, the Company will realize revenue from sales.

The Company operates and manages the business as one reportable segment, which is the business of identifying and advancing mental health innovations. The Company has determined that its chief executive officer is the chief operating decision maker ("CODM"). The CODM reviews consolidated operating expenses to make decisions about allocating resources or capital to specific compounds or projects in line with overall Company's strategies and goals. The Company operates in two geographic regions primarily in the United States and Germany.

Liquidity and Going Concern

The Company has incurred significant losses and negative cash flows from operations since its inception. As of September 30, 2024, the Company had cash and cash equivalents of \$30.0 million, restricted cash of \$15.0 million, and short-term securities of \$56.0 million and its accumulated deficit was \$661.2 million. The Company has historically financed its operations through the sale of equity securities, debt financings, sale of convertible notes and revenue generated from licensing and collaboration arrangements. The Company has not generated any revenues to date from the sale of its product candidates and does not anticipate generating any revenues from the sale of its product candidates unless and until it successfully completes development and obtains regulatory approval to market its product candidates.

The Company currently expects that its existing cash and cash equivalents and short-term securities as of September 30, 2024 will be sufficient to fund its operating expenses and capital expenditure requirements for at least the next 12 months from the date the unaudited condensed consolidated financial statements are issued.

2. Basis of Presentation, Consolidation and Summary of Significant Accounting Policies

Basis of Presentation

The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States ("U.S. GAAP") for interim financial information and follow the requirements of the United States Securities and Exchange Commission ("SEC") for interim financial reporting. Accordingly, these unaudited condensed consolidated financial statements do not include all of the information and disclosures required by U.S. GAAP for complete financial statements as certain footnotes or other financial information that are normally required by U.S. GAAP can be condensed or omitted. These unaudited condensed consolidated financial statements should be read in conjunction with the Company's audited consolidated financial statements and notes thereto included in the Company's Annual Report on Form 10-K for the year ended December 31, 2023 filed with the SEC on March 28, 2024.

The unaudited condensed consolidated financial statements have been prepared on the same basis as the annual financial statements and, in the opinion of management, reflect all adjustments, which include only normal recurring adjustments, necessary for a fair statement of the Company's financial position, its results of operations and comprehensive loss, and its cash flows for the periods presented. The results of operations for the three and nine months ended September 30, 2024 are not necessarily indicative of the results to be expected for the year ending December 31, 2024 or for any other future annual or interim period.

Any reference in these notes to applicable accounting guidance is meant to refer to the authoritative U.S. GAAP included in the Accounting Standards Codification (“ASC”), and Accounting Standards Update (“ASU”) issued by the Financial Accounting Standards Board (“FASB”).

Reclassifications

Certain reclassifications were made to prior period amounts in the unaudited condensed consolidated financial statements and accompanying notes to conform with current year presentation in order to consolidate and simplify the disclosures of changes in assets and liabilities held at fair value.

Consolidation

The Company's unaudited condensed consolidated financial statements include the accounts of atai and its subsidiaries. All intercompany balances and transactions have been eliminated in the consolidation.

The Company's policy is to consolidate all entities that it controls by ownership of a majority of the outstanding voting stock. In addition, entities that meet the definition of a variable interest entity (“VIE”) for which atai is the primary beneficiary are consolidated. The primary beneficiary is the party who has the power to direct the activities of a VIE that most significantly impact the entity’s economic performance and who has an obligation to absorb losses of the entity or a right to receive benefits from the entity that could potentially be significant to the entity. For consolidated entities that are less than wholly-owned, the third-party’s holding of equity interest is presented as Noncontrolling interests in the Company's unaudited condensed consolidated balance sheets and unaudited condensed consolidated statements of stockholders' equity. The portion of net earnings attributable to the noncontrolling interests is presented as Net loss attributable to noncontrolling interests in the Company's unaudited condensed consolidated statements of operations.

Ownership interests in entities over which the Company has significant influence, but not a controlling financial interest, are accounted for under either the alternative measurement under ASC 321 or as an equity method investment. Investments eligible for the measurement alternative under ASC 321 are carried at its initial cost, with remeasurements to fair value upon impairment or upon a price change observed in an orderly transaction of the same or similar investment of the same issuer. For equity method investments where the Company has not elected the fair value option, it records gains (losses) from investments in equity method investees, net of tax, for its proportionate share of the underlying company’s net results until the investment balance is adjusted to zero. If the Company makes subsequent additional investments in that same company, it may record additional gains (losses) based on changes to its investment basis and also may record additional income (loss) in equity method investments. If the Company has elected the fair value option for an equity investment, the fair value of the investment will be recorded upon acquisition and any changes in fair value will be recorded as a component of other income (expense), net.

Significant Accounting Policies

During the nine months ended September 30, 2024, there were no significant changes to the Company’s significant accounting policies as described in the Company’s audited consolidated financial statements as of and for the year ended December 31, 2023 except as described below.

Restricted Cash

The Company maintains certain cash balances restricted as to withdrawal or use. Restricted cash assets as of September 30, 2024 are for the sole purpose of purchasing additional Series C Shares in Beckley Psytech Limited. See Note 5 for further information.

Recently Adopted Accounting Pronouncements

ASU 2016-13 Financial Instruments - Credit Losses

In June 2016, the FASB issued ASU 2016-13, Financial Instruments — Credit Losses. This guidance requires immediate recognition of management’s estimates of current expected credit losses. Under the prior model, losses were recognized only when losses were deemed probable. The new model is applicable to most financial assets and certain other instruments that are not measured at fair value through net income.

The Company utilizes an undiscounted probability-of-default (“PD”) and loss-given-default (“LGD”) method for estimating credit losses on its assets pool, which is comprised of loans to other companies. Under the PD and LGD method, the expected credit loss percentage (or “loss rate”) is calculated as the probability of default (i.e., the probability the asset will default within the given time frame) multiplied by the loss given default (i.e., the percentage of the asset not expected to be collected because of default). To implement the PD and LGD method, the Company utilizes readily observable market information from term-matched public debt to derive market implied current expected credit losses (“MICECL”) grouped by Standard & Poor’s (“S&P”) credit rating scale. The MICECL framework considers risk characteristics of assets pool based on publicly available or estimated S&P credit ratings to calculate an appropriate credit loss reserve for the pool or group of assets.

ASU 2016-13 requires a cumulative effect adjustment to the statement of financial position as of the beginning of the first reporting period in which it is effective. On January 1, 2023, the Company adopted this guidance and applied a modified-retrospective transition approach through a cumulative-effect adjustment to retained earnings upon adoption. At transition, the new accounting guidance’s adoption resulted

in an increase to accumulated deficit of \$0.5 million, net of tax attributable to an increase in the allowance for credit losses related to its long-term notes receivable - related parties.

Further, the FASB issued ASU 2019-04, ASU 2019-05, ASU 2019-11, ASU 2020-03 and ASU 2022-02 to provide additional clarification and guidance on the credit losses standard. The Company adopted ASU 2019-04, ASU 2019-05, ASU 2019-11, ASU 2020-03 and ASU 2022-02 on January 1, 2023. The adoption of these standards did not have a material impact on the Company's consolidated financial statements or disclosures.

Recently Issued Accounting Pronouncements Not Yet Adopted

In November 2023, the Financial Accounting Standard Board ("FASB") issued new guidance designed to improve reportable segment disclosure requirements, primarily through enhanced disclosures about significant expenses per segment. The guidance is effective for all fiscal years beginning after December 15, 2023, and for interim periods beginning after December 15, 2024. The new standard must be adopted on a retrospective basis and early adoption is permitted. The Company is not early adopting the standard. We are currently evaluating this guidance to determine its impact on our consolidated financial statements.

In December 2023, the FASB issued new guidance designed to improve income tax disclosure requirements, primarily through increased disaggregation disclosures within the effective tax rate reconciliation as well as enhanced disclosures on income taxes paid. The guidance is effective for all fiscal years beginning after December 15, 2024. The new standard can be adopted on a prospective basis with an option to be adopted retrospectively and early adoption is permitted. The Company is not early adopting the standard. We are currently evaluating this guidance to determine its impact on our consolidated financial statements.

In November 2024, the FASB issued new guidance designed to improve income statement expense disclosures, primarily by requiring new financial statement disclosures in tabular format and disaggregating information about prescribed categories underlying any relevant income statement captions. The standard is effective for fiscal years beginning after December 15, 2026 and interim periods within fiscal years beginning after December 15, 2027, with early adoption permitted. Upon adoption, the new standard may be applied prospectively or retrospectively. The Company is currently evaluating the impact that the adoption may have on its disclosures in its condensed consolidated financial statements.

3. Acquisitions and Dispositions

2023 Dispositions

Psyber, Inc.

In October 2023, the Company entered into a Framework Agreement with the founders of Psyber, Inc. ("Psyber Founders") through which the Company transferred its equity interest in Psyber, Inc. ("Psyber") to the Founders in exchange for certain intellectual property.

As a result of the disposition, the Company ceased having controlling financial interest in Psyber. The Company determined that it was no longer the primary beneficiary, no longer had the power to direct the significant activities of Psyber, and accordingly, deconsolidated Psyber. The Company derecognized all of Psyber's assets and liabilities, with the exception of the retained intellectual property, from its consolidated balance sheet and recognized a loss of \$0.3 million, which was reported as Loss on deconsolidation of a variable interest entity, a component of other income, net in the consolidated statement of operations for the year ended December 31, 2023.

The Company concluded that the decision to deconsolidate Psyber, which was based on resource capital allocation decisions, did not represent a significant strategic shift that would have a material effect on the Company's operations and financial results. Therefore, the Company did not present the results of Psyber prior to deconsolidation as discontinued operations in its consolidated statements of operations for the year ended December 31, 2023.

TryptageniX, Inc.

In December 2023, the Company finalized and entered into a Framework Agreement with CB Therapeutics, Inc. ("CBT") through which the Company transferred its equity interest in TryptageniX Inc. ("TryptageniX") to CBT in exchange for certain intellectual property and an Amended and Restated Development Services and Exclusive License Agreement.

As a result of the disposition, the Company ceased having controlling financial interest in TryptageniX. The Company determined that it was no longer the primary beneficiary, no longer had the power to direct the significant activities of TryptageniX, and accordingly, deconsolidated TryptageniX. The Company derecognized all of TryptageniX's assets and liabilities from its consolidated balance sheet, and recognized a gain of \$0.4 million, which was reported as Gain on deconsolidation of a variable interest entity, a component of other income, net in the consolidated statement of operations for the year ended December 31, 2023.

The Company concluded that the decision to deconsolidate TryptageniX, which was based on resource capital allocation decisions, did not represent a significant strategic shift that would have a material effect on the Company's operations and financial results. Therefore, the Company did not present the results of TryptageniX prior to deconsolidation as discontinued operations in its consolidated statements of operations for the year ended December 31, 2023.

4. Variable Interest Entities

Consolidated VIEs

At each reporting period, the Company reassesses whether it remains the primary beneficiary for Variable Interest Entities (“VIEs”) consolidated under the VIE model.

The entities consolidated by the Company are comprised of wholly and partially owned entities for which the Company is the primary beneficiary under the VIE model as the Company has (i) the power to direct the activities that most significantly impact the VIE’s economic performance and (ii) the obligation to absorb losses that could potentially be significant to the VIE, or the right to receive benefits from the VIE that could potentially be significant to the VIE. The results of operations of the consolidated entities are included within the Company’s unaudited condensed consolidated financial statements from the date of acquisition to September 30, 2024.

As of September 30, 2024 and December 31, 2023, the Company has accounted for the following consolidated investments as VIEs:

Consolidated Entities	Relationship as of September 30, 2024	Relationship as of December 31, 2023	Date Control Obtained	Ownership % September 30, 2024	Ownership % December 31, 2023
Perception Neuroscience Holdings, Inc.	Controlled VIE	Controlled VIE	November 2018	59.2%	59.2%
Kures, Inc.	Controlled VIE	Controlled VIE	August 2019	64.5%	64.5%
Recognify Life Sciences, Inc.	Controlled VIE	Controlled VIE	November 2020	51.9%	51.9%
PsyProtix, Inc.	Wholly-Owned Subsidiary	Controlled VIE	February 2021	100.0%	75.0%

As of September 30, 2024 and December 31, 2023, the assets of the consolidated VIEs can only be used to settle the obligations of the respective VIEs. The liabilities of the consolidated VIEs are obligations of the respective VIEs and their creditors have no recourse to the general credit or assets of atai.

PsyProtix, Inc.

On February 3, 2021, PsyProtix, Inc. ("PsyProtix") was created as a joint venture between the Company and Chymia (the “Founders”), with the intent of PsyProtix becoming a newly formed corporate subsidiary of ATAI. PsyProtix was created for the purpose of exploring and developing a metabolomics-based precision psychiatry approach. Based on the Company's assessment of the transaction at the time of acquisition, the Company concluded that PsyProtix was not a business and accounted for the Company's investment as an initial consolidation of a VIE that is not a business under ASC 810.

In April 2024, the Company and Chymia entered into a Framework Agreement which resulted in the Company's acquisition of Chymia's 25% equity ownership of PsyProtix (the “Stock Transfer”). As a result of the Stock Transfer, the Company owned 100% of the outstanding common stock of PsyProtix, and PsyProtix became a wholly owned subsidiary of the Company. The Stock Transfer was accounted for as an equity transaction with no gain or loss recognized. The difference between the carrying amount of Chymia's non-controlling interest and the note receivable forgiven in the acquisition of the additional equity interest was recorded as a reduction in additional paid-in capital in the unaudited condensed consolidated balance sheets and unaudited condensed consolidated statements of stockholders' equity.

The following table presents the assets and liabilities (excluding intercompany balances that were eliminated in consolidation) for all VIEs as of September 30, 2024 (in thousands):

	Perception	Kures	Recognify
Assets:			
Current assets:			
Cash	\$ 89	\$ 26	\$ 2,508
Accounts receivable	313	—	—
Prepaid expenses and other current assets	5	37	62
Total current assets	407	63	2,570
Total assets	\$ 407	\$ 63	\$ 2,570
Liabilities:			
Current liabilities:			
Accounts payable	\$ 236	\$ 375	\$ 565
Accrued liabilities	352	174	2,222
Other current liabilities	40	—	3
Total current liabilities	628	549	2,790
Total liabilities	\$ 628	\$ 549	\$ 2,790

The following table presents the assets and liabilities (excluding intercompany balances that were eliminated in consolidation) for all consolidated VIEs as of December 31, 2023 (in thousands):

	Perception	Kures	Recognify	PsyProtix
Assets:				
Current assets:				
Cash	\$ 97	\$ 257	\$ 4,356	\$ 35
Accounts receivable	84	—	—	—
Prepaid expenses and other current assets	257	—	450	—
Total current assets	438	257	4,806	35
Long-term notes receivable	—	—	—	97
Other assets	—	—	—	—
Total assets	\$ 438	\$ 257	\$ 4,806	\$ 132
Liabilities:				
Current liabilities:				
Accounts payable	\$ 31	\$ 329	\$ 1,926	\$ —
Accrued liabilities	718	84	609	26
Other current liabilities	12	—	1	—
Total current liabilities	761	413	2,536	26
Total liabilities	\$ 761	\$ 413	\$ 2,536	\$ 26

Noncontrolling Interests

The Company recognizes noncontrolling interests related to its consolidated VIEs and provides a roll forward of the noncontrolling interests balance, as follows (in thousands):

	Perception	Kures	Recognify	Total
Balance as of December 31, 2023	\$ 428	\$ 369	\$ 557	\$ 1,354
Net loss attributable to noncontrolling interests - preferred	(100)	(25)	(539)	(665)
Comprehensive income attributable to noncontrolling interests	17	7	—	24
Balance as of March 31, 2024	\$ 345	\$ 350	\$ 18	\$ 713
Net loss attributable to noncontrolling interests - preferred	(36)	(4)	(18)	(57)
Comprehensive loss attributable to noncontrolling interests	(9)	(4)	—	(13)
Balance as of June 30, 2024	\$ 300	\$ 343	\$ —	\$ 643
Net loss attributable to noncontrolling interests - preferred	(38)	13	—	(25)
Comprehensive loss attributable to noncontrolling interests	(15)	(6)	—	(22)
Balance as of September 30, 2024	\$ 247	\$ 349	\$ —	\$ 596
	Perception	Kures	Recognify	Total
Balance as of December 31, 2022	\$ 1,731	\$ 451	\$ 2,844	\$ 5,026
Net loss attributable to noncontrolling interests - preferred	(700)	(93)	(426)	(1,219)
Comprehensive loss attributable to noncontrolling interests	6	2	—	8
Balance as of March 31, 2023	\$ 1,037	\$ 360	\$ 2,418	\$ 3,815
Net loss attributable to noncontrolling interests - preferred	(266)	(32)	(431)	(729)
Comprehensive income (loss) attributable to noncontrolling interests	(1)	2	—	1
Balance as of June 30, 2023	\$ 770	\$ 330	\$ 1,987	\$ 3,087
Net loss attributable to noncontrolling interests - preferred	(320)	65	(618)	(873)
Comprehensive income (loss) attributable to noncontrolling interests	17	5	—	22
Balance as of September 30, 2023	\$ 467	\$ 400	\$ 1,369	\$ 2,236

Non-consolidated VIEs

The Company evaluated the nature of its investments in Innoplexus AG (“Innoplexus”), IntelGenx, defined below, and Beckley Psytech Limited (collectively “non-consolidated VIEs”) and determined that the investments are VIEs as of the date of the Company’s initial investment through September 30, 2024. The Company is not the primary beneficiary of the non-consolidated VIEs as it did not have the power to direct the activities that most significantly impact the investments’ economic performance and therefore concluded that it did not have a controlling financial interest in each of the non-consolidated VIEs that would require consolidation as of September 30, 2024 and December 31, 2023.

The Company will reevaluate if the investments meet the definition of a VIE upon the occurrence of specific reconsideration events. The Company accounted for these investments under either the equity method, fair value option, or the measurement alternative included within ASC 321 (See Note 5). As of September 30, 2024, the Company’s maximum exposure for its non-consolidated VIEs was \$15.0 million of Short-term restricted cash for other investments and \$5.7 million of Short-term notes receivable - related party, each as shown in the unaudited condensed consolidated balance sheets.

As of December 31, 2023, the Company’s maximum exposure for its non-consolidated VIEs was \$6.1 million relating to the carrying values in its Other investments, \$0.1 million of Long-term notes receivable – related party, net and \$11.2 million of Convertible notes receivable - related party, each as shown in the condensed consolidated balance sheets.

5. Investments

Other investments held at fair value

COMPASS Pathways plc

COMPASS Pathways plc ("COMPASS") is a mental health care company dedicated to pioneering the development of a new model of psilocybin therapy with its product COMP360. The Company first acquired investments in COMPASS in December 2018 with additional investments through 2021, and accounted for its investment under the equity method until August 2023. In August 2023, COMPASS closed its most recent financing round, in which the Company did not participate, and the Company's ownership interest in COMPASS was reduced to 15.4%.

Following the August 2023 financing, the Company evaluated its ability to continue to exercise significant influence over its investment and determined that it no longer had significant influence and as such will account for its COMPASS investment under ASC 321 at fair value. Any changes in fair value of the Company's investment in COMPASS will be recorded as a Change in fair value of assets and liabilities, net in its unaudited condensed consolidated statements of operations.

In September 2024, the Company sold 2,660,000 American Depositary shares ("ADS") of COMPASS at a price of \$6.05 per ADS in an open market transaction, resulting in net proceeds received of \$16.1 million. The Company recognized a non-cash loss of \$2.1 million on the sale during the three months ended September 30, 2024, which is recorded as a component of Other expense, net in its unaudited condensed consolidated statement of operations.

Based on quoted market prices, the market value of the Company's ownership in COMPASS was \$43.5 million and \$83.7 million as of September 30, 2024 and December 31, 2023, respectively. The Company has recorded the change in fair value of other investments held at fair value in its unaudited condensed consolidated statements of operations of \$3.9 million gain and \$22.0 million loss for the three and nine months ended September 30, 2024, respectively. For the three and nine months ended September 30, 2023, the Company recorded \$69.0 million and \$69.0 million, respectively, of change in fair value of other investments held at fair value in its unaudited condensed consolidated statements of operations.

IntelGenx Technologies Corp.

IntelGenx Technologies Corp. ("IntelGenx") is a novel drug delivery company focused on the development and manufacturing of novel oral thin film products for the pharmaceutical market. In March 2021, IntelGenx and the Company entered into the Strategic Development Agreement and Purchaser Rights Agreement ("PPA"), (described below). In 2023, IntelGenx and the Company entered into a subscription agreement (described below).

Following the initial closing of the IntelGenx SPA (as defined below), the Company held a 25% voting interest in IntelGenx. Pursuant to the PPA, the Company is entitled to designate a number of directors to the IntelGenx's board of directors in the same proportion as the shares of common stock held by the Company to the outstanding IntelGenx Common Shares. As of September 30, 2024, the Company maintains significant influence over IntelGenx through the Company's ownership interest in IntelGenx's equity and its right to noncontrolling representation on IntelGenx's board of directors.

In May 2024, IntelGenx announced that its board of directors authorized IntelGenx to bring an application in the Quebec Superior Court to seek protection from creditors under the Companies' Creditors Arrangement Act ("CCAA") to allow time to review its strategic alternatives. IntelGenx was granted protection pursuant to an initial order ("Initial Order"), which also authorized interim debtor-in-possession financing ("DIP Financing") provided by the Company in order to allow IntelGenx to continue its operations during a restructuring process. Subsequently, IntelGenx obtained approval to implement a sale and investment solicitation process (the "SISP" and the approval, the "SISP Approval Order"). As part of the SISP Approval Order, the Court approved the agreement of purchase and sale between IntelGenx and the Company, solely for the purpose of constituting the "Stalking Horse Bid" under the SISP. The Stalking Horse Bid established a baseline price and deal structure for the solicitation of superior bids from qualified interested parties.

In July 2024, and pursuant to the SISP Approval Order, the SISP did not result in alternative superior bids. The Company and IntelGenx completed the purchase and sale transaction in October 2024.

Concurrent with the CCAA application, trading in the common shares of IntelGenx on the Toronto Stock Exchange has been halted. As of September 30, 2024, considering relevant facts and circumstances, the Company has estimated a fair value of zero for the various warrants to purchase IntelGenx Common Shares and call option to purchase additional convertible debenture units. Additionally, the Company has estimated the fair value of the various notes receivables with IntelGenx based on the fair value of the underlying collateral of the secured debt, as further described in Note 6 below.

2021 Securities Purchase Agreement

In May 2021, IntelGenx and the Company executed a Securities Purchase Agreement (the "IntelGenx SPA") after obtaining IntelGenx shareholder approval, whereby IntelGenx issued shares of its common stock (the "IntelGenx Common Shares") and warrants to the Company at a price of approximately \$12.3 million. Each warrant (the "Initial Warrants") entitles the Company to purchase one share at a price of \$0.35 per share for a period of three years from the closing of the initial investment in March 2021. Pursuant to the IntelGenx SPA,

the Company has the right to purchase (in cash, or in certain circumstances, the Company's equity) additional units for a period of three years from the closing of the initial investment (the "Additional Unit Warrants"). As of the March 15, 2024 expiration date, the Company had not exercised any of the Initial Warrants or the Additional Unit Warrants, which had a carrying value of zero, resulting in no impact to the unaudited condensed consolidated balance sheet or unaudited condensed consolidated statement of operations.

The Company qualified for and elected to account for its investment in the IntelGenx Common Shares under the fair value option. The Company believes that the fair value option better reflects the underlying economics of the IntelGenx Common Shares investment. The Initial Warrants and the Additional Unit Warrants were accounted for at fair value under ASC 321 and recorded in Other investments held at fair value on the consolidated balance sheets. The Company applied a calibrated model and determined that the initial aggregate fair value of its \$12.3 million investment was equal to the transaction price and recorded the IntelGenx Common Shares at \$3.0 million, the Initial Warrants at \$1.2 million and the Additional Unit Warrants at \$8.2 million on a relative fair value basis resulting in no initial gain or loss recognized in the consolidated statements of operations. The Company recognized subsequent changes in fair value of the IntelGenx Common Shares, Initial Warrants (until exercise or expiration) and Additional Unit Warrants (until exercise or expiration) as a Change in fair value of assets and liabilities, net, a component of other income (expense), net in the consolidated statements of operations. The carrying amount of the IntelGenx Common Shares, Initial Warrants and Additional Unit Warrants was reduced to zero as of December 31, 2021, and remained zero as of September 30, 2024 and December 31, 2023. Accordingly, during the three and nine months ended September 30, 2024 and 2023, the Company recognized a zero mark-to-market gain/loss for each of the IntelGenx Common Shares, Initial Warrants and Additional Unit Warrants in the unaudited condensed consolidated statements of operations.

2023 Subscription Agreement, as amended

In August 2023, IntelGenx and the Company entered into a subscription agreement (the "Subscription Agreement"), under which the Company paid IntelGenx \$2.2 million for 2,220 convertible debenture units (the "2023 Initial Units"), with each convertible debenture unit consisting of:

- (i) \$1,000 principal amount convertible promissory notes (the "2023 Initial Notes") bearing interest at a rate of 12.0% per annum, payable quarterly in arrears beginning September 30, 2023, with all principal and accrued interest convertible into common shares of IntelGenx, at any time from the date that is six months following their issuance up to and including August 31, 2026 at a conversion price equal to \$0.185 per common share; and
- (ii) 5,405 common share purchase warrants of IntelGenx (the "2023 Initial Warrants"), each exercisable at an exercise price of \$0.26 per common share for a period of three years following their issuance.

Pursuant to the Subscription Agreement, the Company agreed to subscribe for an additional 750 convertible debenture units (the "2023 Subsequent Units") at a price of \$750,000 subject to obtaining certain shareholder approvals. The Subsequent Units contain the same terms as the Initial Units, with each Subsequent Unit consisting of (i) \$1,000 principal amount convertible promissory notes ("2023 Subsequent Notes") and (ii) 5,405 common share purchase warrants of IntelGenx ("2023 Subsequent Warrants").

Effective September 30, 2023, IntelGenx and the Company amended the Subscription Agreement (the "Amended Subscription Agreement"), allowing the Company, subject to obtaining certain shareholder approvals, the "Call Option" to purchase up to an additional 7,401 convertible debenture units (the "Call Option Units"). The Call Option Units contain the same terms as the Initial Units, with each Call Option Unit consisting of (i) \$1,000 principal amount convertible promissory notes, and (ii) 5,405 common share purchase warrants of IntelGenx.

The issuance of any Call Option Unit shall result in a corresponding reduction in the Company's remaining purchase right pursuant to the IntelGenx SPA executed in May 2021 (the "2021 Purchase Right"), with such right to be reduced by the maximum number of shares of common stock issuable in connection with such Call Option Units, and (ii) in the event that the 2021 Purchase Right has been fully or partially exercised such that the aggregate number of shares of common stock issued thereunder together with the number of shares of common stock issuable in accordance with the Call Option Units would exceed 100,000,000, the number of shares of common stock that may be issued in connection with the Call Option Units shall be reduced such that the aggregate number of shares of common stock issued thereunder together with the number of shares of common stock issuable in accordance with the Call Option Units does not exceed 100,000,000. The maximum number of shares of common stock available under the 2021 Purchase Right was reduced from 130,000,000 shares of common stock to 100,000,000 shares of common stock, such that in no event shall the aggregate number of shares of common stock issuable in accordance with the Call Option Units and the 2021 Purchase Right exceed 100,000,000.

There are limits over the conversion of the Initial Units, Subsequent Units, Call Options Units and the IntelGenx Term Loan (as defined below in Note 6) into common shares.

The Company qualified for and elected to account for its investment in the convertible debenture units and call option under the fair value option. The Company believes that the fair value option better reflects the underlying economics of the convertible debenture units and call option. The convertible promissory notes are accounted for at fair value under ASC 320 and recorded in Short-term convertible notes receivable - related party in the unaudited condensed consolidated balance sheet, as described further in Note 6. The warrants and call option are accounted for pursuant to the fair value option election and recorded in Other investments held at fair value in the unaudited condensed consolidated balance sheet.

For the 2023 Initial Units, the Company determined that the initial aggregate fair value of its \$2.2 million investment was equal to the transaction price and recorded the 2023 Initial Notes at \$1.5 million and the 2023 Initial Warrants at \$0.7 million resulting in no initial gain or loss recognized in the consolidated statements of operations. The Company will recognize subsequent changes in fair value of the 2023 Initial Notes (see Note 6) and 2023 Initial Warrants as Change in fair value of assets and liabilities, net, a component of other income (expense), net in the consolidated statements of operations. As of September 30, 2024 and December 31, 2023, the fair value of the 2023 Initial Warrants was zero and \$0.7 million, respectively. For the three and nine months ended September 30, 2024, the Company recognized no change in fair value and a \$0.7 million loss in Change in fair value of assets and liabilities, net relating to the 2023 Initial Warrants in its unaudited condensed consolidated statements of operations, respectively. There was an immaterial change in fair value relating to the 2023 Initial Warrants in the Company's unaudited condensed consolidated statements of operations for the three and nine months ended September 30, 2023, respectively.

In November 2023, upon shareholder approval, the Company paid \$750,000 for the 2023 Subsequent Units. The Company determined that the initial aggregate fair value of its \$0.8 million investment was equal to the transaction price and recorded the 2023 Subsequent Notes at \$0.6 million and the 2023 Subsequent Warrants at \$0.2 million resulting in no initial gain or loss recognized in the consolidated statements of operations. The Company will recognize subsequent changes in fair value of the 2023 Subsequent Notes (see Note 6) and 2023 Subsequent Warrants as Change in fair value of assets and liabilities, net, a component of other income (expense), net in the consolidated statements of operations. As of September 30, 2024 and December 31, 2023, the fair value of the 2023 Subsequent Warrants was zero and \$0.2 million, respectively. For the three and nine months ended September 30, 2024, the Company recognized no change in fair value and a \$0.2 million loss in Change in fair value of assets and liabilities, net relating to the 2023 Subsequent Warrants in its unaudited condensed consolidated statements of operations, respectively.

At December 31, 2023, the Call Option was recorded in Other investments held at fair value on the consolidated balance sheet with an estimated fair value of \$5.1 million. The Call Option is additional value conveyed to the Company relating to its investment in and Strategic Development Agreement with IntelGenx. Accordingly, the Company also recorded a \$5.1 million deferred credit, included in Other liabilities in the consolidated balance sheet. As appropriate, the Company will account for the deferred credit as a reduction of research and development expense in its consolidated statements of operation until the credit is exhausted or the Company is no longer receiving goods or services from IntelGenx. As of September 30, 2024 and December 31, 2023, the fair value of the Call Option was zero and \$5.2 million, respectively. For the three and nine months ended September 30, 2024, the Company recognized no change in fair value and a \$5.2 million loss in Change in fair value of assets and liabilities, net relating to the Call Option in its unaudited condensed consolidated statements of operations, respectively.

2024 Term Loan Warrants

In March 2024, the Company and IntelGenx entered into a third amendment to the amended and restated loan agreement (the "Third Amendment"), as further described in Note 6 below. In connection with the Third Amendment, the Company received warrants to purchase up to 4 million shares of IntelGenx Common Shares at an exercise price of \$0.17, subject to certain adjustments and beneficial ownership limitations ("2024 Warrants"). The Company recorded the 2024 Warrants fair value of \$0.4 million in Other investments held at fair value in the consolidated balance sheet, with a corresponding deferred vendor credit included in Other liabilities in the consolidated balance sheet. As of September 30, 2024, the 2024 Warrants have a fair value of zero. For the three and nine months ended September 30, 2024, the Company recorded no change in fair value and a \$0.4 million loss in Change in fair value of assets and liabilities, net for the change in fair value of the 2024 Warrants, respectively.

Strategic Development Agreement

Pursuant to the Strategic Development Agreement, the Company engages IntelGenx to conduct research and development projects ("Development Project") using IntelGenx's proprietary oral thin film technology. Under the terms of the Strategic Development Agreement, the Company can select four (4) program products. As of the effective date of the Strategic Development Agreement, the Company nominated two (2) program products - DMT and Salvinorin A. 20% of any funds that IntelGenx received or will receive through the Company's equity investment under the IntelGenx SPA will be available to be credited towards research and development services that IntelGenx conducts for the Company under the Development Projects. The Company is eligible to receive a total credit of \$2.5 million. For the three and nine months ended September 30, 2024, research and development expense relating to the Strategic Development Agreement were \$0.2 million and \$0.6 million, respectively, which was applied as a reduction in research and development expenses in accordance with the Strategic Development Agreement. For the three and nine months ended September 30, 2023, research and development expense relating to the Strategic Development Agreement were \$0.1 million and \$0.3 million, respectively, which was applied as a reduction in research and development expenses in accordance with the Strategic Development Agreement.

Other investments

The Company has accounted for its Other investments that do not have a readily determinable fair value under either the alternative measurement under ASC 321 or as an equity method investment. Under the measurement alternative, the Company measured its Other investments at cost, less any impairment, plus or minus, if any, observable price changes in orderly transactions for an identical or similar investment of the same issuer. For equity method investments where the Company has not elected the fair value option, it records gains (losses) from investments in equity method investees, net of tax, for its proportionate share of the underlying company's net results until

the investment balance is adjusted to zero. If the Company makes subsequent additional investments in that same company, it may record additional gains (losses) based on changes to its investment basis and also may record additional income (loss) in equity method investments.

The Company's investments in the preferred stock of Innoplexus, GABA, defined below, and Beckley Psytech Limited are not considered as in-substance common stock due to the existence of substantial liquidation preferences and therefore did not have subordination characteristics that were substantially similar to the common stock.

During the three and nine months ended September 30, 2024 and 2023, the Company evaluated all of its other investments to determine if certain events or changes in circumstance had a significant adverse effect on the fair value of any of its investments in non-consolidated entities. Based on this analysis, the Company did not note any impairment indicators associated with the Company's Other investments.

During the three and nine months ended September 30, 2024 and 2023 there were no observable changes in price recorded related to the Company's Other investments.

As of September 30, 2024 and December 31, 2023, the carrying values of Other investments, which consisted of investments in the investee's preferred stock not in the scope of ASC 323 were as follows (in thousands):

	September 30, 2024	December 31, 2023
Beckley Psytech Limited	\$ 33,893	\$ —
GABA Therapeutics, Inc.	—	1,838
Innoplexus AG	—	—
Total	<u>\$ 33,893</u>	<u>\$ 1,838</u>

Beckley Psytech Limited

Beckley Psytech Limited ("Beckley Psytech") is a clinical stage biotechnology company dedicated to improving the lives of people suffering from neuropsychiatric disorders by transforming psychedelics into effective and rapid-acting clinical medicines. Its most advanced programs are focused on the development of psychedelic-based medicines to treat people with treatment resistant depression and major depressive disorder.

Subscription and shareholders' agreement

On January 3, 2024, the Company entered into a subscription and shareholders' agreement with Beckley Psytech and certain other shareholders as identified in the agreement (the "SSA"). Pursuant to the terms of the SSA, the Company (a) has the right to acquire 24,096,385 newly issued series C preferred shares, par value £0.0001 per share, of Beckley Psytech (the "Series C Shares") for a total purchase price of \$40 million (the "Primary Investment"); and (b) undertakes to enter into a Share Purchase Deed (the "Secondary Sale SPA") within 10 business days, pursuant to which the Company will acquire a total of 11,153,246 shares of Beckley Psytech from certain existing shareholders of Beckley Psytech (the "Secondary Sale" and together with the Primary Investment, the "Investment"), all of which will be re-designated into Series C Shares immediately prior to completion of the Secondary Sale, for a total purchase price of \$10 million.

In connection with the SSA, the Company acquired, pursuant to an equity warrant instrument between the Company and Beckley Psytech, 24,096,385 warrants to purchase an amount of Series C shares equal to the lesser of (i) 24,096,385 Series C Shares; or (ii) such number of Series C Shares (rounded up to the nearest whole number) as immediately after their issuance would, together with all shares held by the Company in the issued share capital of Beckley Psytech, equal less than 50% of Beckley Psytech's fully diluted share capital, and each such warrant is exercisable at an exercise price of \$2.158 per share ("Series C Warrants").

Also under the SSA, the Company will have the right to receive additional warrants to purchase Series C Shares in the event Beckley Psytech issues equity or equity linked securities pursuant to a deferred equity arrangement in connection with a prior acquisition made by Beckley Psytech, each such warrant is exercisable at an exercise price of \$1.66 per share. Each of the warrants described above is exercisable upon delivery of a written notice to Beckley Psytech ("Additional Warrants").

Initial Subscription

On January 3, 2024, the Company made an initial payment of \$25 million for 15,060,241 Series C Shares at a subscription share price of \$1.66 ("Initial Shares") and delivered the executed deferred payment escrow agreement ("Escrow Agreement") to Beckley Psytech which was the condition for the closing or completion of the transaction ("Initial Subscription").

Secondary Sale

On January 18, 2024, the Company and Beckley Psytech entered into the Secondary Sale SPA pursuant to which the Company agreed to purchase 11,153,246, £0.0001 par value, re-designated Series C shares (the "Secondary Sale Shares") at a price of \$0.8966 from the existing shareholders for an aggregate consideration of \$10 million. On January 18, 2024, the Secondary Sale Shares were acquired by the Company.

The Company paid a total of \$35.0 million upon closing of the Initial Subscription and Secondary Shares Sale.

The Company determined that the Additional Warrants meet the definition of a derivative instrument under ASC 815 and recorded the \$2.6 million fair value in Other investments held at fair value in the unaudited condensed consolidated balance sheet, with subsequent changes in fair value being reflected through the unaudited condensed consolidated statement of operations in the Change in fair value of assets and liabilities, net.

The Company qualified for and elected to account for the remaining investment acquired per the SSA using the measurement alternative under ASC 321, and is included in Other Investments in the unaudited condensed consolidated balance sheet. The Company applied a calibrated model for the remaining \$32.4 million investment, to account for the Initial Shares, option to purchase the Deferred Shares, Secondary Shares, and Series C Warrants, on a relative fair value basis resulting in no initial gain or loss recognized in the consolidated statements of operations.

Deferred Shares

On January 5, 2024, subject to the terms of the Escrow Agreement, the Company deposited \$15.0 million into an escrow account. Prior to April 1, 2025, Beckley Psytech may, at its sole discretion, draw down up to \$5.0 million from the escrow account, with the balance to be paid to Beckley Psytech at April 1, 2025. Beckley shall credit as fully-paid such corresponding number of Series C Shares as corresponds with the value of such draw-down. The total number of deferred payment shares ("Deferred Shares") is 9,036,144 with a share price of \$1.66.

As of September 30, 2024, Beckley Psytech has not made any draws against the escrow account. The Company reflects the \$5.0 million Beckley Psytech may draw down at its sole discretion and the remaining \$10.0 million held in escrow in Short-term restricted cash for other investments within the unaudited condensed consolidated balance sheets as of September 30, 2024.

Additional Warrants

In May 2024, Beckley Psytech issued equity pursuant to the deferred equity arrangement, and, per the SSA, the Company received 4,393,400 warrants. The Company determined that once received the Additional Warrants will no longer meet the definition of a derivative instrument under ASC 815. The Company qualified for and elected to account for the warrants under ASC 321, and recorded the warrants received in Other Investments in the unaudited condensed consolidated balance sheet. At the time of receipt, the warrants had a fair value of \$1.5 million.

As of September 30, 2024, the Additional Warrants had a fair value of \$1.7 million recorded in Other investments held at fair value in the unaudited condensed consolidated balance sheet. The Company recorded a \$0.1 million loss and \$0.6 million gain for the three and nine months ended September 30, 2024 within the Change in fair value of assets and liabilities, net in its unaudited condensed consolidated statements of operations, respectively.

GABA Therapeutics, Inc.

GABA Therapeutics, Inc. ("GABA") is a California based biotechnology company focused on developing GRX-917 for anxiety, depression and a broad range of neurological disorders. The Company is deemed to have significant influence over GABA through its total ownership interest in GABA's equity, including the Company's investment in GABA's preferred stock, and the Company's noncontrolling representation on GABA's board of directors.

Common Stock Investment

The Company's investment in GABA's common stock was accounted for in accordance with the equity method.

In November 2020 the Company exercised its option to purchase additional shares of common stock of GABA at a price of approximately \$1.8 million pursuant to an Omnibus Amendment Agreement under which the Right of First Refusal and Co-Sale Agreement was amended. Pursuant to the amended Right of First Refusal and Co-Sale Agreement, the Company also has the option but not the obligation to purchase additional shares of common stock for up to \$2.0 million from the existing common shareholders.

The carrying value of the investment in GABA common stock was reduced to zero as of December 31, 2020 due to IPR&D charges with no alternative future use and remained zero as of September 30, 2024.

The Company's ownership of GABA common stock was 7.2% and 3.6% as of September 30, 2024 and December 31, 2023, respectively.

Preferred Stock Investment

The Company's investment in GABA's preferred stock did not meet the criteria for in-substance common stock. As such, the investment in GABA's preferred stock is accounted for under the measurement alternative under ASC 321.

In August 2019, GABA and the Company entered into the Preferred Stock Purchase Agreement (the "GABA PSPA"), whereby GABA issued shares of its Series A preferred stock to the Company at a price of approximately \$5.5 million. At closing, the Company had an overall ownership interest of over 20% in GABA and a noncontrolling representation on the board.

Pursuant to the GABA PSPA, the Company was obligated to purchase additional shares of Series A preferred stock for up to \$10.0 million with the same price per share as its initial investment, upon the achievement of specified contingent clinical development milestones, which were purchased in April and May 2021.

The completion of the Series A Preferred stock purchase in May 2021 was deemed to be a reconsideration event at which point GABA was no longer deemed a VIE as GABA now had sufficient equity at risk to finance its activities through the initial development period without additional subordinated financial support. Entities that do not qualify as a VIE are assessed for consolidation under the voting interest model ("VOE model"). Under the VOE model, the Company consolidates the entity if it determines that it, directly or indirectly, has greater than 50% of the voting shares and that other equity holders do not have substantive voting, participating or liquidation rights. While the Company holds greater than 50% of the outstanding equity interest of GABA, the Company does not have the power to control the entity. Concurrent with the exercise of the option, the Company executed a side letter with the other equity holders of GABA agreeing to forego the rights to additional seats on the board of directors, resulting in the Company lacking the ability to control the investee. The Company concluded that it does not have a controlling financial interest that would require consolidation under the VOE model and accounted for the investments in GABA preferred stock under the measurement alternative per ASC 321.

In May 2021, GABA and the Company entered into an Amendment to Preferred Stock Purchase Agreement (the "Amended GABA PSPA") under which the GABA PSPA was amended and shares of its Series A preferred stock were issued to the Company at a price of approximately \$0.6 million. Pursuant to the Amended GABA PSPA, the Company is obligated to purchase additional shares of Series A preferred stock from GABA for up to \$1.5 million with the same price per share as its initial investment upon the achievement of specified contingent clinical development milestones. In September 2022, pursuant to the Amended PSPA, GABA issued additional shares of its Series A preferred stock to the Company at a price of approximately \$0.6 million based on the achievement of certain development milestones.

As of September 30, 2024 the Company's remaining obligation to purchase additional shares of Series A preferred stock from GABA is for up to \$0.9 million at the same price per share as its initial investment upon the achievement of specified contingent milestones. In accordance with the Amended GABA PSPA, the Company also has the option but not the obligation to purchase the aforementioned additional shares of Series A preferred stock at any time prior to the achievement of any milestone at the same price per share as its initial investment. As of September 30, 2024 and December 31, 2023, the investment in GABA's preferred stock was recorded in Other Investments on the unaudited condensed consolidated balance sheets.

GABA's net losses attributable to the Company were determined based on the Company's ownership percentage of preferred stock in GABA and recorded to the Company's investments in GABA preferred stock. During the three months ended September 30, 2024 and 2023, the Company recognized its proportionate share of GABA's net loss of an immaterial amount and \$0.2 million, respectively, as losses from investments in equity method investees, net of tax on the unaudited condensed consolidated statements of operations. During the nine months ended September 30, 2024 and 2023, the Company recognized its proportionate share of GABA's net loss of \$2.0 million and \$3.2 million, respectively, as losses from investments in equity method investees, net of tax on the unaudited condensed consolidated statements of operations.

Innoplexus AG

Innoplexus is a technology company that provides "Data as a Service" and "Continuous Analytics as a Service" solutions that aims to help healthcare organizations leverage their technologies and expedite the drug development process across all stages—preclinical, clinical, regulatory and commercial. The Company first acquired investments in Innoplexus in August 2018.

As of December 31, 2020, the Company owned 35.0% of the common stock issued by Innoplexus. The Company had significant influence over Innoplexus through its noncontrolling representation on the investee's supervisory board. Accordingly, the Company's investment in Innoplexus' common stock was accounted for in accordance with the equity method. The Company's investment in Innoplexus' preferred stock did not meet the criteria for in-substance common stock. As such, the investment in Innoplexus' preferred stock was accounted for under the measurement alternative under ASC 321 as discussed below.

In February 2021, the Company entered into a Share Purchase and Assignment Agreement (the "Innoplexus SPA") to sell its shares of common and preferred stock held in Innoplexus to a current investor of Innoplexus (the "Purchaser") in exchange for an initial purchase price of approximately \$2.4 million. In addition, the Company is entitled to receive contingent payments based on the occurrence of subsequent equity transactions or liquidity events at Innoplexus as determined under the Innoplexus SPA.

Pursuant to the Innoplexus SPA, the Purchaser is required to hold a minimum number of shares equivalent to the number of shares purchased from the Company through December 31, 2026. In the event that the Purchaser is in breach of this requirement, the Purchaser is required to pay the Company an additional purchase price of approximately \$9.6 million. The transaction was accounted for as a secured financing as it did not qualify for sale accounting under ASC Topic 860, *Transfers and Servicing* (ASC 860), due to the provision under the Innoplexus SPA which constrained the Purchaser from its right to pledge or exchange the underlying shares and provided more than a trivial benefit to the Company. The initial proceeds from the transaction are reflected as a secured borrowing liability of \$2.4 million and \$2.4 million as of September 30, 2024 and December 31, 2023, which is included in Other liabilities in the Company's condensed consolidated balance sheets. The Company will continue to account for its investment in Innoplexus' common stock under the equity method of accounting and its investment in Innoplexus' preferred shares under the measurement alternative under ASC 321.

In addition, the Innoplexus SPA also provides the right for the Company to receive additional consideration with a maximum payment outcome of \$22.3 million should the equity value of Innoplexus exceed certain thresholds upon the occurrence of certain events. The Company concluded that this feature met the definition of a derivative which required bifurcation. As the probability of the occurrence of certain events defined in the Innoplexus SPA was less than remote, the Company concluded that the fair value of the embedded derivative ascribed to this feature was de minimis as of September 30, 2024.

The carrying value of the Company's investment in Innoplexus was zero as of September 30, 2024 and December 31, 2023.

The Company's ownership of Innoplexus common stock was 35.0% as of September 30, 2024 and December 31, 2023.

Summarized Financial Information

The following is a summary of financial data for investments accounted for under the equity method of accounting (in thousands):

Balance Sheets

	<u>September 30, 2024</u>		<u>December 31, 2023</u>	
	GABA		GABA	
Current assets	\$	181	\$	1,720
Total assets	\$	181	\$	1,720
Current liabilities	\$	2,330	\$	1,546
Total liabilities	\$	2,330	\$	1,546

Statements of operations

	<u>For the three months ended September 30, 2024</u>		<u>For the three months ended September 30, 2023</u>	
	GABA		GABA	
Loss from continuing operations	\$	(623)	\$	(238)
Net loss	\$	(623)	\$	(238)
	<u>For the nine months ended September 30, 2024</u>		<u>For the nine months ended September 30, 2023</u>	
	GABA		GABA	
Loss from continuing operations	\$	(2,597)	\$	(3,199)
Net loss	\$	(2,597)	\$	(3,199)

6. Notes Receivable

IntelGenx Technologies Corp.

As of September 30, 2024, considering relevant facts and circumstances, the Company has estimated the fair value of the various notes receivables with IntelGenx to be based on the fair value of the underlying collateral of the secured debt and the relative seniority of the debt. As the DIP Loan (as defined below) is the senior secured debt, the Company will apply the fair value of the underlying collateral first to the DIP loan with the residual fair value in excess of the DIP Loan (as defined below) principal and interest being applied to the IntelGenx Term Loan. The Initial Order is an event of default under the terms of the various notes receivables, and, accordingly, the notes receivables have all been reflected as short-term as of September 30, 2024.

IntelGenx Term Loan, as amended

In March 2021, the Company and IntelGenx entered into a loan agreement (the "Original Loan Agreement") under which the Company provided a loan to IntelGenx for an aggregate principal amount of \$2.0 million. In May 2021, the Company paid an additional advance of \$0.5 million as an additional term loan. In September 2021, the Company entered into an amended and restated loan agreement which, among other things, increased the principal amount of loans available to IntelGenx by \$6.0 million, for a total of up to \$8.5 million, collectively the "Initial Tranches". The additional \$6.0 million loan amount was funded via two separate \$3.0 million tranches in January 2022 and January 2023. The loan bears an annualized interest rate of 8% and such interest is accrued daily.

On January 1, 2023, the Company adopted ASU 2016-13, Financial Instruments – Credit Losses, as further discussed in Note 2, which resulted in a \$0.4 million increase to accumulated deficit and allowance for credit losses related to the IntelGenx loan.

In August 2023, the Company and IntelGenx entered into the first amendment to the amended and restated loan agreement (the "First Amendment") which, among other things, extended the maturity date from January 5, 2024 to January 5, 2025 and granted the Company additional security over any non-licensed intellectual property owned or controlled by IntelGenx.

Effective September 2023, the Company and IntelGenx entered into a second amendment to the amended and restated loan agreement (the “Second Amendment”) which, subject to obtaining certain shareholder approvals, entitles the Company to convert any portion of the outstanding and unpaid principal and accrued interest into common shares of IntelGenx at a conversion price per share of \$0.185 (the “Conversion Feature”). There are limits over the conversion of the IntelGenx Term Loan (as defined below), along with Initial Units, Subsequent Units, and Call Options Units into common shares.

In November 2023, upon shareholder approval, the Conversion Feature was effective. The Company evaluated this modification subject to accounting guidance in ASU 2022-02, Financial Instruments – Credit Losses and determined the Conversion Feature was considered the addition of a substantive conversion option and the modification is more than minor. Therefore, the Second Amendment was treated as an extinguishment of the existing loan and the issuance of a new convertible debt instrument. The IntelGenx Term Loan, as amended, meets the definition of a security and was accounted for under ASC 320. Pursuant to the remeasurement event, the Company was eligible and has elected the fair value option to account for its investment in the IntelGenx Term Loan. The Company believes that the fair value option better reflects the underlying economics of the loan. The Company recorded the new convertible debt instrument at its fair value of \$9.2 million in Convertible notes receivable – related party on the consolidated balance sheets. The IntelGenx Term Loan will be subsequently remeasured at each reporting date until settled or converted. The Company will recognize subsequent changes in fair value, including interest earned of the IntelGenx Term Loan in Change in fair value of assets and liabilities, net, a component of other income (expense), net in its consolidated statements of operations.

In March 2024, the Company and IntelGenx entered into the Third Amendment (together with the Original Loan Agreement, the First Amendment, and the Second Amendment, the “IntelGenx Term Loan”) pursuant to which the Company immediately provided an additional \$1.0 million term loan (“Tranche 1 Additional Term Loan”), and would provide an additional \$1.0 million term loan (“Tranche 2 Additional Term Loan”) contingent upon certain of the Company's clinical milestones. The IntelGenx Term Loan, as amended includes a conversion feature that allows for:

- a) any portion of the outstanding and unpaid principal under the Initial Tranches and/or the Tranche 1 Additional Term Loan into conversion shares (the “Conversion Shares”) at a conversion price per share of \$0.185 (the “Initial Conversion Price”);
- b) any accrued interest under the Initial Tranches into Conversion Shares at the Initial Conversion Price;
- c) any portion of the outstanding and unpaid principal under the Tranche 2 Additional Term Loan into Conversion Shares at a conversion price per share equal to the greater of: (1) the Initial Conversion Price; and (2) the 5-day volume-weighted average price (the “5-day VWAP”) of the Shares, less the maximum permitted discount under the applicable rules of the Stock Exchange, ending on the date immediately prior to the advancement of the Tranche 2 Additional Term Loan (the “Tranche 2 Conversion Price”); and
- d) any accrued interest under the Tranche 1 Additional Term Loan into Conversion Shares at the 5-day VWAP of the shares, less the maximum permitted discount under the applicable rules of the Stock Exchange, ending on the day that is the second business day before the day the Interest become due and payable (the “Interest Conversion Price” and, together with the Initial Conversion Price and the Tranche 2 Conversion Price, the “Conversion Price”), subject to Stock Exchange approval.

In connection with the Third Amendment, the Company received warrants to purchase up to 4 million shares of IntelGenx Common Shares at an exercise price of \$0.17, subject to certain adjustments and beneficial ownership limitations, which were recorded at fair value of \$0.4 million in Other investments held at fair value in the consolidated balance sheet, with a corresponding deferred vendor credit included in Other liabilities in the consolidated balance sheet. See Note 5 above for further discussion.

As a result of the Third Amendment, the Company recorded the Tranche 1 Additional Term Loan principal of \$1.0 million in Convertible notes receivable – related party on the consolidated balance sheet.

In May 2024, the Company paid the Tranche 2 Additional Term Loan and recorded the principal of \$1.0 million in Convertible notes receivable – related party on the consolidated balance sheet.

As of September 30, 2024, the Company estimated that the fair value of the underlying collateral of the secured debt is less than the principal and interest of the DIP Loan (as defined below). Accordingly, the Company determined that the fair value of the IntelGenx Term Loan is zero as of September 30, 2024. As of December 31, 2023, the \$8.6 million fair value of the amended IntelGenx Term Loan was recorded in Convertible notes receivable – related party on the consolidated balance sheet. For the three months ended September 30, 2024, the Company recorded \$7.0 million in Change in fair value of assets and liabilities, net for the change in fair value of IntelGenx Term Loan. For the nine months ended September 30, 2024, the Company recorded \$11.1 million in Change in fair value of assets and liabilities, net for the change in fair value of IntelGenx Term Loan.

For the three months ended September 30, 2024 and 2023, the Company recognized zero and \$0.2 million of interest income, respectively, associated with the IntelGenx Term Loan. For the nine months ended September 30, 2024 and 2023, the Company recognized zero and \$0.5 million of interest income, respectively, associated with the IntelGenx Term Loan.

IntelGenx Convertible Notes

On August 30, 2023, the Company and IntelGenx entered into the Subscription Agreement (as defined in Note 5), under which the Company paid IntelGenx \$2.2 million for 2,220 convertible debenture units (the "Initial Units"), with each convertible debenture unit consisting of:

- (i) \$1,000 principal amount convertible promissory notes (the "2023 Initial Notes") bearing interest at a rate of 12.0% per annum, payable quarterly in arrears beginning September 30, 2023, with all principal and accrued interest convertible into common shares of IntelGenx, at any time from the date that is six months following their issuance up to and including August 31, 2026 at a conversion price equal to \$0.185 per common share; and
- (ii) 5,405 common share purchase warrants of IntelGenx, each exercisable at an exercise price of \$0.26 per common share for a period of three years following their issuance.

Pursuant to the Subscription Agreement, the Company agreed to subscribe for an additional 750 convertible debenture units (the "2023 Subsequent Units") at a price of \$750,000 subject to obtaining certain shareholder approvals. The Subsequent Units contain the same terms as the Initial Units, with each Subsequent Unit consisting of (i) \$1,000 principal amount convertible promissory notes ("2023 Subsequent Notes") and (ii) 5,405 common share purchase warrants of IntelGenx ("2023 Subsequent Warrants").

The Company qualified for and elected to account for its investment in the convertible debenture units and call option under the fair value option. The Company believes that the fair value option better reflects the underlying economics of the convertible debenture units and call option. The convertible promissory notes related to the debenture units are accounted for at fair value under ASC 320 and recorded in Short-term convertible notes receivable - related party in the unaudited condensed consolidated balance sheet. The Company will recognize unpaid interest and subsequent changes in fair value of the convertible promissory notes related to the debenture units as Change in fair value of assets and liabilities, net, a component of other income (expense), net in the unaudited condensed consolidated statements of operations.

The Company determined that the initial aggregate fair value of its \$2.2 million investment was equal to the transaction price and recorded the 2023 Initial Notes at \$1.5 million and the 2023 Initial Warrants at \$0.7 million resulting in no initial gain or loss recognized in the consolidated statements of operations.

In November 2023, upon shareholder approval, the Company paid \$750,000 for the subscription of the 2023 Subsequent Units. The Company determined that the initial aggregate fair value of its \$0.8 million investment was equal to the transaction price and recorded the 2023 Subsequent Notes at \$0.6 million and the 2023 Subsequent Warrants at \$0.2 million resulting in no initial gain or loss recognized in the unaudited condensed consolidated statements of operations.

As of September 30, 2024, the Company has estimated the fair value of various notes receivables with IntelGenx based on the fair value of the underlying collateral of the secured debt. As the 2023 Initial Notes and 2023 Subsequent Notes are not secured by underlying collateral, the Company has determined the fair value of the 2023 Initial Notes and 2023 Subsequent Notes are zero, respectively, as of September 30, 2024. As of December 31, 2023, the fair value of the 2023 Initial Notes and 2023 Subsequent Notes were \$1.8 million and \$0.5 million, respectively, and recorded in Convertible notes receivable - related party in the unaudited condensed consolidated balance sheets.

For the three months ended September 30, 2024, the Company recognized \$0.9 million and \$0.3 million in Change in fair value of assets and liabilities, net relating to the 2023 Initial Notes and 2023 Subsequent Notes, respectively, in its unaudited condensed consolidated statements of operations. For the nine months ended September 30, 2024, the Company recognized \$1.8 million and \$0.5 million in Change in fair value of assets and liabilities, net relating to the 2023 Initial Notes and 2023 Subsequent Notes, respectively in its unaudited condensed consolidated statements of operations. For the three and nine months ended September 30, 2023, the company recognized \$0.1 million and \$0.1 million in Change in fair value of assets and liabilities, net relating to the 2023 Initial Notes, respectively, in its unaudited condensed consolidated statements of operations.

Debtor-in-Possession Loan

In May 2024, pursuant to the Initial Order authorizing the DIP Financing, the Company and IntelGenx entered into a senior secured super-priority, interim, non-revolving multiple draw credit facility ("DIP Loan") up to a maximum of CDN 8.0 million (USD \$5.9 million). The DIP Loan bears an annualized interest rate equal to the National Bank of Canada prime rate, which was 6.45% at September 30, 2024. The outstanding principal and interest of the DIP Loan is due and payable on the earlier of (i) September 30, 2024, (ii) the termination of the stay period in the CCAA proceedings, (iii) the CCAA proceedings are converted into a bankruptcy or receivership, (iv) implementation of a restructuring plan or sale of the IntelGenx business during the CCAA proceedings, or (v) an event of default as defined in the DIP Loan agreement.

The Company qualified for and elected to account for the DIP Loan under the fair value option. The Company believes that the fair value option better reflects the underlying economics of the DIP Loan. The DIP Loan is accounted for at fair value under ASC 825 and recorded in Short term notes receivable - related party, net in the unaudited condensed consolidated balance sheet. The Company will recognize

unpaid interest and subsequent changes in fair value of the DIP Loan Note as Change in fair value of assets and liabilities, net, a component of other income (expense), net in the unaudited condensed consolidated statements of operations.

As of September 30, 2024, IntelGenx has drawn CDN \$7.8 million (USD \$5.7 million) pursuant to the DIP Loan. As of September 30, 2024, the fair value of the DIP Loan was \$5.7 million and recorded in Short-term notes receivable - related party, net in the unaudited condensed consolidated balance sheets. For the three and nine months ended September 30, 2024, the Company recognized \$0.2 million gain and an immaterial loss in Change in fair value of assets and liabilities, net, respectively, relating to the DIP Loan in its unaudited condensed consolidated statements of operations.

The Company is committed to fund IntelGenx up to an additional CDN \$0.2 million (USD \$0.1 million) as of September 30, 2024. Accordingly, the Company recorded a liability for the remaining balance of the DIP Loan ("Subsequent DIP Loan Commitment"). The Company qualified for and elected to account for the Subsequent DIP Loan Commitment under the fair value option. The Company believes that the fair value option better reflects the underlying economics of the Subsequent DIP Loan Commitment. The Subsequent DIP Loan Commitment is accounted for at fair value under ASC 825 and recorded at fair value and is recorded in Other current liability in the unaudited condensed consolidated balance sheet. The Company will recognize changes in fair value of the contingent forward as Change in fair value of assets and liabilities, net, a component of other income (expense), net in the unaudited condensed consolidated statements of operations.

As of September 30, 2024, the fair value of the Subsequent DIP Loan Commitment was \$0.1 million and recorded in Other current liability in the unaudited condensed consolidated balance sheet. For the three and nine months ended September 30, 2024, the Company recognized a \$0.5 million gain and a \$0.5 million gain, respectively.

IntelGenx 2023 Term Loan Note

In December 2023, the Company and IntelGenx entered into a new term loan agreement under which the Company provided the aggregate principal amount of \$500,000 (the "2023 Term Loan Note"). The loan bears an annualized interest rate of 14.0% compounding monthly. Principal and interest outstanding shall be due and payable from proceeds of future IntelGenx fundraising. The outstanding principal and interest on the 2023 Term Loan Note is due and payable under the terms of the agreement.

The Company qualified for and elected to account for the 2023 Term Loan Note under the fair value option. The Company believes that the fair value option better reflects the underlying economics of the 2023 Term Loan Note. The IntelGenx 2023 Term Loan Note is accounted for at fair value under ASC 825 and recorded in Short-term notes receivable - related party, net in the consolidated balance sheet. The Company will recognize unpaid interest and subsequent changes in fair value of the IntelGenx 2023 Term Loan Note as Change in fair value of assets and liabilities, net, a component of other income (expense), net in the consolidated statements of operations.

As of September 30, 2024, the Company has estimated the fair value of various notes receivables with IntelGenx based on the fair value of the underlying collateral of the secured debt. As the 2023 Term Loan Note is not secured by underlying collateral, the Company has determined the fair value of the 2023 Term Loan Note is zero as of September 30, 2024. As of December 31, 2023, the 2023 Term Loan Note had a fair value of \$0.5 million and recorded in Short-term notes receivable - related party, net.

For the three and nine months ended September 30, 2024, the Company recognized a \$0.2 million loss and \$0.5 million loss, respectively in Change in fair value of assets and liabilities, net relating to the IntelGenx 2023 Term Loan Note in its unaudited condensed consolidated statements of operations.

7. Fair Value Measurement

The following table presents information about the Company's financial assets and liabilities that are measured at fair value on a recurring basis and indicates the fair value hierarchy of the valuation (in thousands):

	Fair Value Measurements as of September 30, 2024			
	Level 1	Level 2	Level 3	Total
Assets:				
Cash equivalents:				
Money market funds	\$ 829	\$ —	\$ —	\$ 829
Investment in securities at fair value:				
U.S. treasuries	—	51,358	—	51,358
U.S. government agencies	—	4,599	—	4,599
Other investments held at fair value	43,506	—	1,721	45,227
Short-term notes receivable - related party, net	—	—	5,700	5,700
	<u>\$ 44,335</u>	<u>\$ 55,957</u>	<u>\$ 7,421</u>	<u>\$ 107,713</u>
Liabilities:				
Other current liability	\$ —	\$ —	\$ 147	\$ 147
Contingent consideration liability - related parties	—	—	650	650
Contingent consideration liability	—	—	1,388	1,388
2018 convertible promissory note conversion option - related party	—	—	758	758
2018 convertible promissory note conversion option	—	—	1,239	1,239
	<u>\$ —</u>	<u>\$ —</u>	<u>\$ 2,796</u>	<u>\$ 2,796</u>
Fair Value Measurements as of December 31, 2023				
	Level 1	Level 2	Level 3	Total
Assets:				
Cash equivalents:				
Money market funds	\$ 56	\$ —	\$ —	\$ 56
Investment in securities at fair value:				
U.S. treasuries	—	67,119	—	67,119
Corporate notes/bonds	—	5,007	—	5,007
U.S. government agencies	—	37,097	—	37,097
Other investments held at fair value	83,701	—	6,124	89,825
Convertible notes receivable - related party	—	—	11,202	11,202
	<u>\$ 83,757</u>	<u>\$ 109,223</u>	<u>\$ 17,326</u>	<u>\$ 210,306</u>
Liabilities:				
Contingent consideration liability - related parties	\$ —	\$ —	\$ 620	\$ 620
Contingent consideration liability	—	—	1,637	1,637
2018 convertible promissory note conversion option	—	—	2,385	2,385
	<u>\$ —</u>	<u>\$ —</u>	<u>\$ 4,643</u>	<u>\$ 4,643</u>

Investment in securities at fair value

The Company elected the fair value option for the securities in the investment portfolio. The fair value is based on quoted market prices, when available. When a quoted market price is not readily available, the Company uses the market price from its last sale of similar assets. The cash and cash equivalents held by the Company are categorized as Level 1 investments as quoted market prices are readily available for these investments. All other investments in the investment portfolio are categorized as Level 2 investments as inputs utilized to fair value these securities are either directly or indirectly observable, such as the market price from the last sale of similar assets.

The Company purchases investment grade short-term debt securities which are rated by nationally recognized statistical credit rating organizations in accordance with its investment policy. This policy is designed to minimize the Company's exposure to credit losses and to ensure that adequate liquidity is maintained at all times to meet anticipated cash flow needs.

The unrealized gains and losses on the available-for-sale securities, represented by change in the fair value of the investment portfolio, is reported in other income (expense), net in the unaudited condensed consolidated statements of operations. Since the investment in the

available-for-sale securities are already measured at fair value, no separate credit losses would be recorded in the unaudited condensed consolidated financial statements.

For three months ended September 30, 2024 and 2023, the Company recognized a \$0.9 million and \$1.8 million gain, respectively, related to the change in fair value in its available for sale securities recorded as a Change in fair value of assets and liabilities, net in its unaudited condensed consolidated statements of operations. For nine months ended September 30, 2024 and 2023, the Company recognized a \$3.2 million and \$3.3 million gain, respectively, related to the change in fair value in its available for sale securities recorded as a Change in fair value of assets and liabilities, net in its unaudited condensed consolidated statements of operations.

Other investments held at fair value

COMPASS Pathways plc

As described in Note 5 above, pursuant to the August 2023 financing, the Company determined that it no longer had significant influence and accounted for its COMPASS investment at fair value under ASC 321 with any changes in fair value recorded as a Change in fair value of assets and liabilities, net in its unaudited condensed consolidated statements of operations. The Company determines the fair value of its COMPASS investment by taking the publicly available share price as of the balance sheet date multiplied by the number of shares the Company holds. There are no non-observable inputs in determining the fair value. For the three and nine months ended September 30, 2024, the Company recorded \$3.9 million and \$22.0 million of Change in fair value of assets and liabilities, net, respectively. For the three and nine months ended September 30, 2023, the Company recorded \$69.0 million and \$69.0 million of Change in fair value of assets and liabilities, net, respectively.

IntelGenx

As described in Note 5, the Company's investment in IntelGenx includes common shares, 2023 Initial Warrants, 2023 Subsequent Warrants, and 2024 Warrants, (the 2023 Initial Warrants, 2023 Subsequent Warrants, and 2024 Warrants are collectively referred to as the "Warrants"), and Call Option. The Company determined that the Warrants and the Call Option do not meet the definition of a derivative instrument under ASC 815. The Company has classified the common shares as Level 2 assets and the Warrants and the Call Option as Level 3 assets in the fair value hierarchy. The Warrants and Call Option are measured at fair value on a quarterly basis and any changes in the fair value will be recorded as Change in fair value of assets and liabilities, net, a component of other income (expense), net in the consolidated statements of operations.

As of September 30, 2024, considering relevant facts and circumstances, the Company has estimated zero fair value for the Warrants and the Call Option (Note 5).

The fair value of IntelGenx Common Shares, which is included in Other investments held at fair value in the consolidated balance sheet, was also zero as of September 30, 2024 and December 31, 2023 (Note 5).

As of December 31, 2023, the Warrants and Call Option were recorded at fair value utilizing the Black-Scholes option pricing model. The Black Scholes option pricing model is based on the estimated market value of the underlying IntelGenx Common Shares at the valuation measurement date, the remaining contractual term of the Warrants and Call Option, risk-free interest rates, expected dividends, and expected volatility of the price of the underlying IntelGenx Common Shares. The expected volatility is based on a peer group volatility which is a Level 3 input within the fair value hierarchy.

As of September 30, 2024, the fair value of the 2023 Initial Warrants, 2023 Subsequent Warrants, 2024 Warrants and Call Option were all zero (Note 5). As of December 31, 2023, the fair value of the 2023 Initial Warrants, the 2023 Subsequent Warrants and Call Option was \$0.7 million, \$0.2 million and \$5.2 million, respectively, and recorded in Other investments held at fair value in the unaudited condensed consolidated balance sheets.

The significant unobservable inputs that are included in the valuation of the Warrants and Call Option as of December 31, 2023 are (i) estimated market value of the underlying IntelGenx Common Shares of \$0.13, including discount for lack of marketability of 5% and (ii) volatility of 100% for the period.

An additional significant unobservable input that is included in the valuation of the Call Option as of December 31, 2023 is discount rate of 45.9% based on an assessment of IntelGenx credit risk and market yields of companies with similar credit risk.

IntelGenx notes receivable

As described in Note 6, the Company's notes receivable with IntelGenx include the IntelGenx Term Loan, the 2023 Initial Notes, the 2023 Subsequent Notes, the DIP Loan, and the 2023 Term Loan Note.

As of September 30, 2024, considering relevant facts and circumstances, the Company has estimated the fair value of the various notes receivables with IntelGenx based on the fair value of the underlying collateral of the secured debt and the relative seniority of the debt. As the DIP loan is the senior secured debt, the Company will apply the fair value of the underlying collateral first to the DIP loan with the residual fair value in excess of the DIP Loan principal and interest being applied to the IntelGenx Term Loan. The Company has estimated the fair value of the underlying collateral, which includes the fair value of the intangible assets which was determined based on probability

adjusted forecasted revenue and expenses and a discount rate of 12.5%. As of September 30, 2024, the fair value of the DIP Loan was \$5.7 million and recorded in Short-term notes receivable - related party, net in the unaudited condensed consolidated balance sheets. As the 2023 Initial Notes, 2023 Subsequent Notes, and the 2023 Term Loan Note (collectively the "IntelGenx Unsecured Debt") are not secured by the underlying collateral, the Company has determined the fair value of IntelGenx Unsecured Debt to be zero as of September 30, 2024.

IntelGenx subsequent DIP loan commitment

As described in Note 6, the Company is committed to fund up to an additional CDN \$0.2 million (USD \$0.1 million) pursuant to the DIP Loan. For the Subsequent DIP Loan Commitment, the Company estimated the fair value based on the present value of the estimated net fair value of the Subsequent DIP Loan Commitment based on expected future payments pursuant to the DIP Loan.

Beckley Psytech

Under the Beckley Psytech SSA, the Company will have the right to receive Additional Warrants to purchase Series C Shares in the event Beckley Psytech issues equity or equity linked securities pursuant to a deferred equity arrangement in connection with a prior acquisition made by Beckley Psytech. The Company determined that the Additional Warrants meet the definition of a derivative instrument under ASC 815 and recorded the Additional Warrants at fair value with subsequent changes in fair value being reflected through the condensed consolidated statement of operations in the Change in fair value of assets and liabilities, net. The Additional Warrants have a fair value of \$1.7 million as of September 30, 2024.

The significant unobservable inputs that are included in the valuation of the Additional Warrants as of September 30, 2024 are (i) probability of issuances under the deferred equity arrangement of 50%-80%, and (ii) volatility of 90%.

Contingent consideration liability – related parties

The contingent consideration liability—related parties in the table above relates to milestone and royalty payments in connection with the 2018 acquisition of Perception Neuroscience Holdings, Inc. ("Perception") and InnarisBio, Inc. ("InnarisBio"). The fair value of the contingent consideration liability—related parties was determined based on significant inputs not observable in the market, which represent Level 3 measurements within the fair value hierarchy. The fair value of the contingent milestone and royalty liabilities was estimated based on the discounted cash flow valuation technique. The technique considered the following unobservable inputs:

- the probability and timing of achieving the specified milestones and royalties as of each valuation date,
- the probability of executing the license agreement,
- the expected first year of revenue, and
- market-based discount rates.

Perception

The fair value of the Perception contingent milestone and royalty liabilities could change in future periods depending on prospects for the outcome of R-Ketamine milestone meetings with the FDA or other regulatory authorities, and whether the Company realizes a significant increase or decrease in sales upon commercialization. The most significant assumptions in the discounted cash flow valuation technique that impacts the fair value of the milestone contingent consideration are the projected milestone timing and the probability of the milestone being met. Further, significant assumptions in the discounted cash flow that impacts the fair value of the royalty contingent consideration are the projected revenue over ten years, the timing of royalties on commercial revenue, and the probability of success rate for a commercial R-Ketamine product. The valuations as of September 30, 2024 and December 31, 2023, respectively, used inputs that were unobservable inputs with the most significant being the discount rates for royalties on projected commercial revenue and clinical milestones and probability of success estimates over the following ten years, which represent Level 3 measurements within the fair value hierarchy.

The fair value of the contingent milestone and royalty liabilities for Perception was estimated to be \$0.7 million and \$0.6 million as of September 30, 2024 and December 31, 2023, respectively.

The fair value of the Perception contingent consideration liability – related parties was calculated using the following significant unobservable inputs:

Valuation Technique	Significant Unobservable Inputs	September 30, 2024	December 31, 2023
		Input Range	Input Range
Discounted cash flow	Milestone contingent consideration:		
	Discount rate	11.3%	13.5%
	Probability of the milestone	28.0%	28.0%
Discounted cash flow with Scenario-Based Method	Royalty contingent consideration:		
	Discount rate for royalties	11.0%-12.7%	13.0% - 14.2%
	Discount rate for royalties on milestones	11.0%-12.7%	13.0% - 14.2%
	Probability of success rate	28.0%	13.4% - 28.0%

InnarisBio

The fair value of the contingent milestone and royalty liabilities for InnarisBio was immaterial as of September 30, 2024 and December 31, 2023, respectively.

Contingent Consideration Liability

The contingent consideration liability in the table above relates to milestone payments in connection with the acquisition of DemeRx IB and TryptageniX. The fair value of the contingent consideration liability was determined based on significant inputs not observable in the market, which represent Level 3 measurements within the fair value hierarchy. The fair value of the contingent milestone and royalty liabilities was estimated based on the discounted cash flow valuation technique. The technique considered the following unobservable inputs:

- market-based discount rates, and
- the probability and timing of achieving the specified milestones as of each valuation date.

DemeRx

In October 2023, the Company and DemeRx, Inc. entered into a Stock Purchase and Framework Agreement which resulted in the Company's acquisition of DemeRx, Inc.'s equity ownership of DemeRx IB (the "Stock Purchase"), in exchange for consideration that included, among other items, earn-out consideration of up to an additional \$8.0 million payable to DemeRx, Inc. ("DemeRx") contingent upon the achievement of certain development milestones directly related to DemeRx IB's oral capsule formulation of ibogaine ("DMX-1002") program. The earn-out consideration was recorded at fair value in contingent consideration as a liability under ASC 480 and the fair value is adjusted each quarter and reflected in other income and expense in the statement of operations.

The fair value of the DemeRx contingent milestone could change in future periods depending on prospects for the outcome of ibogaine milestone meetings with the FDA or other regulatory authorities. The most significant assumptions in the discounted cash flow valuation technique that impacts the fair value of the milestone contingent consideration are the projected milestone timing and the probability of the milestone being met. The valuations as of September 30, 2024 and December 31, 2023 used inputs that were unobservable inputs with the most significant being the discount rates and the probability of success of certain clinical milestones, which represent Level 3 measurements within the fair value hierarchy.

The fair value of the contingent milestone for DemeRx was estimated to be \$1.2 and \$1.4 million as of September 30, 2024 and December 31, 2023.

The fair value of the DemeRx contingent consideration liability – related parties was calculated using the following significant unobservable inputs:

Valuation Technique	Significant Unobservable Inputs	September 30, 2024	December 31, 2023
		Input Range	Input Range
Discounted cash flow	Milestone contingent consideration:		
	Discount rate	11.3%-11.4%	13.9%
	Probability of the milestone	20.0% - 25.0%	20.0% - 25.0%

TryptageniX

The fair value of the contingent liability for TryptageniX was estimated to be \$0.2 million and \$0.2 million as of September 30, 2024, and December 31, 2023, respectively. The contingent liability is comprised of R&D milestone success fee payments and royalties payments. The fair value of the success fee liability was estimated based on the scenario-based method within the income approach. The fair value of the success fee liability for TryptageniX was determined based on significant unobservable inputs, including the discount rate, estimated probabilities of success, and timing of achieving certain clinical milestones. The fair value of the royalties liability was determined to be de minimis as the products are in the early stages of development. The Company will continue to assess the appropriateness of the fair value of the contingent liability as the products continue through development.

Convertible Promissory Note

As described in Note 11, in December 2023 and April 2024, the Company entered into subscription agreements with each of a noteholder and a related party noteholder, respectively (together the "Subscription Agreement") whereby each of the noteholder and the related party noteholder exchanged their ATAI Life Sciences AG notes (the "Old AG Notes") into the same principal amount of new convertible notes issued by ATAI Life Sciences N.V. (the "New NV Notes"). The exchange resulted in the New NV Notes conversion option no longer meeting the equity classification criteria. Accordingly, at the time of the exchange modification, the Company bifurcated the conversion option and reclassified the conversion option fair value from equity to a liability and is included in Short-term convertible promissory notes and derivative liability and Short-term convertible promissory notes and derivative liability - related party, respectively, in the unaudited condensed consolidated balance sheets. The conversion option is measured at fair value on a quarterly basis and any changes in the fair value will be recorded as Change in fair value of assets and liabilities, net, a component of other income (expense), net in the unaudited condensed consolidated statements of operations. For the three and nine months ended September 30, 2024, the Company recognized a loss of \$1.0 million and \$3.9 million, respectively, as a result of the change in fair value of the New NV Notes.

The conversion option fair value was estimated utilizing the Black-Scholes option pricing model. The Black Scholes option pricing model is based on the estimated market value of the underlying common stock at the valuation measurement date, the remaining contractual term of the Conversion Feature, risk-free interest rates, expected dividends, and expected volatility of the price of the underlying common stock. The expected volatility is based upon the historical volatility of daily lognormal returns on atai shares, which is a Level 3 input within the fair value hierarchy.

The significant unobservable input that is included in the valuation of the Conversion Feature as of September 30, 2024 and December 31, 2023 is volatility of 75.0% and 78.6%, respectively.

The following table provides a roll forward of the aggregate fair values of the Company's financial instruments described above, for which fair value is determined using Level 3 inputs (in thousands):

	IntelGenx Debt ⁽¹⁾	IntelGenx Investments Held at Fair Value ⁽²⁾	IntelGenx Subsequent DIP Loan Commitment	Contingent Consideration Liability - Related Parties ⁽³⁾	Contingent Consideration Liability ⁽⁴⁾	New NV Notes Conversion Feature	Beckley Psytech Additional Warrants
Balance as of December 31, 2023	\$ 11,202	\$ 6,124	\$ —	\$ 620	\$ 1,637	\$ 2,385	\$ —
Initial fair value of instrument	988	420	—	—	—	—	2,645
Change in fair value, including interest	1,712	1,429	—	(13)	(231)	1,734	—
Balance as of March 31, 2024	\$ 13,902	\$ 7,973	\$ —	\$ 607	\$ 1,406	\$ 4,119	\$ 2,645
Initial fair value of instrument	3,425	—	680	—	—	3,590	—
Change in fair value, including interest	(7,455)	(7,973)	—	(27)	(32)	(4,780)	720
Balance as of June 30, 2024	\$ 9,872	\$ —	\$ 680	\$ 580	\$ 1,373	\$ 2,929	\$ 3,364
Initial fair value of instrument	3,830	—	—	—	—	—	—
Additional Warrants received	—	—	—	—	—	—	(1,538)
Change in fair value, including interest	(8,002)	—	(533)	70	15	(932)	(105)
Balance as of September 30, 2024	\$ 5,700	\$ —	\$ 147	\$ 650	\$ 1,388	\$ 1,997	\$ 1,721

	Convertible notes receivable - related party	IntelGenx 2023 Initial Warrants	Contingent Consideration Liability - Related Parties
Balance as of December 31, 2022	\$ —	\$ —	\$ 953
Initial fair value of instrument	—	—	—
Change in fair value	—	—	(35)
Extinguishment of liability	—	—	—
Balance as of March 31, 2023	\$ —	\$ —	\$ 918
Initial fair value of instrument	—	—	—
Change in fair value	—	—	(76)
Extinguishment of liability	—	—	—
Balance as of June 30, 2023	\$ —	\$ —	\$ 842
Initial fair value of instrument	1,497	724	—
Change in fair value, including interest	22	—	58
Extinguishment of liability	—	—	—
Balance as of September 30, 2023	\$ 1,519	\$ 724	\$ 900

- (1) Includes the IntelGenx Term Loan, the 2023 Initial Notes, the 2023 Subsequent Notes, the DIP Loan, and the 2023 Term Loan Note.
- (2) Includes the 2023 Initial Warrants, the 2023 Subsequent Warrants, the 2024 Warrants, and the Call Option Units.
- (3) Includes Perception milestone based contingent consideration liability.
- (4) Includes contingent consideration liability related to DemeRx IB Stock Purchase and contingent consideration liability related to the TryptageniX research and development milestone success fee payments and royalties payments.

8. Prepaid Expenses and Other Current Assets

Prepaid expenses consist of the following (in thousands):

	September 30, 2024	December 31, 2023
Prepaid research and development related expenses	\$ 4,208	\$ 1,822
Tax receivables	1,253	1,752
Prepaid insurance	1,074	1,410
Other	919	846
Total	\$ 7,454	\$ 5,830

9. Accrued Liabilities

Accrued liabilities consist of the following (in thousands):

	September 30, 2024	December 31, 2023
Accrued accounting, legal, and other professional fees	\$ 4,540	\$ 5,468
Accrued external research and development expenses	3,657	3,031
Accrued payroll	2,350	4,941
Other liabilities	1,114	1,101
Taxes payable	182	715
Accrued restructuring costs	110	—
Total	\$ 11,953	\$ 15,256

10. Leases

The Company leases certain office space under long-term operating leases that expire at various dates through 2028. The Company generally has options to renew lease terms on its facilities, which may be exercised at the Company's sole discretion. The Company evaluates renewal and termination options at the lease commencement date to determine if it is reasonably certain to exercise the option and has concluded on all operating leases that it is not reasonably certain that any options will be exercised. The weighted-average remaining lease term for the Company's operating leases as of September 30, 2024 was 3.6 years. The weighted-average discount rate for the Company's operating leases as of September 30, 2024 was 12.8%.

ROU assets and lease liabilities related to the Company's operating leases are as follows (in thousands):

	Balance Sheet Classification	September 30, 2024	December 31, 2023
Right-of-use assets	Operating lease right-of-use asset, net	\$ 1,032	\$ 1,223
Current lease liabilities	Current portion of lease liability	257	275
Non-current lease liabilities	Non-current portion of lease liability	808	990

Expenses related to leases is recorded on a straight-line basis over the lease term. The following table summarizes lease costs by component for the three and nine months ended September 30, 2024 and 2023 (in thousands):

Lease Cost Components	Statement of Operations Classification	For the Three Months Ended September 30,		For the Nine Months Ended September 30,	
		2024	2023	2024	2023
Operating lease cost	Operating expenses: General and administrative	\$ 87	\$ 120	\$ 317	\$ 431
Short-term lease cost	Operating expenses: General and administrative	33	102	110	384
Total lease cost		\$ 120	\$ 222	\$ 427	\$ 815

Future minimum commitments under all non-cancelable operating leases are as follows (in thousands):

Year Ended	
2024 (excluding nine months ended September 30, 2024)	\$ 94
2025	375
2026	375
2027	375
2028	125
Total lease payments	1,344
Less: Imputed interest	(279)
Present value of lease liabilities	\$ 1,065

Supplemental cash flow information related to the Company's operating leases for the nine months ended September 30, 2024 and 2023 are as follows (in thousands):

	2024	2023
Cash paid for amounts included in the measurement of lease liabilities:		
Operating cash flows from operating leases	\$ 326	\$ 304
Right-of-use assets obtained in exchange for new operating lease liabilities	\$ —	\$ 1,356

11. Debt

Convertible Promissory Notes

2018 Convertible Promissory Notes—Related Parties

During November 2018 and October 2020, the Company executed a terms and conditions agreement (the "Convertible Note Agreement") under which it would issue convertible promissory notes to investors. An investor would become a party to the Convertible Note Agreement and would be issued a convertible promissory note by executing and delivering a subscription form. In November 2018 and October 2020, certain investors subscribed to the Convertible Note Agreement and the Company issued convertible promissory notes in the aggregate principal amount of €1.0 million or \$1.2 million (collectively, the "2018 Convertible Notes"). The 2018 Convertible Notes are non-interest-bearing, unsecured and are due and payable on September 30, 2025, unless previously redeemed, converted, purchased or cancelled (the "Maturity Date"). Each 2018 Convertible Note has a face value of €1 and is convertible into one share of ATAI Life Sciences AG upon the payment of €17.00. Conversion rights may be exercised by a noteholder at any time prior to maturity, except during certain periods subsequent to the consummation of the IPO. The 2018 Convertible Notes may be declared for early redemption by the noteholders upon occurrence of specified events of default, including payment default, insolvency and a material adverse change in the Company's business, operations or financial or other condition. Upon early redemption, the conversion right with respect to the 2018 Convertible Notes may no longer be exercised.

The Company concluded that both the embedded conversion feature, which is exercisable by the investor at any time during the maturity, and the contingent put option, which would trigger upon the occurrence of an event of default of the 2018 Convertible Notes, do not meet the criteria to be bifurcated and separately accounted for as derivatives and the notes were recorded net of discount and issuance costs, or a

reduction to the carrying value of the notes issued in November 2018, with a corresponding adjustment to additional paid in capital. The discount is being amortized using the effective interest method over the period from the respective date of issuance to the Maturity Date.

The Company determined that the October 2020 notes were issued in exchange for services previously provided by the Company's founders and other shareholders and were fully vested and non-forfeitable upon issuance. These instruments were therefore considered stock-based compensation awards to non-employees, and the instruments were initially measured and recorded at their grant date fair value based on a Black-Scholes option pricing model. The fair value of the October 2020 notes exceeded the principal amount that will be due at maturity. Therefore, at initial recognition, the October 2020 notes were accounted for as convertible debt issued at a substantial premium, such that the face value of the note is recorded as a liability and the premium was recorded as paid-in capital.

Exchange of 2020 Convertible Promissory Notes

In November 2023 and April 2024, a noteholder and a related party noteholder, respectively, of the October 2020 notes and ATAI Life Sciences AG executed exchange agreements (together the "Exchange Agreements") where each noteholder agreed to exchange its 2020 convertible notes issued by ATAI Life Sciences AG ("Old AG Notes") into the same principal amount of new convertible notes issued by ATAI Life Sciences NV ("New NV Notes"). The New NV Notes are non-interest-bearing, unsecured and are due and payable on September 30, 2025, unless previously redeemed, converted, purchased or cancelled (the "Maturity Date"). Each New NV Note has a face value of €1 and is convertible into sixteen shares of ATAI Life Sciences NV upon the payment of €17.00. Conversion rights may be exercised by a noteholder at any time prior to maturity. The New NV Notes may be declared for early redemption by the noteholders upon occurrence of specified events of default, including payment default, insolvency and a material adverse change in the Company's business, operations or financial or other condition. Upon early redemption, the conversion right with respect to the New NV Notes may no longer be exercised.

In December 2023 and April 2024, the Company entered into subscription agreements with each of the noteholder and related party noteholder, respectively (together the "Subscription Agreements") and exchanged their respective Old AG Notes into New NV Notes. The Company determined that the note exchanges were modifications of the debt. The Exchange Agreements and Subscription Agreements resulted in the New NV Notes conversion option no longer meeting the equity classification criteria. Accordingly, at the time of the Exchange Agreements modification, the Company bifurcated the conversion option and reclassified the conversion option fair value from equity to a liability and is included in Convertible promissory notes and derivative liability in the unaudited condensed consolidated balance sheet. The conversion option is measured at fair value on a quarterly basis and any changes in the fair value will be recorded as Change in fair value of assets and liabilities, net, a component of other income (expense), net in the unaudited condensed consolidated statements of operations. For the three and nine months ended September 30, 2024, the Company recognized a gain of \$1.0 million \$3.9 million, respectively, as a result of the change in fair value of the New NV Notes.

As of September 30, 2024 and December 31, 2023, the fair value of the Convertible promissory note and derivative liability was \$1.5 million and \$2.7 million, respectively. As of September 30, 2024, the fair value of the Short-term convertible promissory note and derivative liability - related party was \$0.9 million. As of December 31, 2023, the carrying amount and fair value amount of the 2018 Convertible Notes was \$0.2 million and \$1.5 million, respectively.

Term Loan

Hercules Loan and Security Agreement

In August 2022 (the "Closing Date"), the Company and certain subsidiaries, as guarantors, and Hercules Capital, Inc., a Maryland corporation ("Hercules"), entered into a Loan and Security Agreement the "Initial Hercules Loan Agreement". The Initial Hercules Loan Agreement provides for term loans in an aggregate principal amount of up to \$175.0 million under multiple tranches (as amended by that certain First Amendment to Loan and Security Agreement, dated as of March 13, 2023, the "First Amendment", that Second Amendment to Loan and Security Agreement, dated as of May 26, 2023, the "Second Amendment," and that Third Amendment to Loan and Security Agreement, dated August 14, 2024, the "Third Amendment," and collectively, the "2022 Term Loan Facility").

On May 26, 2023, the Company, ATAI Life Sciences AG ("ATAI AG" and together with the Company, the "Borrowers") and certain subsidiary guarantors of the Company (collectively, the "Subsidiary Guarantors") entered into the Second Amendment with the several banks and other financial institutions or entities from time to time parties to the Hercules Loan Agreement, defined below, (collectively, the "Lenders") and Hercules, in its capacity as administrative agent and collateral agent for itself and for the Lenders (the "Agent") which amended that certain Loan and Security Agreement, dated August 9, 2022 (as amended by the First Amendment, the "Existing Loan Agreement," and as amended by the Second Amendment, the "Hercules Loan Agreement") to, among other things, (i) extend the availability of Tranche 1B of \$10.0 million, from May 1, 2023, under the Existing Loan Agreement, to November 15, 2024, (ii) extend the availability of Tranche 1C of \$15.0 million, from December 15, 2023, under the Existing Loan Agreement, to December 15, 2024, (iii) provide Tranche 1D of \$20.0 million, available upon the earlier of (x) the full draw of Tranche 1C and (y) the expiration of Tranche 1C availability, through February 15, 2025, (iv) extend the availability of Tranche 2 of \$15.0 million, from June 30, 2024, under the Existing Loan Agreement, subject to certain conditions under the Hercules Loan Agreement, to the earlier of (x) the full draw of Tranche 1D and (y) the expiration of Tranche 1D availability, through March 15, 2025, subject to the Tranche 2 Draw Test, (v) extend the timeline to achieve the second amortization extension condition, from June 30, 2024, in the Existing Loan Agreement, to December 15, 2024, (vi)

amend the Tranche 2 Draw Test, satisfaction of which is a condition to draw Tranche 2 under the Hercules Loan Agreement and (vii) extend the financial covenant commencement date, from the later of (x) July 1, 2023, and (y) the date that the outstanding debt under the facility is equal to or greater than \$40.0 million, in the Existing Loan Agreement, to the later of (x) May 1, 2024, and (y) the date that the outstanding debt under the facility is equal to or greater than \$30.0 million, provided, that the financial covenant is waived if the Company has a market capitalization of at least \$550.0 million.

On August 14, 2024 (the “Third Amendment Date”), the Borrowers and certain Subsidiary Guarantors” entered into the Third Amendment with the Lenders and Hercules, in its capacity as the Agent, which amended that certain Loan and Security Agreement, dated August 9, 2022 (as amended by the First Amendment, the Second Amendment and the Third Amendment, the “2022 Term Loan Agreement”) to, among other things, (i) provide Tranche 1B of \$5.0 million on the Third Amendment Date, (ii) reduce the remainder of available Tranche 1 to \$25.0 million, and extend the availability thereof (x) with respect to Tranche 1C, to be available after the Third Amendment Date until March 31, 2025, and (y) with respect to Tranche 1D, to be available upon the earlier to occur of (1) March 31, 2025 and (2) full borrowing of Tranche 1C, until June 30, 2025, (iii) increase Tranche 2 to \$30.0 million, and extend the availability thereof to be available upon the earlier to occur of (1) June 30, 2025, and (2) full borrowing of Tranche 1D, until September 30, 2025, subject to the Tranche 2 Draw Test, (iv) extend the availability of Tranche 3 of \$100.0 million, through March 31, 2026, available subject to lender’s investment committee approval, (v) extend the amortization date to September 1, 2025, and extend the timeline to achieve the second amortization extension condition, to June 30, 2025, upon the occurrence of which the amortization date may be extended to March 1, 2026, (vi) amend the financial covenant to commence on October 1, 2024, and require that so long as the Company’s market capitalization is less than \$550.0 million, Borrowers shall maintain qualified cash equal to at least 50% of the sum of (x) the amount of outstanding debt under the facility plus (y) Qualified Cash A/P Amount (as defined in the Agreement), or upon the occurrence of certain conditions, 70% of the sum of (x) the amount of outstanding debt under the facility plus (y) Qualified Cash A/P Amount, and (vii) reduce the interest rate to equal the greater of (x) 9.05% or (y) prime rate plus 4.30% (or, upon achieving certain conditions, (y) shall equal prime rate plus 4.05%).

The 2022 Term Loan Facility will mature on August 1, 2026 (the “Maturity Date”), which may be extended until February 1, 2027 if the Company raises at least \$175.0 million of unrestricted new net cash proceeds from certain permitted sources after the Closing Date and prior to June 30, 2025, and satisfies certain other specified conditions (the “Extension Condition Two”). The outstanding principal balance of the 2022 Term Loan Facility bears interest at a floating interest rate per annum equal to the greater of either (i) the prime rate as reported in the Wall Street Journal plus 4.30% and (ii) 9.05%; provided, that if the Extension Condition Two is satisfied, the rate of interest in the foregoing clause (i) is prime rate as reported in The Wall Street Journal plus 4.05%. Accrued interest is payable monthly following the funding of each term loan advance. The Company may make payments of interest only, without any loan amortization payments, until September 1, 2025, which date may be extended to (i) March 1, 2026 if Extension Condition Two is achieved. At the end of the interest only period, the Company is required to begin repayment of the outstanding principal of the 2022 Term Loan Facility in equal monthly installments.

The 2022 Term Loan Agreement contains customary closing and commitment fees, prepayment fees and provisions, events of default and representations, warranties and affirmative and negative covenants, including a financial covenant requiring the Company to maintain certain levels of cash in accounts subject to a control agreement in favor of the Agent (the “Qualified Cash”) at all times commencing from the Closing Date, which includes a cap on the amount of cash that can be held by, among others, certain of our foreign subsidiaries in Australia and the United Kingdom. In addition, the financial covenant under the 2022 Term Loan Agreement requires that beginning on October 1, 2024, the Company shall maintain Qualified Cash in an amount no less than the sum of (1) 50% of the outstanding amount under the 2022 Term Loan Facility, and (2) the amount of the Borrowers’ and Subsidiary Guarantors’ accounts payable that have not been paid within 180 days from the invoice date of the relevant account payable, subject to certain exceptions; provided, upon the occurrence of certain conditions, the Company shall at all times maintain Qualified cash in an amount no less than the sum of (1) 70% of the outstanding amount under the 2022 Term Loan Facility, and (2) the amount of the Borrowers’ and Subsidiary Guarantors’ accounts payable that have not been paid within 180 days from the invoice date of the relevant account payable, subject to certain exceptions; provided, further, that the financial covenant shall not apply on any day that the Company’s market capitalization is at least \$550.0 million measured on a consecutive 10-business day period immediately prior to such date of measurement and tested on a daily basis. Upon the occurrence of an event of default, including a material adverse effect, subject to certain exceptions, on the Company and ATAI AG’s, taken together, business, operations, properties, assets or financial condition, and subject to any specified cure periods, all amounts owed by the Company may be declared immediately due and payable by the Lenders. As of September 30, 2024, the Company was in compliance with all applicable covenants under the 2022 Term Loan Agreement.

In addition, the Company is required to make a final payment fee (the “End of Term Charge”) upon the earlier of (i) the Maturity Date, (ii) the date that the Company prepays, in full or in part, the principal balance of the 2022 Term Loan Facility, or (iii) the date that the outstanding balance of the 2022 Term Loan Facility becomes due and payable. The End of Term Charge is 6.95% of the aggregate original principal amount of the term loans so repaid or prepaid under the 2022 Term Loan Agreement.

The Company may, at its option, prepay the term loans in full or in part, subject to a prepayment penalty equal to (i) 2.00% of the principal amount prepaid if the prepayment occurs on or prior to the first anniversary of the Closing Date, (ii) 1.0% of the principal amount prepaid if the prepayment occurs after the first anniversary and on or prior to the second anniversary of the Closing Date, and (iii) 0.5% of the principal amount prepaid if the prepayment occurs after the second anniversary and prior to the Maturity Date.

The Company incurred financing expenses related to the 2022 Term Loan Agreement, which are recorded as an offset to long-term debt on the Company's consolidated balance sheets. These deferred financing costs are being amortized over the term of the debt using the effective interest method, and are included in other income, net in the Company's unaudited condensed consolidated statements of operations. During the three months ended September 30, 2024 and 2023, interest expense included \$0.1 million and \$0.1 million of amortized deferred financing costs related to the 2022 Term Loan Facility. During the nine months ended September 30, 2024 and 2023, interest expense included \$0.3 million and \$0.3 million of amortized deferred financing costs related to the 2022 Term Loan Facility.

Outstanding debt obligations are as follows (in thousands):

	September 30, 2024	December 31, 2023
Principal amount	\$ 20,000	\$ 15,000
End of the term charge	1,042	1,042
Less: unamortized issuance discount	(144)	(204)
Less: unamortized issuance costs	(60)	(84)
Less: unamortized end of term charge	(502)	(707)
Net carrying amount	20,336	15,047
Less: current maturities	—	—
Long-term debt, net of current maturities and unamortized debt discount and issuance costs	<u>\$ 20,336</u>	<u>\$ 15,047</u>

The fair value of the outstanding debt obligations under the 2022 Term Loan Facility was \$20.4 million as of September 30, 2024, and \$16.2 million as of December 31, 2023, respectively. The fair value of the debt obligations under the 2022 Term Loan Facility represent Level 3 measurements within the fair value hierarchy.

12. Common Stock

All common shareholders have identical rights. Each common share entitles the holder to one vote on all matters submitted to the shareholders for a vote.

All holders of common shares are entitled to receive dividends, as may be declared by the Company's board of supervisory directors. Upon liquidation, common shareholders will receive distribution on a pro rata basis. As of September 30, 2024 and December 31, 2023, no cash dividends have been declared or paid.

In November 2022, the Company entered into an Open Market Sale Agreement with Jefferies LLC ("Jefferies"), pursuant to which the Company may issue and sell its common shares, nominal value €0.10 per share, having an aggregate offering price of up to \$150,000,000, from time to time through an "at the market" equity offering program under which Jefferies will act as sales agent. There have been no sales under the Sales Agreement through September 30, 2024.

13. Stock-Based Compensation

atai Equity Incentive Plans

The Company has options and restricted stock units ("RSUs") outstanding under various equity incentive plans, including the 2020 Incentive Plan, 2021 Incentive Plan, defined below, and HSOP Plan, which are further described in Note 13 of the Company's audited consolidated financial statements included in the Company's Annual Report on Form 10-K filed with the SEC on March 28, 2024.

As of September 30, 2024, there were no shares available for future grants under the 2020 Incentive Plan and any shares subject to outstanding options originally granted under the 2020 Equity Incentive Plan that terminate, expire or lapse for any reason without the delivery of shares to the holder thereof shall become available for issuance pursuant to the atai Life Sciences N.V. 2021 Incentive Award Plan (the "2021 Incentive Plan").

Shares that are expired, terminated, surrendered, or canceled without having been fully exercised will be available for future awards. As of September 30, 2024, 40,791,437 shares were available for future grants under the 2021 Incentive Plan.

As of September 30, 2024, 257,419 HSOP Options were available for future grants under the HSOP Plan.

Stock Option activity under 2020 Incentive Plan and 2021 Incentive Plan

The stock options outstanding noted below consist primarily of both service and performance-based options to purchase common stock. These stock options have a five-year or ten-year contractual term. These awards are subject to the risk of forfeiture until vested by virtue of continued employment or service to the Company.

The following is a summary of stock option activity from December 31, 2023 to September 30, 2024:

	Number of Options	Weighted-Average Exercise Price	Weighted-Average Remaining Contractual Term (Years)	Aggregate Intrinsic Value
Outstanding as of December 31, 2023	39,066,454	\$ 4.62	5.56	\$ 6,294
Granted	10,783,294 ⁽¹⁾	1.75	—	—
Exercised	(322,857)	2.06	—	—
Cancelled or forfeited	(7,589,498)	5.35	—	—
Outstanding as of September 30, 2024	41,937,393 ⁽²⁾	\$ 3.78	5.82	\$ 3,367
Options exercisable as of September 30, 2024	23,616,028	\$ 4.69	3.76	\$ 3,350

(1) Includes (a) 7,757,000 stock options with 25% vesting on January 1, 2025 and the remaining over a three-year service period, (b) 1,016,094 stock options that will vest upon the satisfaction of specified market-based conditions tied to the price of the Company's publicly traded shares, (c) 1,083,200 stock options that will vest over a four-year service period, (d) 515,000 stock options that will vest after a one-year service period, and (e) 412,000 stock options with 33% vesting on the first anniversary of the grant date and the remaining over a two-year service period.

(2) The 18,321,366 outstanding unvested stock options includes (a) 9,199,618 stock options that will continue to vest over a one to four-year service period, (b) 7,013,000 options with 25% vesting on January 1, 2025 and the remaining over a three-year service period, (c) 1,016,094 stock options that will vest upon the satisfaction of specified market-based conditions tied to the price of the Company's publicly traded shares, (d) 992,654 that will continue to vest over a three to four-year service period and upon the satisfaction of specified performance-based vesting conditions, and (e) 100,000 stock options that will continue to vest over a two-year service period and upon the satisfaction of specified market-based conditions tied to the price of the Company's publicly traded shares.

The weighted-average grant-date fair value of options granted during the nine months ended September 30, 2024 was \$1.19. The weighted-average grant-date fair value of options granted during the nine months ended September 30, 2023 was \$0.97.

The Company estimates the fair value of each stock option using the Black-Scholes option-pricing model on the date of grant. During the nine months ended September 30, 2024, the assumptions used in the Black-Scholes option pricing model were as follows:

	September 30,	
	2024	2023
Weighted average expected term in years	5.95	6.15
Weighted average expected stock price volatility	73.9%	87.5%
Risk-free interest rate	3.78% - 4.40%	3.50% - 4.09%
Expected dividend yield	0%	0%

For the three months ended September 30, 2024 and 2023, the Company recorded stock-based compensation expense of \$4.6 million and \$6.9 million, respectively. For the nine months ended September 30, 2024 and 2023, the Company recorded stock-based compensation expense of \$15.5 million and \$21.6 million, respectively.

As of September 30, 2024, total unrecognized compensation cost related to the unvested stock options was \$23.6 million, which is expected to be recognized over a weighted average period of 2.03 years.

Restricted Stock Unit activity under the 2021 Incentive Plan

The restricted stock units noted below consist of service-based awards vesting over a two-year period, subject to the risk of forfeiture until vested by virtue of continued employment or service to the Company. The Company reflects restricted stock units as issued and outstanding common stock when vested and the shares have been delivered to the individual.

The following is a summary of restricted stock unit activity from December 31, 2023 to September 30, 2024:

	Restricted Stock Units	Weighted Average Grant Date Fair Value
Unvested at December 31, 2023	2,944,935	\$ 1.18
Granted	—	—
Vested	1,469,063	1.18
Forfeited	348,815	1.18
Unvested at September 30, 2024	1,127,057	\$ 1.18

For the three months ended September 30, 2024 and 2023, the Company recorded stock-based compensation expense of \$0.5 million and \$0.5 million, respectively. For the nine months ended September 30, 2024 and 2023, the Company recorded stock-based compensation expense of \$1.3 million and \$1.0 million, respectively.

The total fair value of restricted stock units vested during the nine months ended September 30, 2024 was \$1.7 million. As of September 30, 2024, total unrecognized compensation cost related to the unvested stock-based awards was \$0.5 million, which is expected to be recognized over a weighted average period of 0.40 years.

Stock Option activity under HSOP Plan

The HSOP Options outstanding noted below consist of service and performance-based options to request the distribution of HSOP Shares. These HSOP Options have a fifteen-year contractual term. These HSOP Options vest over a three to four-year service period. These awards are subject to the risk of forfeiture until vested by virtue of continued employment or service to the Company.

The following is a summary of stock option activity from December 31, 2023 to September 30, 2024:

	Number of Options	Weighted-Average Exercise Price	Weighted-Average Remaining Contractual Term (Years)	Aggregate Intrinsic Value
Outstanding as of December 31, 2023	6,921,829	\$ 6.64	12.01	\$ —
Granted	—	—	—	—
Exercised	—	—	—	—
Cancelled or forfeited	—	—	—	—
Outstanding as of September 30, 2024	6,921,829	\$ 6.64	11.34	\$ —
Options exercisable as of September 30, 2024	6,921,829	\$ 6.64	11.34	\$ —

For the three months ended September 30, 2024 and 2023, the Company recorded stock-based compensation expense of zero and \$0.7 million, respectively. For the nine months ended September 30, 2024 and 2023, the Company recorded stock-based compensation expense of \$0.1 million and \$2.5 million, respectively.

As of September 30, 2024, there was no unrecognized compensation cost related to the unvested stock-based awards.

Subsidiary Equity Incentive Plans

Certain controlled subsidiaries of the Company adopted their own equity incentive plans (each, an “EIP”). Each EIP is generally structured so that the applicable subsidiary, and its affiliates’ employees, directors, officers and consultants are eligible to receive non-qualified and incentive stock options and restricted stock unit awards under their respective EIP. Standard option grants have time-based vesting requirements, generally vesting over a period of four years with a contractual term of ten years. Such time-based stock options use the Black-Scholes option pricing model to determine grant date fair value.

For the three months ended September 30, 2024 and 2023, the Company recorded stock-based compensation expense of an immaterial amount and \$0.1 million, respectively, in relation to subsidiary EIPs. For the nine months ended September 30, 2024 and 2023, the Company recorded stock-based compensation expense of \$0.1 million and \$0.3 million, respectively, in relation to subsidiary EIPs. As of September 30, 2024, there was an immaterial amount of total unrecognized stock-based compensation expense related to unvested EIP awards to employees and non-employee directors expected to be recognized over a weighted-average period of approximately 0.89 years.

Stock-Based Compensation

Stock-based compensation expense is allocated to either research and development or general and administrative expense on the unaudited condensed consolidated statements of operations based on the cost center to which the option holder belongs.

The following table summarizes the total stock-based compensation expense by function for the three and nine months ended September 30, 2024, which includes expense related to stock options and restricted stock unit awards (in thousands):

	Three months ended September 30, 2024			
	atai 2020 and 2021 Incentive Plans	atai HSOP	Other Subsidiaries Equity Plan	Total
Research and development	\$ 1,949	\$ —	\$ 15	\$ 1,964
General and administrative	3,082	—	—	3,082
Total stock-based compensation expense	\$ 5,031	\$ —	\$ 15	\$ 5,046

	For the nine months ended September 30, 2024			Total
	atai 2020 and 2021 Incentive Plans	atai HSOP	Other Subsidiaries Equity Plan	
Research and development	\$ 6,317	\$ —	\$ 135	\$ 6,452
General and administrative	10,506	117	13	\$ 10,636
Total stock-based compensation expense	\$ 16,823	\$ 117	\$ 148	\$ 17,088

The following table summarizes the total stock-based compensation expense by function for the three and nine months ended September 30, 2023, which includes expense related to stock options and restricted stock unit awards (in thousands):

	Three months ended September 30, 2023			Total
	atai 2020 and 2021 Incentive Plans	atai HSOP	Other Subsidiaries Equity Plan	
Research and development	\$ 3,285	\$ —	\$ 107	\$ 3,392
General and administrative	4,110	744	7	\$ 4,861
Total stock-based compensation expense	\$ 7,395	\$ 744	\$ 114	\$ 8,253

	For the nine months ended September 30, 2023			Total
	atai 2020 and 2021 Incentive Plans	atai HSOP	Other Subsidiaries Equity Plan	
Research and development	\$ 9,866	\$ —	\$ 320	\$ 10,186
General and administrative	12,947	2,512	33	\$ 15,492
Total stock-based compensation expense	\$ 22,813	\$ 2,512	\$ 352	\$ 25,677

14. Income Taxes

The Company records its quarterly income tax expense by utilizing an estimated annual effective tax rate applied to its period to date earnings as adjusted for any discrete items arising during the quarter. The tax effect for discrete items are recorded in the period in which they occur. The Company recorded a \$0.2 million income tax benefit and a \$0.2 million income tax expense for the three months ended September 30, 2024 and 2023, respectively. The Company recorded a \$0.2 million income tax benefit and a \$0.6 million income tax expense for the nine months ended September 30, 2024 and 2023, respectively. The decrease in income tax expense shown in 2024 was primarily driven by a reduction in global earnings, a favorable return to provision from one of the Company's Australian subsidiaries, and the release of an uncertain tax liability associated with a 2021 subsidiary tax return. The primary difference between the effective tax rate and the statutory tax rate relates to the income tax treatment of stock compensation expense, which impacts the current and overall tax expense due to the applicable valuation allowance. The Company continues to maintain a full valuation allowance against its deferred tax assets.

15. Net Loss Per Share

Basic and diluted net loss per share attributable to atai stockholders were calculated as follows (in thousands, except share and per share data):

	For the three months ended September 30,		For the nine months ended September 30,	
	2024	2023	2024	2023
Basic EPS				
Numerator:				
Net income (loss)	\$ (26,311)	\$ 43,371	\$ (111,058)	\$ (24,753)
Net loss attributable to noncontrolling interests	(25)	(873)	(747)	(2,821)
Net income (loss) attributable to ATAI Life Sciences N.V. shareholders — basic (numerator)	\$ (26,286)	\$ 44,244	\$ (110,311)	\$ (21,932)
Denominator:				
Weighted average common shares outstanding attributable to ATAI Life Sciences N.V. Shareholders (denominator)	160,621,817	155,792,490	159,973,201	155,793,601
Net income (loss) per common share attributable to ATAI Life Sciences N.V. Shareholders - basic	\$ (0.16)	\$ 0.28	\$ (0.69)	\$ (0.14)
Diluted EPS				
Net income (loss)	\$ (26,311)	\$ 43,371	\$ (111,058)	\$ (24,753)
Net loss attributable to noncontrolling interests	(25)	(873)	(747)	(2,821)
Net income (loss) attributable to ATAI Life Sciences N.V. shareholders — diluted (numerator)	\$ (26,286)	\$ 44,244	\$ (110,311)	\$ (21,932)
Denominator:				
Weighted average common shares outstanding attributable to ATAI Life Sciences N.V. Shareholders	160,621,817	155,792,490	159,973,201	155,793,601
Effect of dilutive securities:				
Options to purchase common stock	—	12,426,724	—	—
Unvested restricted stock units	—	3,144,935	—	—
2018 Convertible Promissory Note - Related Parties (note 11)	—	6,201,824	—	—
Weighted average common shares outstanding attributable to ATAI Life Sciences N.V. shareholders (denominator)	160,621,817	177,565,973	159,973,201	155,793,601
Net income (loss) per common share attributable to ATAI Life Sciences N.V. shareholders — diluted	\$ (0.16)	\$ 0.25	\$ (0.69)	\$ (0.14)

HSOP Shares issued to the Partnership and allocated to the HSOP Participants are not considered outstanding for accounting purposes and not included in the calculation of basic weighted average common shares outstanding in the table above because the HSOP Participants have a forfeitable right to distributions until the HSOP Options vest and are exercised, at which time the right becomes nonforfeitable.

The following also represents the maximum amount of outstanding shares of potentially dilutive securities that were excluded from the computation of diluted net loss per share attributable to common shareholders for the periods presented because including them would have been antidilutive:

	As of September 30,	
	2024	2023
Options to purchase common stock	41,937,393	27,974,365
HSOP options to purchase common stock	6,921,829	6,921,829
2018 short-term convertible promissory notes - related parties	2,367,200	—
2018 short-term convertible promissory notes	3,818,704	—
Unvested restricted stock units	1,127,057	—
	56,172,183	34,896,194

16. Commitments and Contingencies

Research and Development Agreements

The Company may enter into contracts in the ordinary course of business with clinical research organizations for clinical trials, with contract manufacturing organizations for clinical supplies and with other vendors for preclinical studies, supplies and other services and products for operating purposes.

Indemnification

In the ordinary course of business, the Company may provide indemnifications of varying scope and terms to vendors, lessors, business partners, board members, officers and other parties with respect to certain matters, including, but not limited to, losses arising out of breach of such agreements, services to be provided by the Company, negligence or willful misconduct of the Company, violations of law by the Company, or intellectual property infringement claims made by third parties. In addition, the Company has entered into indemnification agreements with directors and certain officers and employees that will require the Company, among other things, to indemnify them against certain liabilities that may arise by reason of their status or service as directors, officers or employees. No demands have been made upon the Company to provide indemnification under such agreements, and thus, there are no claims that the Company is aware of that could have a material effect on the Company's unaudited condensed consolidated financial statements.

The Company also maintains director and officer insurance, which may cover certain liabilities arising from its obligation to indemnify the Company's directors. To date, the Company has not incurred any material costs and has not accrued any liabilities in the unaudited condensed consolidated financial statements as a result of these provisions.

Contingencies

From time to time, the Company may become involved in legal proceedings arising in the ordinary course of business. The Company is unable to predict the outcome of these matters or the ultimate legal and financial liability, and at this time cannot reasonably estimate the possible loss or range of loss and accordingly has not accrued a related liability. At each reporting date, the Company evaluates whether or not a potential loss amount or a potential range of loss is probable and reasonably estimable under the provisions of the authoritative guidance that addresses accounting for contingencies. The Company accrues a liability when a loss is considered probable and the amount can be reasonably estimated. When a material loss contingency is reasonably possible but not probable, the Company does not record a liability, but instead discloses the nature and the amount of the claim, and an estimate of the loss or range of loss, if such an estimate can be made. Legal fees are expensed as incurred.

17. License Agreements

Otsuka License and Collaboration Agreement

In March 2021, Perception entered into a license and collaboration agreement (the "Otsuka Agreement") with Otsuka under which Perception granted exclusive rights to Otsuka to develop and commercialize products containing arketamine, known as PCN-101 in Japan for the treatment of any depression, including treatment-resistant depression, or major depressive disorder or any of their related symptoms or conditions at its own cost and expense. Perception retained all rights to PCN-101 outside of Japan.

With the execution of the Otsuka Agreement, Perception received an upfront, non-refundable payment of \$20.0 million. Perception is also entitled to receive aggregate payments of up to \$35.0 million if certain development and regulatory milestones are achieved for the current or a new intravenous formulation of a product and up to \$66.0 million in commercial milestones upon the achievement of certain commercial sales thresholds. Otsuka is obligated to pay Perception a tiered, double-digit royalty on net sales of products containing PCN-101 in Japan, subject to reduction in certain circumstances.

For the three and nine months ended September 30, 2024 and 2023, respectively, there were no milestones achieved under the Otsuka Agreement.

For the three months ended September 30, 2024 and 2023, respectively, the company recognized an immaterial amount and \$0.1 million of license revenue related to certain research and development services. For the nine months ended September 30, 2024 and 2023, respectively, the company recognized \$0.3 million and \$0.3 million of license revenue related to certain research and development services.

National University Corporation Chiba University License Agreement

In August 2017, Perception entered into a license agreement (the “CHIBA License”), with the National University Corporation Chiba University (“CHIBA”), relating to Perception’s drug discovery and development initiatives. Under the CHIBA License, Perception has been granted a worldwide exclusive license under certain patents and know-how of CHIBA to research, develop, manufacture, use and commercialize therapeutic products.

During the three and nine months ended September 30, 2024 and 2023, respectively, the Company made no material payments pursuant to the CHIBA License.

Allergan License Agreement

In February 2020, Recognify entered into an amended and restated license agreement (the “Allergan License Agreement”), with Allergan Sales, LLC (“Allergan”), under which Allergan granted Recognify an exclusive (non-exclusive as to know-how), sublicensable and worldwide license under certain patent rights and know-how controlled by Allergan to develop, manufacture and commercialize certain products for use in all fields including the treatment of certain diseases and conditions of the central nervous system.

During the three and nine months ended September 30, 2024 and 2023, respectively, Recognify made no material payments pursuant to the Allergan License Agreement.

Columbia Stock Purchase and License Agreement

In June 2020, Kures, Inc. (“Kures”) entered into a license agreement with Trustees of Columbia University (“Columbia”), pursuant to which, Kures obtained an exclusive license under certain patents and technical information to discover, develop, manufacture, use and commercialize such patents or other products in all uses and applications (“Columbia IP”). In addition, in consideration for the rights to the Columbia IP, Kures entered into a Stock Purchase Agreement (the “SPA”) with Columbia in contemplation of the license agreement. Pursuant to the SPA, Kures issued to Columbia certain shares of the Kures’ capital stock, representing 5.0% of Kures common stock on a fully diluted basis. Furthermore, the SPA provided that from time to time, Kures shall issue to Columbia additional shares of Kures’ common stock, at a per share price equal to the then fair market value of each such share, which price shall be deemed to have been paid in partial consideration for the execution, delivery and performance by Columbia of the License Agreement, such that the common stock held by Columbia shall equal to 5.0% of the common stock on a fully diluted basis, at all times up to and through the achievement of certain funding threshold.

During the three and nine months ended September 30, 2024 and 2023, respectively, Kures made no material payments or share issuances in connection with the Columbia agreement.

Dalriada License Agreement

In December 2021, Invyxis, Inc. (“Invyxis”), a wholly owned subsidiary of the Company, entered into an exclusive services and license agreement (the “Invyxis ESLA”) with Dalriada Drug Discovery Inc. (“Dalriada”). Under the Invyxis ESLA, Dalriada is to exclusively collaborate with Invyxis to develop products, services and processes with the specific purpose of generating products consisting of new chemical entities. Invyxis will pay Dalriada up to \$12.8 million in service fees for research and support services. In addition, Invyxis will pay Dalriada success milestone payments and low single digit royalty payments based on net product sales. Invyxis has the right, but not the obligation, to settle future royalty payments based on net product sales with the Company's common stock. Invyxis and Dalriada will determine the equity settlement based on a price per share determined by both parties.

In January 2022, in accordance with the Invyxis ESLA, Invyxis paid an upfront deposit of \$1.1 million, which was capitalized as prepaid research and development expense. In December 2022, the Company executed an amendment to the Invyxis ESLA, which reduced the upfront deposit from \$1.1 million to \$0.5 million. As such, the remaining \$0.6 million was applied against research and development expense incurred. The Company will expense the remaining deposit as the services are performed as a component of research and development expense in the consolidated statements of operations. As of September 30, 2024, the upfront deposit has been applied against research and development expenses in the consolidated statement of operations.

During the three months ended September 30, 2024 and 2023, respectively, the Company recorded an immaterial amount and \$0.4 million as research and development expense in the unaudited condensed consolidated statement of operations. During the nine months ended September 30, 2024 and 2023, respectively, the Company recorded \$0.4 million and \$1.5 million as research and development expense in the unaudited condensed consolidated statements of operations. For the three and nine months ended September 30, 2024 and 2023, respectively, Invyxis made no other service fee payments to Dalriada.

18. Related Party Transactions

atai Formation

In connection with the formation of atai in 2018, the Company entered into a series of transactions with its shareholders, Apeiron, Galaxy Group Investments LLC. (“Galaxy”) and HCS Beteiligungsgesellschaft mbH (“HCS”) whereby these shareholders contributed their investments in COMPASS, Innoplexus and Juvenescence to the Company in exchange for the Company's common stock of equivalent value. Apeiron is the family office of the Company's co-founder who owns 20.2% and 19.7% of the outstanding common stock in the Company as of September 30, 2024 and December 31, 2023, respectively. Galaxy is a NYC-based multi-strategy investment firm that owns 6.4% and 6.5% of the outstanding common stock in the Company as of September 30, 2024 and December 31, 2023, respectively.

Directed Share Program

In connection with the Company's initial public offering, the underwriters reserved 27% of the common shares for sale at the initial offering price to the Company's managing directors, supervisory directors and certain other parties. Apeiron participated in the program and purchased \$10.5 million common shares.

Consulting Agreement with Mr. Angermayer

In January 2021, the Company entered into a consulting agreement, (the “Consulting Agreement”), with Mr. Angermayer, one of the Company's co-founders and supervisory director. Apeiron is the family office and merchant banking business of Mr. Angermayer. Pursuant to the Consulting Agreement, Mr. Angermayer agreed to render services to the Company on business and financing strategies in exchange for 624,000 shares under the 2020 Incentive Plan upon achievement of certain performance targets.

In January 2024, the Company and Mr. Angermayer entered into the Termination and New Consultancy Agreement (the “2024 Consultancy Agreement”). Pursuant to the 2024 Consultancy Agreement, the parties agreed to terminate the Consulting Agreement (as defined above) between ATAI AG and Mr. Angermayer dated January 16, 2021 (the “Original Consultancy Agreement”) and enter into a new consultancy agreement between the Company and Mr. Angermayer to, among other things, extend the term of the Original Consultancy Agreement to January 5, 2028, increase the services to include various business objectives (including related to business and finance, communication and investor relations), and provide for the grant of an option to purchase 1,658,094 shares of the Company that vests over four years in part based on continued service and in part based on the Company's total shareholder return compared to the four-year total shareholder return of the companies comprising the XBI.

As a result of the 2024 Consulting Agreement, for the three and nine months ended September 30, 2024, the Company recorded \$0.1 million and \$0.3 million, respectively, of stock-based compensation included in general and administrative expense in its unaudited condensed consolidated statements of operations. Additionally, as a result of the Consulting Agreement, for the three and nine months ended September 30, 2023, the Company recorded \$0.2 million and \$0.6 million, respectively, of stock-based compensation included in general and administrative expense in its unaudited condensed consolidated statements of operations.

For the three and nine months ended September 30, 2024, the Company recorded an immaterial amount and \$0.3 million, respectively, of stock-based compensation included in general and administrative expense in its unaudited condensed consolidated statements of operations related to Mr. Angermayer's service as Chairman of the Company's board of supervisory directors. Additionally, for the three and nine months ended September 30, 2023, the Company recorded \$0.1 million and \$0.4 million, respectively, of stock-based compensation included in general and administrative expense in its unaudited condensed consolidated statements of operations related to Mr. Angermayer's service as Chairman of the Company's board of supervisory directors.

19. Defined Contribution Plan

The Company has a defined contribution retirement savings plan under Section 401(k) of the Internal Revenue Code. This plan allows eligible employees to defer a portion of their annual compensation. Employees may make contributions by having the Company withhold a percentage of their salary up to the Internal Revenue Service annual limit. The Company recognized \$0.1 million and \$0.1 million of related compensation expense for the three months ended September 30, 2024 and 2023. Additionally, the Company recognized \$0.3 million and \$0.4 million of related compensation expense for the nine months ended September 30, 2024 and 2023.

20. Corporate Restructuring

2024 Restructuring

In February 2024, the Company restructured its workforce and eliminated approximately 10% of its global workforce in order to more effectively allocate its research and development and other resources supporting the revised business and program priorities and to reduce operational costs.

Restructuring expense related to the workforce reduction incurred during the nine months ended September 30, 2024, resulted in \$2.0 million of restructuring expense, which consisted of \$1.6 million of cash expenditures for severance and other employee separation-related costs and \$0.4 million of stock-based compensation expense. Of the restructuring expense, for the nine months ended September 30, 2024, \$0.3 million and \$1.7 million were recorded in research and development expenses and general and administrative expenses, respectively, in the unaudited condensed consolidated statement of operations. The Company recorded an immaterial amount of restructuring expense for the three months ended September 30, 2024.

As of September 30, 2024, net restructuring liabilities totaled approximately \$0.1 million included in accrued expenses on the Company's unaudited condensed consolidated balance sheets.

2023 Restructuring

In February 2023, the Company restructured its workforce and eliminated approximately 30% of its global workforce in order to more effectively allocate its research and development and other resources supporting the revised business and program priorities and to reduce operational costs.

Restructuring expense related to the workforce reduction incurred during the nine months ended September 30, 2023, resulted in \$3.2 million of restructuring expense, which consisted of \$3.0 million of cash expenditures for severance and other employee separation-related costs and \$0.2 million of stock-based compensation expense. Of the restructuring expense, for the nine months ended September 30, 2023, \$1.8 million and \$1.4 million were recorded in research and development expenses and general and administrative expenses, respectively, in the unaudited condensed consolidated statement of operations.

As of September 30, 2023, all restructuring liabilities had been paid in full and there were no restructuring liabilities included in accrued expenses on the Company's unaudited condensed consolidated balance sheets.

A reconciliation of the restructuring charges and related payments for the nine months ended September 30, 2024 and 2023 is as follows:

	<u>As of September 30,</u>	
	<u>2024</u>	<u>2023</u>
Restructuring costs expensed during the period	\$ 2,026	\$ 3,206
Non-cash impact of stock-based compensation	(358)	(195)
Cash payments of restructuring liabilities, net	(1,558)	(3,011)
Ending Restructuring liability	<u>\$ 110</u>	<u>\$ —</u>

21. Subsequent Events

In October 2024, the Company acquired all of the issued and outstanding shares of IntelGenx Corp., a subsidiary of IntelGenx Technologies Corp., following the approval and vesting order obtained on September 30, 2024 from the Superior Court of Québec (Commercial Division) issued in connection with the proceedings instituted pursuant to the CCAA. No Company equity or cash was exchanged in connection with this transaction.

In October 2024, pursuant to the terms of the Beckley Psytech Escrow Agreement, Beckley Psytech, at its sole discretion, drew \$5.0 million from the escrow account and the Company was credited 3,012,048 Series C shares.

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations.

You should read the following discussion and analysis of our financial condition and results of operations together with our unaudited condensed consolidated financial statements and related notes thereto included in this Quarterly Report and our audited consolidated financial statements and related notes thereto for the year ended December 31, 2023, included in our Form 10-K filed with the SEC on March 28, 2024 (the "Annual Report"). This discussion contains forward-looking statements based upon current expectations that involve risks and uncertainties. Our actual results may differ materially from those anticipated in these forward-looking statements as a result of various factors, including those set forth in the section titled "Risk Factors" in our Annual Report, and may be updated from time to time in our other filings with the SEC.

All references to years, unless otherwise noted, refer to our fiscal years, which end on December 31. Unless the context otherwise requires, all references in this subsection to “we,” “us,” “our,” “atai” or the “Company” refer to atai and its consolidated subsidiaries.

Business Overview

We are a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders. We were founded in 2018 in response to the significant unmet need and lack of innovation in the mental health treatment landscape. We are dedicated to efficiently developing innovative therapeutics to treat depression, anxiety, addiction, and other mental health disorders. By pooling resources and best practices, we aim to responsibly accelerate the development of new medicines to achieve clinically meaningful and sustained behavioral change in mental health patients.

We have a bold and ambitious vision: to heal mental health disorders so that everyone, everywhere can live a more fulfilled life.

Mental health disorders such as depression, substance use disorder, and anxiety, which are among our initial focus indications, are highly prevalent and estimated to affect more than one billion people globally. In addition, the total costs of mental health disorders are significant and expected to increase substantially. Between 2009 and 2019, spending on mental health care in the United States increased by more than 50%, reaching \$225 billion, and a Lancet Commission report estimates the global economic cost will reach \$16 trillion by 2030. While current treatments, such as selective serotonin reuptake inhibitors, or SSRIs, and serotonin-norepinephrine reuptake inhibitors, or SNRIs, are well established and effective for certain patients, a significant percentage of patients either respond inadequately or relapse, translating to a significant unmet patient need.

Since our inception in 2018, we have focused substantially all of our efforts and financial resources on acquiring and developing product and technology rights, establishing our platform, building our intellectual property portfolio and conducting research and development activities for our product candidates within our atai companies that we consolidate based on our controlling financial interest of such entities. We operate a decentralized model to enable scalable drug or technological development at our atai companies. Our atai companies drive the development of our programs and enabling technologies for which we have either acquired a controlling or significant interest in or created de novo. We believe that this model provides our development teams the support and incentives to rapidly advance their therapeutic candidates or technologies in a cost-efficient manner. We look to optimize deployment of our capital in order to maximize value for our stakeholders.

We provide our development teams with access to shared services including scientific, intellectual property, clinical, and regulatory support, as well as project management, research and development, market strategy, and development and corporate finance. Our global team of subject matter professionals provides deep domain expertise in areas such as mental health drug development and life sciences intellectual property. Development teams have access to relevant expertise specific to each stage of their development. We believe our knowledge and specialization in psychedelics and mental health continuously enhance the quality of the services we provide through the sharing of learnings and experiences across the teams.

We have incurred significant operating losses since our inception. Our net loss attributable to ATAI Life Sciences N.V. stockholders was \$110.3 million and \$21.9 million for the nine months ended September 30, 2024 and 2023, respectively. As of September 30, 2024 and December 31, 2023, our accumulated deficit was \$661.3 million and \$550.9 million, respectively. Our ability to generate product revenue sufficient to achieve profitability will depend substantially on the successful development and eventual commercialization of product candidates at our atai companies that we consolidate based on our controlling financial interest of such entities as determined under the variable interest entity model ("VIE model") or voting interest entity model ("VOE model"). We expect to continue to incur significant expenses and increasing operating losses for at least the next several years.

Our historical losses resulted principally from costs incurred in connection with research and development activities, as well as general and administrative costs associated with our operations. In the future, we intend to continue to conduct research and development, preclinical testing, clinical trials, regulatory compliance, market access, commercialization and business development activities that, together with anticipated general and administrative expenses, will result in incurring further significant losses for at least the next several years. Our operating losses stem primarily from the development of our mental health research programs. Furthermore, we expect to incur additional costs associated with operating as a public company, including audit, legal, regulatory, and tax-related services associated with maintaining compliance with exchange listing and SEC requirements, director and officer insurance premiums, and investor relations costs. As a result, we will need substantial additional funding to support our continuing operations and pursue our growth strategy. Until such time as we can generate significant revenue from sales of our product candidates, if ever, we expect to finance our operations through a combination of

equity offerings, debt financings, strategic collaborations and alliances or licensing arrangements. Our inability to raise capital as and when needed could have a negative impact on our financial condition and our ability to pursue our business strategies. There can be no assurances, however, that our current operating plan will be achieved or that additional funding will be available on terms acceptable to us, or at all.

We do not have any products approved for sale and have not generated any revenue from product sales. We have funded our operations to date primarily with proceeds from the sale of our common shares, issuances of convertible notes and a term loan.

Capital Allocation and Strategic Value Capture

Consistent with our strategy, we provide the necessary funding and operational support to our programs to maximize their probability of success in clinical development and commercialization. We also regularly review the status of our programs to assess whether there are alternative forms of ownership, partnership or other forms of collaboration that would optimize our economic interests and the success of our programs. To that end, we are focusing on clinical phase programs and business development that we expect to generate meaningful data in the near term, and, therefore, prioritizing programs and opportunities that we believe have the highest return potential and value. As a result, in late 2023, we finalized and entered into agreements through which we disposed of our equity interests in Psyber, Inc. and TryptageniX Inc. In 2024, our strategic investment in Beckley Psytech Limited added more programs to our diverse portfolio of clinical-stage psychedelic candidates with multiple upcoming clinical readouts. We are also exploring other opportunities, including but not limited to seeking strategic partnership options, for example, with Recognify Life Sciences, Inc. and Perception Neuroscience Holdings, Inc.

In February 2023, we implemented a realignment initiative resulting in a reduction in force of approximately 30% of our global workforce in order to more effectively allocate our research and development and other resources supporting the revised business and program priorities and to reduce operational costs. In February 2024, we conducted a reduction in force of approximately 10% of our global workforce, predominantly reducing redundancy in our general & administrative functions to reduce operational costs. Refer to Note 20 in the Notes to condensed consolidated financial statements in Part I, Item 1 for further information.

Our Core Clinical Programs

Our pipeline currently consists of therapeutic candidates across multiple neuropsychiatric indications. The table below summarizes the status of our core product candidate portfolio as of the date of this Quarterly Report.

Programs	Primary Indication	Preclin	Phase 1	Phase 2	Phase 3
RL-007¹ Pro-cognitive neuromodulator	Cognitive Impairment Associated with Schizophrenia				
VLS-01 DMT	Treatment Resistant Depression				
EMP-01 R-MDMA	Social Anxiety Disorder				
IBX-210 Ibogaine	Opioid Use Disorder				
Novel 5-HT_{2A} Receptor Agonists (incl. non-hallucinogenic neuroplastogens)	Undisclosed				
STRATEGIC INVESTMENTS					
COMP360² Psilocybin	Treatment Resistant Depression				
BPL-003³ 5-MeO-DMT	Treatment Resistant Depression				
ELE-101³ Psilocin	Major Depressive Disorder				

Abbreviations: DMT = N,N-Dimethyltryptamine; R-MDMA = R enantiomer of 3,4-Methylenedioxyamphetamine; 5-MeO-DMT = 5-methoxy-N,N-dimethyltryptamine

1. Majority ownership stake in Recognify Life Sciences

2. Strategic Investment in Compass Pathways

3. Strategic Investment in Beckley Psytech



Clinical Pipeline Recent Advancements

RL-007: Pro-Cognitive Neuromodulator for Cognitive Impairment Associated with Schizophrenia (CIAS)

Recent Advancements

- RL-007 is an orally bioavailable compound that has demonstrated pro-cognitive effects in multiple pre-clinical and clinical studies, including two Phase 1 and two Phase 2 trials.
- The ongoing Phase 2b study is evaluating 20mg and 40mg of RL-007 versus placebo in patients living with CIAS. We expect to announce topline results in mid-2025.

VLS-01 (N,N-Dimethyltryptamine; ("DMT") for Treatment-Resistant Depression ("TRD"))

Recent Advancements:

- VLS-01 is a proprietary oral transmucosal film formulation of DMT applied to the buccal surface designed to fit within a two-hour in-clinic treatment paradigm.
- The United States Food and Drug Administration (the "FDA") cleared the investigational new drug (the "IND") application for VLS-01, enabling us to proceed with our plans to initiate a randomized, double-blind, placebo-controlled Phase 2 study to assess the safety, efficacy and durability of response of repeated doses of VLS-01 buccal film in patients with TRD.
- We expect the Phase 2 study to be initiated in the U.S. around year-end 2024.

EMP-01: R-enantiomer of 3,4-methylenedioxy-methamphetamine (R-MDMA) for Social Anxiety Disorder (SAD)

Recent Advancements

- SAD is an area of high unmet medical need with approximately 18 million people in the U.S. diagnosed in the past year and no novel molecules approved in over two decades.
- EMP-01 is an oral formulation of R-MDMA that demonstrated a unique, dose-dependent subjective effect profile in a Phase 1 trial that was generally found to be more similar to classical psychedelics than to racemic MDMA.
- We expect to initiate an exploratory, randomized, double-blind, placebo-controlled Phase 2 study to assess the safety, tolerability and efficacy of EMP-01 in adults with SAD around year-end 2024.

IBX-210: Intravenous (IV)-Ibogaine for Opioid Use Disorder (OUD)

Recent Advancements

- IBX-210 is a novel IV formulation of ibogaine, which is an indole alkaloid with potential for clinical benefit for substance use disorder
- We completed a productive FDA pre-IND meeting to initiate discussions and alignment on a modern ibogaine IND.
- We plan to run additional non-clinical studies prior to launching a Phase 1b study.

Novel 5-HT_{2A} Receptor Agonists

Recent Advancements

- Discovery program to identify novel, non-hallucinogenic 5-HT_{2A}R agonists for TRD using artificial intelligence (AI)/machine learning (ML)-informed drug design and medicinal chemistry.
- We presented data at the Society for Neuroscience (SfN) annual meeting aimed to show that these compounds are promising chemical starting points for new analogs with further improved 5-HT_{2A}R versus 5-HT_{2B}R agonist selectivity that maintain translational antidepressant-like activity with potential for non-hallucinogenic effects.

Financial Overview

Since our inception in 2018, we have focused substantially all of our efforts and financial resources on acquiring and developing product and technology rights, establishing our platform, building our intellectual property portfolio and conducting research and development activities for our product candidates within our atai companies that we consolidate based on our controlling financial interest of such entities. We operate a decentralized model to enable scalable drug or technological development at our atai companies. Our atai companies drive the development of our programs and enabling technologies for which we have either acquired a controlling or significant interest in or created de novo. We believe that this model provides our development teams the support and incentives to rapidly advance their therapeutic candidates or technologies in a cost-efficient manner. We look to optimize deployment of our capital in order to maximize value for our stakeholders.

We do not have any products approved for sale and have not generated any revenue from product sales. We have funded our operations to date primarily with proceeds from the sale of our common shares, issuances of convertible notes, and a term loan.

Factors and Trends Affecting our Results of Operations

We believe that the most significant factors affecting our results of operations include:

Research and Development Expenses

We believe that our ability to successfully develop innovative product candidates through our programs will be the primary factor affecting our future growth. Our approach to the discovery and development of our product candidates is still being demonstrated. As such, we do not know whether we will be able to successfully develop any of our product candidates. Developing novel product candidates requires a significant investment of resources over a prolonged period of time, and a core part of our strategy is to continue making sustained investments in this area. We have chosen to leverage our platform to focus initially on advancing our product candidates in the area of mental health.

All of our product candidates are still in development stages, and we have incurred and will continue to incur significant research and development costs for preclinical studies and clinical trials. We expect that our research and development expenses will constitute the most significant part of our expenses in future periods in line with the advancement and expansion of the development of our product candidates.

Acquisitions/Investments

To continue to grow our business and to aid in the development of our various product candidates, we have strategically acquired and invested in companies that share our common goal towards advancing transformative treatments, including psychedelic compounds and digital therapeutics, for patients that suffer from mental health disorders.

Stock-Based Compensation

In August 2020, we adopted the 2020 Equity Incentive Plan (the "2020 Incentive Plan") and the Hurdle Share Option Plan (the "HSOP Plan"), which allowed us to grant stock-based awards to executive officers, directors, employees and consultants.

Effective April 23, 2021, we adopted and our shareholders approved the atai Life Sciences N.V. 2021 Incentive Award Plan (the "2021 Incentive Plan"). The 2021 Incentive Plan enables us to grant incentive stock options or nonqualified stock options, restricted stock awards and other stock-based awards to our executive officers, directors and other employees and consultants. Any shares subject to outstanding options originally granted under the 2020 Incentive Plan that terminate, expire or lapse for any reason without the delivery of shares to the holder thereof shall become available for issuance pursuant to the 2021 Incentive Plan.

Basis of Presentation

The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States ("U.S. GAAP") and follow the requirements of the United States Securities and Exchange Commission ("SEC"), and in the opinion of management, reflect all adjustments, which include only normal recurring adjustments, necessary for a fair statement of our financial position, results of operations and comprehensive loss, and cash flows for the periods presented.

Any reference in these notes to applicable accounting guidance is meant to refer to the authoritative U.S. GAAP included in the Accounting Standards Codification ("ASC"), and Accounting Standards Update ("ASU") issued by the Financial Accounting Standards Board ("FASB").

Consolidation

Since our inception, we have created wholly owned subsidiaries or made investments in certain controlled entities, including partially-owned subsidiaries for which we have majority voting interest under the VOE model or for which we are the primary beneficiary under the

VIE model, which we refer to collectively as our consolidated entities. Ownership interests in consolidated entities that are held by entities other than us are reported as noncontrolling interests in our unaudited condensed consolidated balance sheets and unaudited condensed consolidated statements of stockholders' equity. The portion of net earnings attributable to the noncontrolling interests is presented as Net loss attributable to noncontrolling interests in our unaudited condensed consolidated statements of operations. All intercompany balances and transactions have been eliminated in the consolidation.

Ownership interests in entities over which we have significant influence, but not a controlling financial interest, are accounted for under either the alternative measurement pursuant to ASC 321 or as an equity method investment. Investments eligible for the measurement alternative under ASC 321 are carried at its initial cost, with remeasurements to fair value upon impairment or upon a price change observed in an orderly transaction of the same or similar investments. For equity method investments where we have not elected the fair value option, we record gains (losses) from investments in equity method investees, net of tax, for our proportionate share of the underlying company's net results until the investment balance is adjusted to zero. If we make subsequent additional investments in that same company, we may record additional gains (losses) based on changes to our investment basis and also may record additional income (loss) in equity method investments. If we have elected the fair value option for an equity investment, the fair value of the investments will be recognized upon acquisition and any changes in fair value will be recognized as a component of other income (expense), net.

Components of Our Results of Operations

License Revenue

On March 11, 2021, we entered into a license and collaboration agreement (the "Otsuka Agreement"), with Otsuka Pharmaceutical Co., LTD ("Otsuka"), under which we granted exclusive rights to Otsuka to develop and commercialize certain products containing arketamine in Japan for the treatment of depression and other select indications. We received an upfront, non-refundable payment of \$20.0 million in June 2021 and we are also eligible to receive up to \$35.0 million if certain development and regulatory milestones are achieved and up to \$66.0 million in commercial milestones upon the achievement of certain commercial sales thresholds. We are eligible to receive tiered, royalties ranging from low-teens to high-teens on net sales of licensed products subject to reduction in certain circumstances.

For the foreseeable future, we may generate revenue from reimbursements of services under the Otsuka Agreement, as well as milestone payments under our current and/or future collaboration agreements. We do not expect to generate any revenue from the sale of products unless and until such time that our product candidates have advanced through clinical development and regulatory approval, if ever. We expect that any revenue we generate, if at all, will fluctuate from year-to-year as a result of the timing and amount of payments relating to such services and milestones and the extent to which any of our products are approved and successfully commercialized. Our ability to generate future revenues will also depend on our ability to complete preclinical and clinical development of product candidates or obtain regulatory approval for them.

Operating Expenses

Research and development expenses

Research and development expenses consist primarily of costs incurred for our research activities, including our discovery efforts and the development of our product candidates, which include:

- employee-related expenses, including salaries, related benefits and stock-based compensation, for employees engaged in research and development functions;
- expenses incurred in connection with the preclinical and clinical development of our product candidates, including our agreements with third parties, such as consultants and contract research organizations ("CROs");
- expenses incurred under agreements with consultants who supplement our internal capabilities;
- the cost of lab supplies and acquiring, developing and manufacturing preclinical study materials and clinical trial materials;
- costs related to compliance with regulatory requirements; and
- payments made in connection with third-party licensing agreements.

Research and development costs, including costs reimbursed under the Otsuka Agreement, are expensed as incurred, with reimbursements of such amounts being recognized as revenue. We account for nonrefundable advance payments for goods and services that will be used in future research and development activities as expenses when the service has been performed or when the goods have been received.

Our direct research and development expenses are tracked on a program-by-program basis for our product candidates and consist primarily of external costs, such as fees paid to outside consultants, CROs, contract manufacturing organizations ("CMOs") and research laboratories in connection with our preclinical development, process development, manufacturing and clinical development activities. Our direct research and development expenses by program also include fees incurred under third-party license agreements.

Certain internal research and development expenses consisting of employee and contractor-related costs are not allocated to specific product candidate programs because these costs are deployed across multiple product candidate programs under research and development expense.

Research and development activities are central to our business model. Product candidates in later stages of clinical development generally have higher development costs than those in earlier stages of clinical development, primarily due to the increased size and duration of later-stage clinical trials. We expect that our research and development expenses will continue to increase for the foreseeable future in connection with our planned preclinical and clinical development activities in the near term and in the future.

The successful development of our product candidates is highly uncertain. As such, at this time, we cannot reasonably estimate or know the nature, timing and estimated costs of the efforts that will be necessary to complete the remainder of the development of these product candidates. We are also unable to predict when, if ever, material net cash inflows will commence from our product candidates. This is due to the numerous risks and uncertainties associated with developing products, including the uncertainty of whether (i) any clinical trials will be conducted or progress as planned or completed on schedule, if at all, (ii) we obtain regulatory approval for our product candidates and (iii) we successfully commercialize product candidates.

General and administrative expenses

General and administrative ("G&A") expenses consist primarily of salaries and other related costs, including stock-based compensation, for personnel in our executive, finance, corporate and business development and administrative functions, professional fees for legal, patent, accounting, auditing, tax and consulting services, travel expenses and facility-related expenses, advertising, and information technology-related expenses.

We are actively controlling G&A spend and expect that our on-going G&A expenses will continue to decrease in the near future. We may add more general and administrative head count in the future to support the potential commercialization of our product candidates.

Other income (expense), net

Interest income

Interest income consists of interest earned on cash balances held in interest-bearing accounts and interest earned on notes receivable. We expect that our interest income will fluctuate based on the timing and ability to raise additional funds as well as the amount of expenditures for the research and development of our product candidates and ongoing business operations.

Interest expense

Interest expense consists primarily of interest expense incurred in connection with our 2022 Term Loan Facility, defined below.

Benefit from research and development tax credit

Benefit from research and development tax credit consists of tax credits received in Australia under the Research and Development Tax Incentive, or RDTI, program. Qualifying expenditures include employment costs for research staff, consumables, and relevant, permitted CRO costs incurred as part of research projects.

Change in fair value of assets and liabilities, net

The Company carries various assets and liabilities at fair value and subsequent remeasurements are recorded as a Change in fair value of assets and liabilities, net as a component of Other income (expense), net. Assets held at fair value include securities held at fair value, investments held at fair value, and convertible notes receivable. Liabilities held at fair value include contingent considerations, short-term convertible promissory notes and derivative liability, debtor-in-possession loan commitment, and warrant liability.

Change in fair value of securities carried at fair value

Change in fair value of securities consists of changes in fair value of our available for sale securities for which we have elected the fair value option.

Change in fair value of short-term notes receivable - related party, net

Change in fair value of short-term notes receivable - related party, net, consists of subsequent remeasurements of our notes receivable with IntelGenx for which we have elected the fair value option.

Change in fair value of short-term convertible notes receivable - related party

Change in fair value of short-term convertible notes receivable - related party, consists of subsequent remeasurements of our convertible notes receivable with IntelGenx for which we have elected the fair value option.

Change in fair value of other investments held at fair value

Change in fair value of other investments held at fair value consists of subsequent remeasurements of our investments held at fair value, including COMPASS Pathways plc ("COMPASS"), IntelGenx Technologies Corp. ("IntelGenx"), and Beckley Psytech Limited ("Beckley Psytech") for which we have elected the fair value option.

Change in fair value of contingent consideration liability - related parties

Change in fair value of contingent consideration liability - related parties, consists of subsequent remeasurements of our contingent consideration liability related to our acquisition of Perception Neuroscience Holdings, Inc. for which we record at fair value.

Change in fair value of contingent consideration liability

Change in fair value of contingent consideration liability, consists of subsequent remeasurements of our contingent consideration liability related to our acquisition of DemeRx IB, Inc. ("DemeRx IB") and TryptageniX, Inc. ("TryptageniX") for which we record at fair value.

Change in the fair value of short-term convertible promissory notes and derivative liability

Change in fair value of short-term convertible promissory notes and derivative liability consists of subsequent remeasurements of certain convertible notes issued in 2020.

Change in fair value of subsequent debtor-in-possession loan commitment

Change in fair value of subsequent debtor-in-possession loan commitment consists of subsequent remeasurements of our liability for the remaining balance of the credit facility between the Company and IntelGenx (the "DIP Loan") for which we have elected the fair value option.

Gain on deconsolidation of a variable interest entity

Gain on deconsolidation of a variable interest entity is the result of removing assets and liabilities from our consolidated balance sheet following a loss of control or divestment of a variable interest entity.

Foreign exchange gain (loss), net

Foreign exchange gain (loss), net consists of the impact of changes in foreign currency exchange rates on our foreign exchange denominated assets and liabilities, relative to the U.S. dollar. The impact of foreign currency exchange rates on our results of operations fluctuates period over period based on our foreign currency exposures resulting from changes in applicable exchange rates associated with our foreign denominated assets and liabilities.

Other income (expense), net

Other income (expense), net consists principally of the impact of accounting adoptions, changes in the carrying values of our assets and liabilities, or net gains (losses) recognized on the sale of certain of our assets.

Benefit from (provision for) income taxes

For our consolidated entities, deferred income taxes are provided for the effects of temporary differences between the amounts of assets and liabilities recognized for financial reporting purposes and the amounts recognized for income tax purposes. Deferred income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes.

We regularly assess the need to record a valuation allowance against net deferred tax assets if, based upon the available evidence, it is more likely than not that some or all of the deferred tax assets will not be realized. Accordingly, we maintain a full valuation allowance against net deferred tax assets for all entities as of September 30, 2024. In assessing the realizability on deferred tax assets, we consider whether it is more-likely-than-not that some or all of deferred tax assets will not be realized. The future realization of deferred tax assets is subject to the existence of sufficient taxable income of the appropriate character (e.g., ordinary income or capital gain) as provided under the carryforward provisions of local tax law.

We consider the scheduled reversal of deferred tax liabilities (including the effect in available carryback and carryforward periods), future projected taxable income, including the character and jurisdiction of such income, and tax-planning strategies in making this assessment.

Unrecognized tax benefits arise when the estimated benefit recognized in the financial statements differs from the amounts taken or expected to be taken in a tax return because of the considerations described above. As of September 30, 2024, we had no additional unrecognized tax benefits and the Company accrued interest on the tax positions recognized in 2023 through September 30, 2024.

Losses from Investments in Equity Method Investees, Net of Tax

Losses from investments in equity method investees, net of tax consists of our share of equity method investees losses on the basis of our equity ownership percentage related to our equity method investments.

Net Loss Attributable to Noncontrolling Interests

Net loss attributable to noncontrolling interests in our unaudited condensed consolidated statements of operations is a result of our investments in certain of our consolidated VIEs and consists of the portion of the net loss of these consolidated entities that is not allocated to us. Net losses in consolidated VIEs are attributed to noncontrolling interests considering the liquidation preferences of the different classes of equity held by the shareholders in the VIE and their respective interests in the net assets of the consolidated VIE in the event of liquidation, and their pro rata ownership. Changes in the amount of net loss attributable to noncontrolling interests are directly impacted by changes in the net loss of our VIEs and our ownership percentage changes.

Results of Operations

Comparison of the Three Months Ended September 30, 2024 and 2023 (unaudited)

	For the three months ended September 30,		\$ Change	% Change
	2024	2023		
	(in thousands, except percentages)			
License revenue	\$ 40	\$ 87	\$ (47)	(54 %)
Operating expenses:				
Research and development	12,377	13,290	(913)	(7 %)
General and administrative	10,265	13,631	(3,366)	(25 %)
Total operating expenses	22,642	26,921	(4,279)	(16 %)
Loss from operations	(22,602)	(26,834)	4,232	(16 %)
Other income (expense), net:				
Interest income	160	612	(452)	(74 %)
Interest expense	(783)	(686)	(97)	14 %
Benefit from research and development tax credit	31	—	31	100 %
Change in fair value of assets and liabilities, net	(1,964)	70,810	(72,774)	(103 %)
Foreign exchange gain, net	770	253	517	204 %
Other expense, net	(2,075)	(308)	(1,767)	574 %
Total other income (expense), net	(3,861)	70,681	(74,542)	(105 %)
Net income (loss) before income taxes	(26,463)	43,847	(70,310)	(160 %)
Benefit from (provision for) income taxes	178	(238)	416	(175 %)
Losses from investments in equity method investees, net of tax	(26)	(238)	212	(89 %)
Net loss	\$ (26,311)	\$ 43,371	\$ (69,682)	(161 %)
Net loss attributable to noncontrolling interests	(25)	(873)	848	(97 %)
Net loss attributable to ATAI Life Sciences N.V. stockholders	\$ (26,286)	\$ 44,244	\$ (70,530)	(159 %)

License Revenue

We recognized an immaterial amount and \$0.1 million of license revenue for the three months ended September 30, 2024 and 2023, respectively, related to certain research and development services performed by the Company pursuant to the Otsuka Agreement.

Research and Development Expenses

The table and discussion below present research and development expenses for the three months ended September 30, 2024 and 2023:

	Three months ended September 30,		\$ Change	% Change
	2024	2023		
(in thousands, except percentages)				
Direct research and development expenses by program:				
Psychedelic Programs				
VLS-01	\$ 1,582	\$ 1,179	\$ 403	34 %
IBX-210 & DMX-1002	1,247	368	879	239 %
Novel 5-HT2A Receptor Agonists	880	539	341	63 %
EMP-01	355	556	(201)	(36 %)
Non-Psychedelic Programs				
RL-007	3,953	2,418	1,535	63 %
Other Programs	80	803	(723)	(90 %)
Enabling Technologies and Drug Discovery Platforms	11	507	(496)	(98 %)
Unallocated research and development expenses:				
Personnel expenses	4,046	6,457	(2,411)	(37 %)
Professional and consulting services	93	363	(270)	(74 %)
Other	130	100	30	30 %
Total research and development expenses	<u>\$ 12,377</u>	<u>\$ 13,290</u>	<u>\$ (913)</u>	<u>(7 %)</u>

Research and development expenses were \$12.4 million for the three months ended September 30, 2024, compared to \$13.3 million for the three months ended September 30, 2023. The \$0.9 million decrease was primarily attributable to \$2.2 million increase of direct costs in our clinical programs as discussed below, mostly offset by \$0.5 million decrease of costs related to our enabling technologies and drug discovery platform as discussed below, \$2.4 million decrease in personnel expenses (inclusive of \$1.3 million decrease in stock-based compensation), and a \$0.2 million decrease in professional services costs and other costs.

Psychedelic Programs

VLS-01: N,N-dimethyltryptamine; (“DMT”) for Treatment Resistant Depression

The \$0.4 million increase in direct costs for our VLS-01 program was primarily due to \$1.1 million increase of clinical development costs related to our Phase 1b trial of VLS-01 designed to evaluate the efficacy, safety, tolerability, PK and PD of VLS-01 delivered using our proprietary OTF formulation as well as our upcoming randomized, double-blind, placebo-controlled Phase 2 study. These costs were partially offset by \$0.5 million decrease in preclinical development costs and \$0.2 million decrease in manufacturing costs.

IBX-210 & DMX-1002: Ibogaine for Opioid Use Disorder

The \$0.9 million increase in direct costs was primarily due to \$0.7 million of preclinical development costs, \$0.3 million of clinical development costs, and \$0.2 million of manufacturing costs related to the IBX-210 program in the third quarter of 2024, as compared to \$0.2 million of clinical development costs, \$0.1 million of manufacturing costs, and \$0.1 million of personnel costs related to conduct our DMX-1002 Phase 1/2 trial in the third quarter of 2023.

Novel 5-HT2A Receptor Agonists

The \$0.3 million increase in direct costs for novel 5-HT2A receptor agonists was primarily due to an increase of \$0.6 million of preclinical development costs, partially offset by a \$0.3 million decrease in manufacturing costs.

EMP-01: 3,4-methylenedioxy-methamphetamine (MDMA) derivative for Post Traumatic Stress Disorder

The \$0.2 million decrease in direct costs for our EMP-01 program was primarily due to \$0.3 million decrease in clinical development costs relating to our Phase 1 single ascending dose trial to assess the safety and tolerability of orally administered EMP-01. These were partially offset by \$0.1 million increase in manufacturing costs.

Non-Psychedelic Programs

RL-007: Pro-Cognitive Neuromodulator for Cognitive Impairment Associated with Schizophrenia

The \$1.5 million increase in direct costs for our RL-007 program was due to \$1.5 million increase of clinical development costs relating to our Phase 2b proof-of-concept clinical trial for RL-007 in CIAS.

Other Programs

The \$0.7 million decrease in direct costs for our other programs was primarily due to \$0.7 million decrease in our PCN-101 program.

Enabling Technologies and Drug Discovery Platforms

The \$0.5 million decrease in our enabling technologies and drug discovery platforms primarily relates to \$0.5 million decreased costs in our Invyxis program.

General and Administrative Expenses

General and administrative expenses were \$10.3 million for the three months ended September 30, 2024 compared to \$13.6 million for the three months ended September 30, 2023. The decrease of \$3.3 million was largely attributable to \$3.5 million decrease in personnel related costs (inclusive of \$1.8 million decrease in stock-based compensation), \$0.7 million decrease in legal and professional service expenses, and \$0.5 million decrease in insurance expenses. These were partially offset by a \$1.3 million increase in VAT and non-income tax (due to non-recurring prior year refund) and an increase of \$0.1 million in investor relations and public company compliance fees.

Other income (expense), net

Interest income

Interest income for the three months ended September 30, 2024 and 2023 primarily consisted of interest earned on our cash balances and notes receivable during these periods. We recognized interest income of \$0.2 million and \$0.6 million for the three months ended September 30, 2024 and 2023, respectively.

Interest expense

Interest expense for the three months ended September 30, 2024 and 2023 primarily consisted of interest expense incurred in connection with our 2022 Term Loan Facility, defined below. Interest expense was \$0.8 million and \$0.7 million for the three months ended September 30, 2024 and 2023, respectively.

Benefit from research and development tax credit

We recognized an immaterial amount of research and development tax credit from the Australian Tax Authorities for the three months ended September 30, 2024 and 2023.

Change in fair value of assets and liabilities, net:

Change in fair value of securities carried at fair value

Changes in fair value of securities consists of changes in the fair value of our available for sale securities for which we have elected the fair value option. During the three months ended September 30, 2024 and 2023 we recognized a gain of \$0.9 million and \$1.8 million, respectively, relating to the change in fair value of securities.

Change in fair value of short-term notes receivable - related party, net

Changes in fair value of short-term notes receivable - related party, net, including interest, consists of subsequent remeasurement of our notes receivable with IntelGenx for which we have elected the fair value option. During the three months ended September 30, 2024 we recognized an immaterial loss related to the change in the fair value. We recorded an immaterial change in fair value of short-term notes receivable - related party during the three months ended September 30, 2023. See Note 6 in the Notes to unaudited condensed consolidated financial statements in Part I, Item 1 for further information.

Change in fair value of short-term convertible notes receivable - related party

Changes in fair value of short-term convertible notes receivable - related party, including interest, consists of subsequent remeasurement of our convertible notes receivable with IntelGenx for which we have elected the fair value option. During the three months ended September 30, 2024 we recognized an \$8.0 million loss related to the change in the fair value. An immaterial change in fair value of convertible notes receivable - related party was recognized during the three months ended September 30, 2023. See Note 6 in the Notes to unaudited condensed consolidated financial statements in Part I, Item 1 for further information.

Change in fair value of other investments held at fair value

Changes in fair value of other investments held at fair value consists of subsequent remeasurement of our investments held at fair value, including our ADS holding in COMPASS, IntelGenx related investments, and warrants issued by Beckley Psytech Limited. During the three months ended September 30, 2024, we recognized a \$3.9 million gain related to our ADS holding in COMPASS and a \$0.1 million loss related to our warrants issued by Beckley Psytech Limited. During the three months ended September 30, 2023, we recognized a \$69.0

million non-cash change in fair value of other investments held at fair value related to an accounting method change for our ADS holdings in COMPASS resulting in our election of fair value accounting. See Note 5 in the Notes to unaudited condensed consolidated financial statements in Part I, Item 1 for further information.

Change in fair value of contingent consideration liability—related parties

The milestone and royalty payments in relation to the acquisition of Perception were recognized at the acquisition date, and are subsequently remeasured to fair value. For the three months ended September 30, 2024 and 2023 we recognized a \$0.1 million loss and a \$0.1 million loss, respectively.

Change in fair value of contingent consideration liability

In October 2023, we acquired the noncontrolling interest's shares of DemeRx IB making DemeRx IB a wholly owned subsidiary. An earn-out of up to \$8.0 million was part of the consideration and was recognized at fair value at the transaction date and subsequently remeasured at fair value. For the three months ended September 30, 2024, we recognized an immaterial change in the fair value related to the DemeRx IB contingent consideration. In December 2023, we disposed of our equity interest in TryptageniX, but retained the contingent consideration liability, which is subsequently remeasured to fair value. For the three and nine months ended September 30, 2024 and 2023, we recognized an immaterial gain related to the TryptageniX contingent consideration.

Change in fair value of convertible promissory notes and derivative liability

In December 2023 and April 2024, certain 2020 convertible noteholders exchanged the 2020 convertible notes issued by ATAI Life Sciences AG for notes issued by ATAI Life Sciences NV, which are convertible into ATAI NV common shares. We determined that this was a modification to the convertible notes and record the fair value of the conversion option quarterly. For the three months ended September 30, 2024, we recognized a \$0.9 million gain due to a change in the fair value of the conversion option of the convertible notes issued by ATAI Life Sciences NV.

Change in fair value of subsequent debtor-in-possession loan commitment

Change in fair value of subsequent debtor-in-possession loan commitment consists of subsequent remeasurements of our liability for the remaining balance of the DIP Loan for which we have elected the fair value option. During the three months ended September 30, 2024 we recognized \$0.5 million gain related to the change in the fair value.

Foreign exchange gain, net

We recognized a gain of \$0.8 million related to foreign currency exchange rates for the three months ended September 30, 2024 and a gain of \$0.3 million related to foreign currency exchange rate for the three months ended September 30, 2023. This was due to the impact of fluctuations in the foreign currency exchange rate between the Euro and the U.S. dollar on our foreign denominated balances.

Other expense, net

We incurred a non-cash loss of \$2.1 million on the sale of our ADS holdings in COMPASS during the three months ended September 30, 2024. We incurred a \$0.3 million other expense, net for the three months ended September 30, 2023, which primarily consisted of a \$0.3 million increase to the allowances on receivables, partially offset by a \$0.1 million gain recognized on the Company divestment of its investment in Juvenescence Limited ("Juvenescence").

Benefit from (provision for) income taxes

We incurred \$0.2 million of current income tax benefit for the three months ended September 30, 2024 compared to a \$0.2 million income tax expense for the three months ended September 30, 2023. The decrease in income tax expense in 2024 was primarily driven by a reduction in global earnings, a favorable return to provision from one of our Australian subsidiaries and the release of an uncertain tax liability associated with a 2021 tax return for one of our subsidiaries.

Losses from Investments in Equity Method Investees

Losses from investment in equity method investees for the three months ended September 30, 2024 and 2023 was immaterial and \$0.2 million, respectively. Loss from investment in equity method investees represents our share of equity method investee losses on the basis of our equity ownership percentages or based on our proportionate share of the respective class of securities in our other investments in the event that the carrying amount of our equity method investments was zero.

Comparison of the Nine Months Ended September 30, 2024 and 2023 (unaudited)

	For the nine months ended September 30,		\$ Change	% Change
	2024	2023		
	(in thousands, except percentages)			
License revenue	\$ 313	\$ 296	\$ 17	6%
Operating expenses:				
Research and development	36,513	48,047	(11,534)	(24)%
General and administrative	36,226	44,159	(7,933)	(18)%
Total operating expenses	72,739	92,206	(19,467)	(21)%
Loss from operations	(72,426)	(91,910)	19,484	(21)%
Other income (expense), net:				
Interest income	585	1,191	(606)	(51)%
Interest expense	(2,172)	(1,965)	(207)	11%
Benefit from research and development tax credit	617	—	617	100%
Change in fair value of assets and liabilities, net	(33,764)	72,411	(106,175)	(147)%
Foreign exchange gain (loss), net	676	(593)	1,269	(214)%
Other expense, net	(2,737)	(100)	(2,637)	2637%
Total other income (expense), net	(36,795)	70,944	(107,739)	(152)%
Net loss before income taxes	(109,221)	(20,966)	(88,255)	421%
Benefit from (provision for) income taxes	163	(588)	751	(128)%
Losses from investments in equity method investees, net of tax	(2,000)	(3,199)	1,199	(37)%
Net loss	\$ (111,058)	\$ (24,753)	\$ (86,305)	349%
Net loss attributable to noncontrolling interests	(747)	(2,821)	2,074	(74)%
Net loss attributable to ATAI Life Sciences N.V. stockholders	\$ (110,311)	\$ (21,932)	\$ (88,379)	403%

License Revenue

We recognized \$0.3 million and \$0.3 million of license revenue for the nine months ended September 30, 2024 and 2023, respectively, related to certain research and development services performed by the Company pursuant to the Otsuka Agreement.

Research and Development Expenses

The table and discussion below present research and development expenses for the nine months ended September 30, 2024 and 2023:

	Nine months ended September 30,		\$ Change	% Change
	2024	2023		
	(in thousands, except percentages)			
Direct research and development expenses by program:				
Psychedelic Programs				
VLS-01	\$ 6,362	\$ 6,351	\$ 11	0%
IBX-210 & DMX-1002	3,224	1,324	1,899	143%
Novel 5-HT2A Receptor Agonists	1,705	1,395	311	22%
EMP-01	622	2,124	(1,501)	(71)%
Non-Psychedelic Programs				
RL-007	8,452	5,797	2,655	46%
Other Programs	550	6,122	(5,572)	(91)%
Enabling Technologies and Drug Discovery Platforms	563	2,711	(2,149)	(79)%
Unallocated research and development expenses:				
Personnel expenses	13,945	20,566	(6,621)	(32)%
Professional and consulting services	765	1,279	(514)	(40)%
Other	324	378	(54)	(14)%
Total research and development expenses	\$ 36,513	\$ 48,047	\$ (11,534)	(24)%

Research and development expenses were \$36.5 million for the nine months ended September 30, 2024, compared to \$48.0 million for the nine months ended September 30, 2023. The decrease of \$11.5 million was primarily attributable to \$2.2 million decrease of direct costs in our clinical programs as discussed below, \$2.1 million decrease of costs related to our enabling technologies and drug discovery platform as discussed below, \$6.6 million decrease in personnel expenses (inclusive of \$3.2 million decrease in stock-based compensation and a \$1.6 million decrease in restructuring costs), \$0.5 million decrease in professional service costs, and a \$0.1 million decrease in other expenses.

Psychedelic Programs

VLS-01: N,N-dimethyltryptamine; (“DMT”) for Treatment Resistant Depression

The direct costs for our VLS-01 program remained consistent for the nine months ended September 30, 2024 as compared to the nine months ended September 30, 2023. This was primarily due to \$1.0 million increase of clinical development costs and \$0.2 million increase of preclinical development costs related to our Phase 1 three-part trial and Phase 1b trial of VLS-01 designed to evaluate the safety, tolerability, PK and PD of VLS-01 delivered by intravenous (IV) infusion and using our proprietary OTF formulation as well as our upcoming randomized, double-blind, placebo-controlled Phase 2 study. These increases were partially offset by a \$1.2 million decrease in manufacturing costs.

IBX-210 & DMX-1002: Ibogaine for Opioid Use Disorder

The \$1.9 million net increase in direct costs was primarily due to \$1.6 million of preclinical development costs, \$0.9 million of clinical development costs, and \$0.7 million of manufacturing costs related to the IBX-210 program for the nine months ended September 30, 2024, as compared to \$0.7 million of clinical development costs, \$0.4 million of manufacturing costs, and \$0.2 million of personnel costs related to the conduct our DMX-1002 Phase 1/2 trial for the nine months ended September 30, 2023.

Novel 5-HT2A Receptor Agonists

The \$0.3 million increase in direct costs for novel 5-HT2A receptor agonists was primarily due to \$0.3 million increase in preclinical development costs.

EMP-01: 3,4-methylenedioxy-methamphetamine (MDMA) derivative for Post Traumatic Stress Disorder

The \$1.5 million decrease in direct costs for our EMP-01 program was primarily due to \$1.2 million decrease in clinical development costs and \$0.3 million decrease in preclinical development costs relating to our Phase 1 single ascending dose trial to assess the safety and tolerability of orally administered EMP-01.

Non-Psychedelic Programs

RL-007: Pro-Cognitive Neuromodulator for Cognitive Impairment Associated with Schizophrenia

The \$2.7 million increase in direct costs for our RL-007 program was primarily due to an increase of \$2.5 million in clinical development costs, \$0.2 million of manufacturing costs, and \$0.2 million in preclinical development costs, all relating to our Phase 2b proof-of-concept clinical trial for RL-007 in CIAS. These costs were partially offset by a decrease of \$0.2 million in personnel costs.

Other Programs

The \$5.6 million decrease in direct costs for our other programs was primarily due to \$5.3 million decrease in our PCN-101 program, \$0.2 million decrease in our KUR-101 program, and \$0.1 million decrease in our RLS-01 program.

Enabling Technologies and Drug Discovery Platforms

The \$2.1 million decrease in our enabling technologies and drug discovery platforms primarily relates to \$1.1 million decrease in our Invyxis program, \$0.4 million decrease in our TryptageniX program, \$0.4 million decrease in our InnarisBio program, and \$0.2 million decrease in our Psyber program.

General and Administrative Expenses

General and administrative expenses were \$36.2 million for the nine months ended September 30, 2024 compared to \$44.2 million for the nine months ended September 30, 2023. The decrease of \$8.0 million was largely attributable to \$8.3 million decrease in personnel related costs (inclusive of \$5.1 million decrease in stock-based compensation and \$0.4 million increase in restructuring costs), \$2.3 million decrease in legal and professional services, and \$1.1 million decrease in insurance costs, partially offset with \$3.3 million increase in VAT and non-income tax (due to non-recurring prior year refund) and \$0.4 million increase in investor relations and public company fees.

Other income (expense), net

Interest income

Interest income for the nine months ended September 30, 2024 and 2023 primarily consisted of interest earned on our cash balances and notes receivable during these periods. We recognized interest income of \$0.6 million and \$1.2 million for the nine months ended September 30, 2024 and 2023, respectively.

Interest expense

Interest expense for the nine months ended September 30, 2024 and 2023 primarily consisted of interest expense incurred in connection with our 2022 Term Loan Facility, defined below. Interest expense was \$2.2 million and \$2.0 million for the nine months ended September 30, 2024 and 2023, respectively.

Benefit from research and development tax credit

We recognized a research and development tax credit from the Australian Tax Authorities as a benefit of \$0.6 million for the nine months ended September 30, 2024. We recognized an immaterial amount of research and development tax credit for the nine months ended September 30, 2023.

Change in fair value of assets and liabilities, net:

Change in fair value of securities carried at fair value

Changes in fair value of securities consists of changes in the fair value of our available for sale securities for which we have elected the fair value option. During the nine months ended September 30, 2024 and 2023, we recognized a gain of \$3.2 million and \$3.3 million, respectively, relating to the change in fair value of securities.

Change in fair value of short-term notes receivable - related party, net

Changes in fair value of short-term notes receivable - related party, net, including interest, consists of subsequent remeasurement of our short-term notes receivable with IntelGenx for which we have elected the fair value option. During the nine months ended September 30, 2024 we recognized a \$0.5 million loss related to the change in the fair value. We recorded an immaterial change in fair value of short-term notes receivable - related party during the nine months ended September 30, 2023. See Note 6 in the Notes to unaudited condensed consolidated financial statements in Part I, Item 1 for further information.

Change in fair value of short-term convertible notes receivable - related party

Changes in fair value of short-term convertible notes receivable - related party, including interest, consists of subsequent remeasurement of our convertible notes receivable with IntelGenx for which we have elected the fair value option. During the nine months ended September 30, 2024 we recognized \$13.2 million loss related to the change in the fair value. We recognized an immaterial change in fair value for our convertible notes receivable - related party during the nine months ended September 30, 2023. See Note 6 in the Notes to unaudited condensed consolidated financial statements in Part I, Item 1 for further information.

Change in fair value of other investments held at fair value

Changes in fair value of other investments held at fair value consists of subsequent remeasurement of our investments held at fair value, including our ADS holdings in COMPASS, IntelGenx related investments, and warrants issued by Beckley Psytech Limited. During the nine months ended September 30, 2024, we recognized a \$22.0 million loss related to our ADS holdings in COMPASS, a \$6.5 million loss related to our investments in IntelGenx, and a \$0.6 million gain related to warrants issued by Beckley Psytech Limited. During the nine months ended September 30, 2023, we recognized a \$69.0 million non-cash change in fair value of other investments held at fair value related to an accounting method change for our ADS holdings in COMPASS resulting in our election of fair value accounting. See Note 5 in the Notes to unaudited condensed consolidated financial statements in Part I, Item 1 for further information.

Change in fair value of contingent consideration liability—related parties

The milestone and royalty payments in relation to the acquisition of Perception were recognized at the acquisition date, and are subsequently remeasured to fair value. For the nine months ended September 30, 2024 and 2023 we recognized an immaterial loss and a \$0.1 million loss, respectively.

Change in fair value of contingent consideration liability

In October 2023, we acquired the noncontrolling interest's shares of DemeRx IB making DemeRx IB a wholly owned subsidiary. An earn-out of up to \$8.0 million was part of the consideration and was recognized at fair value at the transaction date and subsequently remeasured at fair value. For the nine months ended September 30, 2024, we recognized a \$0.2 million gain related to the DemeRx IB contingent consideration. In December 2023, we disposed of our equity interest in TryptageniX, but retained the contingent consideration liability, which is subsequently remeasured to fair value. For the nine months ended September 30, 2024, we recognized an immaterial gain related to the TryptageniX contingent consideration.

Change in fair value of convertible promissory notes and derivative liability

In December 2023 and April 2024, certain 2020 convertible noteholders exchanged the 2020 convertible notes issued by ATAI Life Sciences AG for notes issued by ATAI Life Sciences NV, which are convertible into ATAI NV common shares. We determined that this was a modification to the convertible notes and record the fair value of the conversion option quarterly. For the nine months ended September 30, 2024, we recognized a \$4.0 million gain due to a change in the fair value of the conversion option of the notes issued by ATAI Life Sciences NV.

Change in fair value of subsequent debtor-in-possession loan commitment

Change in fair value of subsequent debtor-in-possession loan commitment consists of subsequent remeasurements of our liability for the remaining balance of the DIP Loan for which we have elected the fair value option. During the nine months ended September 30, 2024 we recognized \$0.5 million gain related to the change in the fair value.

Foreign exchange loss, net

We recognized a gain of \$0.7 million related to foreign currency exchange rates for the nine months ended September 30, 2024 and a loss of \$0.6 million related to foreign currency exchange rate for the nine months ended September 30, 2023. This was due to the impact of fluctuations in the foreign currency exchange rate between the Euro and the U.S. dollar on our foreign denominated balances.

Other expense, net

We incurred \$2.7 million of other expense, net for the nine months ended September 30, 2024, which primarily relates to a non-cash loss of \$2.1 million on the sale of our ADS holdings in COMPASS and our initial recognition of the IntelGenx subsequent debtor-in-possession loan commitment of \$0.7. See Note 5 and Note 6 in the Notes to our unaudited condensed consolidated financial statements in Part I, Item 1 for further information.

We incurred \$0.1 million of other expense, net of for the nine months ended September 30, 2023, which consists primarily of a \$0.3 million increase to the allowances on receivables, partially offset by a \$0.1 million gain recognized on our divestment of our investment in Juvenescence Limited ("Juvenescence") and \$0.1 million of service revenue generated for general and administrative services performed by us on behalf of our platform companies.

Benefit from (provision for) income taxes

We incurred \$0.2 million of current income tax benefit for the nine months ended September 30, 2024 compared to \$0.6 million of income tax expense for the nine months ended September 30, 2023. The decrease in income tax expense shown in 2024 was primarily driven by a reduction in global earnings, a favorable return to provision from one of our Australian subsidiaries and the release of an uncertain tax liability associated with a 2021 subsidiary tax return.

Losses from Investments in Equity Method Investees

Losses from investment in equity method investees for the nine months ended September 30, 2024 and 2023 was \$2.0 million and \$3.2 million, respectively. Loss from investment in equity method investees represents our share of equity method investee losses on the basis of our equity ownership percentages or based on our proportionate share of the respective class of securities in our other investments in the event that the carrying amount of our equity method investments was zero.

Liquidity and Capital Resources

For the nine months ended September 30, 2024 and 2023, we had net losses attributable to ATAI Life Sciences N.V. stockholders of \$110.3 million and \$21.9 million, respectively. As of September 30, 2024 and December 31, 2023, our accumulated deficit was \$661.3 million and \$550.9 million, respectively. We expect to continue to incur losses and operating cash outflows for the foreseeable future as we continue working towards commercializing any of our product candidates. Our primary sources of liquidity are our cash and cash equivalents, short-term securities, convertible promissory notes, investments, sales of common shares under our at-the-market equity offering program, and the 2022 Term Loan Facility, as further described below. We maintain cash balances with financial institutions in excess of insured limits.

Our primary requirements for liquidity and capital are clinical trial costs, manufacturing costs, nonclinical and other research and development costs, funding of strategic investments, public company compliance costs and general corporate needs. Because our product candidates are in various stages of clinical and pre-clinical development and the outcome of these efforts is uncertain, we cannot estimate the actual amounts necessary to successfully complete the development and commercialization of our product candidates or whether, or when, we may achieve profitability.

Until such time, if ever, as we can generate substantial product revenues, we expect to finance our cash needs through a combination of equity or debt financings, collaboration arrangements, license agreements, other business development opportunities with third parties and government grants.

Sources of Liquidity

Convertible Promissory Notes

In November 2018, we issued an aggregate principal amount of \$0.2 million of convertible notes (“2018 Convertible Notes”). The 2018 Convertible Notes are non-interest-bearing, unsecured and have a maturity date of September 30, 2025, unless previously redeemed, converted, purchased or cancelled. In October 2020, we issued an additional principal amount of \$1.0 million of the 2018 Convertible Notes. Each note has a face value of €1 and is convertible into one ordinary share of ATAI Life Sciences AG upon the payment of €17.00.

In December 2023 and April 2024, respectively, a noteholder and a related party noteholder each entered into an agreement with us to exchange their respective 2020 Convertible Notes for new convertible notes issued by ATAI Life Sciences N.V. Each new note has a face value of €1 and is convertible into 16 common shares of ATAI Life Sciences N.V. upon the payment of €17.00. Conversion rights may be exercised by a noteholder at any time prior to maturity.

As of September 30, 2024 the new ATAI Life Sciences N.V. notes had a principal balance of \$0.4 million. If all convertible notes were converted, the Company would receive proceeds of €6.6 million (\$7.4 million) in the aggregate.

Investments

A significant potential source of liquidity resides in our investment in ADSs of COMPASS, subject to market conditions. Based on quoted market prices, the market value of our ownership in COMPASS was \$43.5 million as of September 30, 2024.

In September 2024, the Company sold 2,660,000 ADSs of COMPASS at a price of \$6.05 per ADS in an open market transaction, resulting in net proceeds received of \$16.1 million.

ATM Agreement

In November 2022, we entered into an Open Market Sale Agreement (the “Sales Agreement”) with Jefferies LLC (“Jefferies”), pursuant to which we may issue and sell our common shares, having an aggregate offering price of up to \$150,000,000, from time to time through an “at-the-market” equity offering program under which Jefferies will act as sales agent. Subject to the terms and conditions of the Sales Agreement, Jefferies could sell the common shares by any method deemed to be an “at-the-market” offering as defined in Rule 415 promulgated under the Securities Act of 1933, as amended. There have been no sales under the Sales Agreement through September 30, 2024.

Hercules Term Loan

In August 2022, we entered into a Loan and Security Agreement, with Hercules Capital, Inc., which was most recently amended in August 2024. See “ – Liquidity Risks – *Indebtedness– Hercules Term Loan*” for additional information.

Liquidity Risks

As of September 30, 2024, we had cash and cash equivalents of \$30.0 million, restricted cash of \$15.0 million, and short-term securities of \$56.0 million. Based on our current operating plan, we estimate that our existing cash and cash equivalents, short-term securities, and committed term loan funding as of the date this Quarterly Report will be sufficient to fund our operating expenses and capital expenditure requirements for at least the next 12 months and we believe will be sufficient to fund our operations into 2026.

We expect to continue to incur substantial additional expenditures in the near term to support our ongoing activities. Additionally, we have incurred and expect to continue to incur additional costs as a result of operating as a public company. We expect to continue to incur net losses for the foreseeable future. Our ability to fund our product development and clinical operations as well as commercialization of our product candidates, will depend on the amount and timing of cash received from planned financings.

Our future capital requirements will depend on many factors, including:

- the time and cost necessary to complete ongoing and planned clinical trials;
- the outcome, timing and cost of meeting regulatory requirements established by the FDA, the EMA and other comparable foreign regulatory authorities;
- the progress, timing, scope and costs of our preclinical studies, clinical trials and other related activities for our ongoing and planned clinical trials, and potential future clinical trials;
- the costs of commercialization activities for any of our product candidates that receive marketing approval, including the costs and timing of establishing product sales, marketing, distribution and manufacturing capabilities, or entering into strategic collaborations with third parties to leverage or access these capabilities;
- the amount and timing of sales and other revenues from our product candidates, if approved, including the sales price and the availability of coverage and adequate third party reimbursement;

- the cash requirements for purchasing additional equity from certain atai companies upon the achievement of specified development milestone events;
- the cash requirements for developing our programs and our ability and willingness to finance their continued development;
- the cash requirements for any future acquisitions or discovery of product candidates; and
- the time and cost necessary to respond to technological and market developments, including other products that may compete with one or more of our product candidates.

A change in the outcome of any of these or other variables with respect to the development of any of our product candidates could significantly change the costs and timing associated with the development of that product candidate. Further, our operating plans may change in the future, and we may need additional funds to meet operational needs and capital requirements associated with such operating plans. If we are unable to obtain this funding when needed and on acceptable terms, we could be forced to delay, limit or terminate our product development efforts.

Until such time, if ever, as we can generate substantial product revenue, we expect to finance our operations through a combination of equity financings, debt financings, collaborations with other companies and other strategic transactions. Debt financing and preferred equity financing, if available, may involve agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making acquisitions or capital expenditures or declaring dividends. If we are unable to raise additional funds through equity or debt financings or other arrangements when needed, we may be required to delay, limit, reduce or terminate our product development or future commercialization efforts or grant rights to develop and market product candidates that we would otherwise prefer to develop and market ourselves.

Further, our operating plans may change, and we may need additional funds to meet operational needs and capital requirements for clinical trials and other research and development activities. Because of the numerous risks and uncertainties associated with the development and commercialization of our product candidates, we are unable to estimate the amounts of increased capital outlays and operating expenditures associated with our current and anticipated product development programs.

Cash Flows

The following table summarizes our cash flows for the nine months ended September 30, 2024 and 2023:

	September 30,	
	2024	2023
	(in thousands)	
Net cash used in operating activities	\$ (58,142)	\$ (62,156)
Net cash provided by (used in) investing activities	52,612	(52,472)
Net cash provided by financing activities	5,220	106
Effect of foreign exchange rate changes on cash	239	401
Net decrease in cash, cash equivalents and restricted cash	\$ (71)	\$ (114,121)

Net Cash Used in Operating Activities

Net cash used in operating activities was \$58.1 million for the nine months ended September 30, 2024, which consisted of a net loss of \$111.1 million, adjusted by non-cash charges of \$58.1 million and a net cash outflow of \$5.2 million related to the change in operating assets and liabilities. The non-cash charges primarily consisted of \$36.0 million loss related to the change in fair value of assets and liabilities, net, \$17.1 million of stock-based compensation, \$2.1 million loss from sale of investment held at fair value, \$2.0 million of losses from our equity method investments, \$1.0 million in other expenses, \$0.3 million amortization of debt discount, \$0.2 million in depreciation and amortization expense, and \$0.2 million change in right-of-use asset, partially offset by a \$0.8 million unrealized foreign exchange gain. The net cash outflows from the change in operating assets and liabilities were primarily due to a \$3.8 million decrease in accrued liabilities and a \$1.6 increase in prepaid expenses, partially offset by a \$0.3 million increase in accounts payable.

Net cash used in operating activities was \$62.2 million for the nine months ended September 30, 2023, which consisted of a net loss of \$23.0 million, adjusted by non-cash charges of \$43.9 million and a net cash outflow of \$4.8 million related to the change in operating assets and liabilities. The non-cash benefit primarily consisted \$69.0 million gain related to investments held at fair value and \$3.3 million gain relating to the change in the fair value of our short-term securities, partially offset by \$25.7 million of stock-based compensation, \$3.2 million of losses from our equity method investments, \$0.6 million of unrealized foreign exchange losses, \$0.3 million change in right-of-use asset and \$0.3 million amortization of debt discount. The net cash inflows from the change in operating assets and liabilities were primarily due to a decrease of \$6.7 million in prepaid expenses and other current assets and a \$3.1 million increase in accounts payable, partially offset by a \$5.0 million decrease in accrued liabilities.

Net Cash Provided By (Used in) Investing Activities

Net cash provided by investing activities was \$52.6 million for the nine months ended September 30, 2024, primarily driven by \$54.3 million of proceeds from the sale and maturities of securities carried at fair value and \$16.1 million of proceeds from the sale of other investment held at fair value, partially offset by \$10.0 million cash paid for investments, \$5.7 million of cash paid for short-term notes receivable – related party, net, and \$2.0 million of cash paid for short-term convertible notes receivable and warrant – related party.

Net cash used in investing activities was \$52.5 million for the nine months ended September 30, 2023, primarily driven by \$177.0 million of cash paid for securities at fair value, \$3.0 million of loans to related parties, \$2.2 million cash paid for investments held at fair value, \$0.5 million of cash paid for acquisition of variable interest entity, \$0.3 million of capitalized internal-use software development costs, and \$0.3 million of purchases of property plant and equipment, partially offset by \$130.4 million of proceeds from the sale and maturities of securities carried at fair value and \$0.5 million from the sale of other investments.

Net Cash Provided by Financing Activities

Net cash provided by financing activities was \$5.2 million for the nine months ended September 30, 2024, due to \$5.0 million of proceeds from debt financing and \$0.4 million of proceeds from stock option exercises, partially offset by \$0.2 million of financing costs paid.

Net cash provided by financing activities was \$0.1 million for the nine months ended September 30, 2023, due to \$0.2 million of proceeds from stock option exercises, partially offset by \$0.1 million of financing costs paid.

Indebtedness

Convertible Notes

In November 2018, we issued an aggregate principal amount of \$0.2 million of 2018 Convertible Notes. In October 2020, we issued an additional principal amount of \$1.0 million of 2018 Convertible Notes. The 2018 Convertible Notes are non-interest-bearing and have a maturity date of September 30, 2025, unless previously redeemed, converted, purchased or cancelled. Each note has a face value of €1 and is convertible into one common share of ATAI Life Sciences AG upon the payment of €17.00. Conversion rights may be exercised by a noteholder at any time prior to maturity, except during certain periods subsequent to the consummation of the IPO.

In December 2023 and April 2024, respectively, a noteholder and a related party noteholder each entered into an agreement with us to exchange their respective 2018 Convertible Notes for new convertible notes issued by ATAI Life Sciences N.V. Each new note has a face value of €1 and is convertible into 16 common shares of ATAI Life Sciences N.V. upon the payment of €17.00. Conversion rights may be exercised by a noteholder at any time prior to maturity.

As of September 30, 2024, the new ATAI Life Sciences N.V. notes had a principal balance of \$0.4 million. If all convertible notes were converted, the Company would receive proceeds of €6.6 million (\$7.4 million).

Hercules Term Loan

On August 9, 2022 (the “Closing Date”), we, ATAI Life Sciences AG (“ATAI AG” and together with us, the “Borrowers”) and certain of our subsidiary guarantors (collectively, the “Subsidiary Guarantors”) entered into a Loan and Security Agreement (the “Initial Hercules Loan Agreement”). The Initial Hercules Loan Agreement provides for term loans in an aggregate principal amount of up to \$175.0 million under multiple tranches (as amended by that certain First Amendment to Loan and Security Agreement, dated as of March 13, 2023, the “First Amendment,” that Second Amendment to Loan and Security Agreement, dated as of May 26, 2023, the “Second Amendment,” and that Third Amendment to Loan and Security Agreement, dated August 14, 2024, the “Third Amendment,” and collectively, the “2022 Term Loan Facility”).

On May 26, 2023, we, ATAI AG, and the Subsidiary Guarantors entered into the Second Amendment, with the several banks and other financial institutions or entities from time to time parties to the Hercules Loan Agreement, defined below, (collectively, the “Lenders”) and Hercules, in its capacity as administrative agent and collateral agent for itself and for the Lenders (the “Agent”) which amended that certain Loan and Security Agreement, dated August 9, 2022 (as amended by the First Amendment, the “Existing Loan Agreement” and as amended by the Second Amendment, the “Hercules Loan Agreement”) to, among other things, (i) extend the availability of Tranche 1B of \$10.0 million, from May 1, 2023, under the Existing Loan Agreement, to November 15, 2024, (ii) extend the availability of Tranche 1C of \$15.0 million, from December 15, 2023, under the Existing Loan Agreement, to December 15, 2024, (iii) provide Tranche 1D of \$20.0 million, available upon the earlier of (x) the full draw of Tranche 1C and (y) the expiration of Tranche 1C availability, through February 15, 2025, (iv) extend the availability of Tranche 2 of \$15.0 million, from June 30, 2024, under the Existing Loan Agreement, subject to certain conditions under the Hercules Loan Agreement, to the earlier of (x) the full draw of Tranche 1D and (y) the expiration of Tranche 1D availability, through March 15, 2025, subject to the Tranche 2 Draw Test, (v) extend the timeline to achieve the second amortization extension condition, from June 30, 2024, in the Existing Loan Agreement, to December 15, 2024, (vi) amend the Tranche 2 Draw Test, satisfaction of which is a condition to draw Tranche 2 under the Hercules Loan Agreement and (vii) extend the financial covenant commencement date, from the later of (x) July 1, 2023, and (y) the date that the outstanding debt under the facility is equal to or greater than \$40.0 million, in the Existing Loan Agreement, to the later of (x) May 1, 2024, and (y) the date that the outstanding debt under the

facility is equal to or greater than \$30.0 million, provided, that the financial covenant is waived if the Company has a market capitalization of at least \$550.0 million.

On August 14, 2024 (the “Third Amendment Date”), the Borrowers and certain Subsidiary Guarantors entered into the Third Amendment with the Lenders and Hercules, in its capacity as the Agent, which amended that certain Loan and Security Agreement, dated August 9, 2022 (as amended by the First Amendment, the Second Amendment and the Third Amendment, the “2022 Term Loan Agreement”) to, among other things, (i) provide Tranche 1B of \$5.0 million on the Third Amendment Date, (ii) reduce the remainder of available Tranche 1 to \$25.0 million, and extend the availability thereof (x) with respect to Tranche 1C, to be available after the Third Amendment Date until March 31, 2025, and (y) with respect to Tranche 1D, to be available upon the earlier to occur of (1) March 31, 2025 and (2) full borrowing of Tranche 1C, until June 30, 2025, (iii) increase Tranche 2 to \$30.0 million, and extend the availability thereof to be available upon the earlier to occur of (1) June 30, 2025, and (2) full borrowing of Tranche 1D, until September 30, 2025, subject to the Tranche 2 Draw Test, (iv) extend the availability of Tranche 3 of \$100.0 million, through March 31, 2026, available subject to lender’s investment committee approval, (v) extend the amortization date to September 1, 2025, and extend the timeline to achieve the second amortization extension condition, to June 30, 2025, upon the occurrence of which the amortization date may be extended to March 1, 2026, (vi) amend the financial covenant to commence on October 1, 2024, and require that so long as our market capitalization is less than \$550.0 million, Borrowers shall maintain qualified cash equal to at least 50% of the sum of (x) the amount of outstanding debt under the facility plus (y) Qualified Cash A/P Amount (as defined in the Agreement), or upon the occurrence of certain conditions, 70% of the sum of (x) the amount of outstanding debt under the facility plus (y) Qualified Cash A/P Amount, and (vii) reduce the interest rate to equal the greater of (x) 9.05% or (y) prime rate plus 4.30% (or, upon achieving certain conditions, (y) shall equal prime rate plus 4.05%).

We are permitted to engage in certain specified transactions (subject to mandatory prepayment in certain instances as well as certain limitations, including the pledge of equity interests of certain subsidiaries and VIEs), including but not limited to, (i) entering into non-exclusive and certain specified exclusive licensing arrangements with respect to intellectual property without the consent of the Lenders; and (ii) entering into certain permitted acquisitions.

The 2022 Term Loan Facility will mature on August 1, 2026 (the “Maturity Date”), which may be extended until February 1, 2027 if we raise at least \$175.0 million of unrestricted new net cash proceeds from certain permitted sources after the Closing Date and prior to June 30, 2025, and satisfy certain other specified conditions (the “Extension Condition Two”). The outstanding principal balance of the 2022 Term Loan Facility bears interest at a floating interest rate per annum equal to the greater of either (i) the prime rate as reported in the Wall Street Journal plus 4.30% and (ii) 9.05%; provided, that if the Extension Condition Two is satisfied, the rate of interest in the foregoing clause (i) is prime rate as reported in The Wall Street Journal plus 4.05%. Accrued interest is payable monthly following the funding of each term loan advance. We may make payments of interest only, without any loan amortization payments until September 1, 2025, which date may be extended to March 1, 2026 if Extension Condition Two is achieved. At the end of the interest only period, we are required to begin repayment of the outstanding principal of the 2022 Term Loan Facility in equal monthly installments.

As collateral for the obligations under the 2022 Term Loan Facility, we have granted to the Agent for the benefit of the Lenders a senior security interest in substantially all of our cash and investment accounts and each Subsidiary Guarantor’s property (including a pledge of equity interests of certain subsidiaries and VIEs), exclusive of intellectual property, with certain limited exceptions set forth in the Hercules Loan Agreement.

The 2022 Term Loan Agreement contains customary closing and commitment fees, prepayment fees and provisions, events of default and representations, warranties and affirmative and negative covenants, including a financial covenant requiring us to maintain certain levels of cash in accounts subject to a control agreement in favor of the Agent (the “Qualified Cash”) at all times commencing from the Closing Date, which includes a cap on the amount of cash that can be held by, among others, certain of our foreign subsidiaries in Australia and the United Kingdom. In addition, the financial covenant under the 2022 Term Loan Agreement requires that beginning on October 1, 2024, we shall maintain Qualified Cash in an amount no less than the sum of (1) 50% of the outstanding amount under the 2022 Term Loan Facility, and (2) the amount of the Borrowers’ and Subsidiary Guarantors’ accounts payable that have not been paid within 180 days from the invoice date of the relevant account payable, subject to certain exceptions; provided, upon the occurrence of certain conditions, we shall at all times maintain Qualified Cash in an amount no less than the sum of (1) 70% of the outstanding amount under the 2022 Term Loan Facility, and (2) the amount of the Borrowers’ and Subsidiary Guarantors’ accounts payable that have not been paid within 180 days from the invoice date of the relevant account payable, subject to certain exceptions; provided, further, that the financial covenant shall not apply on any day that our market capitalization is at least \$550.0 million measured on a consecutive 10-business day period immediately prior to such date of measurement and tested on a daily basis. Upon the occurrence of an event of default, including a material adverse effect, subject to certain exceptions, on our and ATAI AG’s, taken together, business, operations, properties, assets or financial condition, and subject to any specified cure periods, all amounts owed by us may be declared immediately due and payable by the Lenders. As of September 30, 2024, we were in compliance with all applicable covenants under the 2022 Term Loan Agreement.

In addition, we are required to make a final payment fee (the “End of Term Charge”) upon the earlier of (i) the Maturity Date, (ii) the date that we prepay, in full or in part, the principal balance of the 2022 Term Loan Facility, or (iii) the date that the outstanding balance of the 2022 Term Loan Facility becomes due and payable. The End of Term Charge is 6.95% of the aggregate original principal amount of the term loans so repaid or prepaid under the 2022 Term Loan Agreement.

We may, at our option, prepay the term loans in full or in part, subject to a prepayment penalty equal to (i) 2.00% of the principal amount prepaid if the prepayment occurs on or prior to the first anniversary of the Closing Date, (ii) 1.0% of the principal amount prepaid if the prepayment occurs after the first anniversary and on or prior to the second anniversary of the Closing Date, and (iii) 0.5% of the principal amount prepaid if the prepayment occurs after the second anniversary and prior to the Maturity Date.

Material Cash Requirements from Known Contractual and Other Obligations and Commitments

We are a party to many contractual obligations involving commitments to make payments to third parties. These obligations impact our short-term and long-term liquidity and capital resource needs. Certain contractual obligations are reflected on the unaudited condensed consolidated balance sheet as of September 30, 2024, while others are considered future commitments. Our contractual obligations primarily consist of milestone payments under existing license agreements. For information regarding our other contractual obligations, refer to Note 10. *Leases*, Note 16. *Commitments and Contingencies*, and Note 17. *License Agreements* and Part II, Item 7 of our Form 10-K.

Recently Adopted Accounting Pronouncements

See Note 2, “Basis of Presentation, Consolidation and Summary of Significant Accounting Policies—Recently Adopted Accounting Pronouncements” to our unaudited condensed consolidated financial statements appearing under Part 1, Item 1 for more information.

Critical Accounting Policies and Estimates

Our critical accounting policies are described under the heading “Management’s Discussion and Analysis of Financial Condition and Results of Operations – Critical Accounting Policies and Estimates” in our Form 10-K and in Note 2 to our consolidated financial statements included in our Form 10-K. As disclosed in Note 2 to our consolidated financial statements included in our Form 10-K, the preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions about future events that affect the amounts reported in the financial statements and accompanying notes. Actual results could differ significantly from those estimates. During the period covered by this Quarterly Report, there were no material changes to our critical accounting policies from those discussed in our Form 10-K other than those disclosed in Note 2 of this Quarterly Report.

Item 3. Quantitative and Qualitative Disclosures About Market Risk.

We are exposed to market risks in the ordinary course of our business. Market risk represents the risk of loss that may impact our financial position due to adverse changes in financial market prices and rates. Our market risk exposure is primarily the result of fluctuations in interest rates and foreign currency exchange rates. In addition, our portfolio of notes receivables is exposed to credit risk in the form of non-payment or non-performance. In mitigating our credit risk, we consider multiple factors, including the duration and terms of the note and the nature of and our relationship with the counterparty.

Interest Rate Sensitivity

Our primary exposure to market risk is interest rate sensitivity, which is affected by changes in the general level of U.S. interest rates. As of September 30, 2024 we had cash and cash equivalents of \$30.0 million, restricted cash of \$15.0 million, and short-term securities of \$56.0 million. We generally hold our cash in interest-bearing demand deposit accounts and short-term securities. Due to the nature of our cash and investment portfolio, a hypothetical 100 basis point change in interest rates would not have a material effect on the fair value of our cash. Our cash is held for working capital purposes. We purchased investment grade short-term debt securities which are rated by nationally recognized statistical credit rating organizations in accordance with its investment policy. This policy is designed to minimize our exposure to credit losses and to ensure that the adequate liquidity is maintained at all times to meet anticipated cash flow needs.

As of September 30, 2024, we had \$0.4 million in convertible promissory notes, which was comprised of non-interest-bearing borrowings under the 2018 Convertible Notes. Based on the principal amounts of the convertible promissory notes and the interest rate assigned to the convertible promissory notes, a hypothetical 10% change in interest rates would not have a material impact on our convertible promissory notes, financial position or results of operations.

As of September 30, 2024, the carrying amount of our short and long-term notes receivables was an aggregate amount of \$5.7 million. Based on the principal amounts of the notes receivable and the interest rates assigned to each note receivable as per their respective contracts, a hypothetical 10% change in the interest rates would not have a material impact on our notes receivables, financial position or results of operations.

Foreign Currency Exchange Risk

Our reporting and functional currency is the U.S. dollar, and the functional currency of our foreign subsidiaries is generally the respective local currency. The assets and liabilities of each of our foreign subsidiaries are translated into U.S. dollars at exchange rates in effect at each balance sheet date. Adjustments resulting from translating foreign functional currency financial statements into U.S. dollars are recorded as a separate component on the unaudited Condensed Consolidated Statements of Comprehensive Loss. Equity transactions are

translated using historical exchange rates. Expenses are translated using the average exchange rate during the previous month. Gains or losses due to transactions in foreign currencies are included in interest and other income (expense), net in our unaudited Condensed Consolidated Statements of Operations.

The volatility of exchange rates depends on many factors that we cannot forecast with reliable accuracy. We have experienced and will continue to experience fluctuations in foreign exchange gains and losses related to changes in foreign currency exchange rates. In the event our foreign currency denominated assets, liabilities, revenue, or expenses increase, our results of operations may be more greatly affected by fluctuations in the exchange rates of the currencies in which we do business, resulting in unrealized foreign exchange gains or losses. We have not engaged in the hedging of foreign currency transactions to date, although we may choose to do so in the future.

A hypothetical 10% change in the relative value of the U.S. dollar to other currencies during any of the periods presented would not have had a material effect on our unaudited condensed consolidated financial statements, but could result in significant unrealized foreign exchange gains or losses for any given period.

Item 4. Controls and Procedures.

Evaluation of Disclosure Controls and Procedures

We maintain disclosure controls and procedures (as that term is defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act) that are designed to ensure that information required to be disclosed in our reports under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC's rules and forms, and that such information is accumulated and communicated to our management, including our Co-Chief Executive Officers and Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosures. In designing and evaluating our disclosure controls and procedures, management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives. In addition, the design of disclosure controls and procedures must reflect the fact that there are resource constraints and that management is required to apply judgment in evaluating the benefits of possible controls and procedures relative to their costs.

Our management, with the participation of our Co-Chief Executive Officers and our Chief Financial Officer, evaluated the effectiveness of our disclosure controls and procedures as of September 30, 2024, the end of the period covered by this Quarterly Report. Based on this evaluation, our Co-Chief Executive Officers and Chief Financial Officer concluded that our disclosure controls and procedures were effective as of September 30, 2024 at the reasonable assurance level.

Changes in Internal Control Over Financial Reporting

There was no change in our internal control over financial reporting (as that term is defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) that occurred during the fiscal quarter ended September 30, 2024 that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

PART II- OTHER INFORMATION

Item 1. Legal Proceedings.

We are, from time to time, party to various claims and legal proceedings arising in the ordinary course of our business. See Part I, Item I “Financial Statements (Unaudited) – Note 16, Commitments and Contingencies” in this Quarterly Report, which are incorporated herein by reference.

Item 1A. Risk Factors.

Investing in our common shares involves a high degree of risk. In addition to the other information set forth in this Quarterly Report and in other documents that we file with the SEC, you should carefully consider the factors described in the section titled "Risk Factors" in our Form 10-K. There have been no material changes to the risk factors described in Part I, Item 1A of our Form 10-K. If any of the risk factors described in the Form 10-K actually materializes, our business, financial condition and results of operations could be materially adversely affected. In such an event, the market price of our common shares could decline and you may lose all or part of your investment. We may disclose changes to such risk factors or disclose additional risk factors from time to time in our future filings with the SEC.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.

None.

Item 3. Defaults Upon Senior Securities.

None.

Item 4. Mine Safety Disclosures.

Not applicable.

Item 5. Other Information.

a) Disclosure in lieu of reporting on a Current Report on Form 8-K.

None.

b) Material changes to the procedures by which security holders may recommend nominees to the board of directors.

None.

c) Insider Trading Arrangement and Policies.

During the three months ended September 30, 2024, no director or “officer” (as defined in Rule 16a-1(f) under the Exchange Act) of the Company adopted or terminated a “Rule 10b5-1 trading arrangement” intended to satisfy the affirmative defense of Rule 10b5-1(c) or a “non-Rule 10b5-1 trading arrangement,” as each term is defined in Item 408(a) of Regulation S-K.

Item 6. Exhibits.

Exhibit Number	Description	Incorporated by Reference				Filed/Furnished Herewith
		Form	File No.	Exhibit	Filing Date	
3.1	Articles of Association of ATAI Life Sciences N.V. (translated into English), currently in effect	S-3	333-265970	3.1	7/01/2022	
3.2	Rules of the Management Board of ATAI Life Sciences N.V.	S-1/A	333- 255383	3.2	6/11/2021	
3.3	Rules of the Supervisory Board of ATAI Life Sciences N.V.	S-1/A	333- 255383	3.3	6/11/2021	
10.1†	Third Amendment to the Loan and Security Agreement between the Registrant, ATAI Life Sciences AG, certain of the Registrant's subsidiaries from time to time party thereto as a guarantor, Hercules Capital, Inc., and the several banks and other financial institutions or entities from time to time party thereto, and Hercules Capital, Inc. as administrative agent and collateral agent for itself and the lenders, dated August 14, 2024.	8-K	001-40493	10.3	8/14/2024	
31.1	Certification of Co-Principal Executive Officer pursuant to Exchange Act Rule 13a-14(a).					*
31.2	Certification of Co-Principal Executive Officer pursuant to Exchange Act Rule 13a-14(a).					*
31.3	Certification of Principal Financial Officer pursuant to Exchange Act Rule 13a-14(a).					*
32.1	Certification of Co-Principal Executive Officers and Principal Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002					**
101.INS	Inline XBRL Instance Document - the Instance Document does not appear in the interactive data file because its XBRL tags are embedded within the Inline XBRL document					*
101.SCH	Inline XBRL Taxonomy Extension Schema Document					*
101.CAL	Inline XBRL Taxonomy Extension Calculation Linkbase Document					*
101.DEF	Inline XBRL Taxonomy Extension Definition Linkbase Document					*
101.LAB	Inline XBRL Taxonomy Extension Label Linkbase Document					*
101.PRE	Inline XBRL Taxonomy Extension Presentation Linkbase Document					*
104	Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)					*

* Filed herewith.

** Furnished herewith.

† Certain confidential portions (indicated by brackets and asterisks) have been omitted from this exhibit pursuant to Item 601(b)(10)(iv).

CERTIFICATION

I, Florian Brand, certify that:

1. I have reviewed this Quarterly Report on Form 10-Q/A of ATAI Life Sciences N.V.;
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4. The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
 - (a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
 - (b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
 - (c) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
 - (d) Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and
5. The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):
 - (a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
 - (b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date: November 14, 2024

By: _____ /s/ Florian Brand

Florian Brand
Co-Chief Executive Officer
(Co-Principal Executive Officer)

